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Crystallisation of organic molecules is a fundamental process routinely used for 
purification and isolation of active pharmaceutical ingredients (APIs). In the 
formulation of traditional dry powder inhaler (DPI) products, harvested primary 
crystalline APIs are secondarily processed and subsequently blended with 
excipients to form an ordered mixture. In DPI formulations containing drug 
particles and coarse carrier material, the delicate balance of cohesive and 
adhesive forces between the drug(s) and carrier enable delivery of respirable 
APIs to the targeted regions of the lungs. The destructive and relative 
uncontrolled nature of secondary-processing techniques such as milling, leads 
to the generation of respirable formulations of varying performance, resulting in 
varying clinical efficacy. The relationship between the primary crystallisation of 
APIs and the physical, chemical, mechanical properties of the primary crystals 
and the relationship to the secondary processing of these materials remain 
poorly understood. This body of work aimed to address the paucity of data 
within this area, within the context of DPI formulations.  
 
A nanoindentation approach using atomic force microscopy (AFM) developed to 
determine the elastic modulus of crystalline pharmaceutical samples provided 
the Young’s modulus of a range of pharmaceutical materials. Differences were 
observed indicating lactose monohydrate to have the highest stiffness (high 
Young’s modulus) and formoterol fumerate dihydrate having the lowest of the 
materials tested (0.93 GPa).  Utilising AFM cohesive-adhesive force 
measurements against a reference Highly Ordered Pyrolytic Graphite (HOPG) 
substrate, fluticasone propionate was seen to have the greatest cohesive 
tendency of 1.13 times greater to itself over HOPG. In contrast, budesonide had 
the most adhesive tendency towards HOPG, with a cohesive-adhesive balance 
(CAB) value of 0.65, indicating that the differences in DPI performance of these 
materials may be as a result of differences in their interfacial properties which 
could be a influenced by prior processing history.  
 
Crystallisation of fluticasone propionate (FP) was conducted using four different 
solvent/anti-solvent combinations to investigate the influence of different end-






behaviour and in vitro performance in carrier based DPI formulations. The 
Young’s modulus of FP crystals produced varied significantly and these 
differences were reflected in the number of passes required in the microniser to 
reduce the particle size of the primary crystals to less than 5 µm. Furthermore, 
the resultant micronised materials were determined to have different cohesive-
adhesive balance values, supporting differences in their respective DPI 
formulation performance attributes, both in binary formulation and in 
combination with a second drug, salmeterol xinafoate.  
 
The impact of changes in crystal habit on the mechanical properties of 
budesonide crystals was investigated alongside the resultant effect on 
interactive forces of the micronised material and the performance in a DPI 
formulation. The Young’s modulus determined by AFM nanoindentation on the 
{002} face of each habit confirmed a Young’s modulus four times greater for 
one of the habits and supported the particle size data of the resultant 
micronised materials from each primary crystal samples. Cohesive-adhesive 
balance measurements of the micronised budesonide samples with respect to 
lactose monohydrate supported in vitro aerosolisation performance studies, 
whereby the fine particle dose and fine particle fraction of the emitted dose of 
the sample with lower adhesive tendency towards the lactose carrier particle 
was greater.   
 
The relative mechanical and processing differences between anhydrous and 
monohydrate forms of ipratropium bromide (IB) was evaluated using 
supercritical fluid technology and temperature drop crystallisation techniques, 
respectively. The aerosolisation efficiency of these materials from DPI 
formulations determined the effect of crystal form on the functionality of the 
two samples. Repeated force-distance measurements revealed no significant 
differences between the anhydrous and monohydrate form of IB and revealed 
both forms to have an average elastic modulus of approximately 4 GPa. No 
differences were seen in the secondary processing of these materials relating 
the milling behaviour, interfacial properties or aerosolisation performance in 
vitro, demonstrating the suitability of supercritical fluid technology in 
producing an anhydrous form of ipratropium bromide for inclusion in a carrier-
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Chapter 1: Introduction 
1.1 Respiratory Medicine 
 
The delivery of medication to the lungs is seen as one approach in delivering 
therapeutic agents to the local airways and increasingly for systemic delivery. 
As a non-invasive drug delivery strategy, inhaling active pharmaceutical 
ingredients avoids the harsh conditions of the gastro-intestinal tract, first pass 
effects of the gastro or hepatic system and in many cases, limits systemic 
toxicity. The pharmaceutical engineering of formulations for this process is 
however, demanding. Variables arising from the production of active ingredients 
combined with the effects of processing and device performance lead to 
significant challenges in developing and manufacturing consistently high-quality 
products.  
 
1.1.1 The Respiratory Tract 
The human lungs are primarily responsible for the exchange of gases between 
the external environment and systemic circulation. They work together with the 
heart and blood to extract oxygen from inspired air and expel waste gases, 
principally carbon dioxide (Kumar, 2002). Given the limited space for this 
process to occur, the lungs have to provide a large surface area within which 
gaseous exchange can take place and ensure adequate defence mechanisms 
are in place. Prevention of damage from inspired particular matter and infective 
agents is achieved by a combination of structural and immunological barriers to 
foreign material.   
 
1.1.1.1 Structure of the Respiratory System 
The upper respiratory zone encompasses the nose, nasal passages, mouth, 
pharynx, larynx, trachea and bronchi and is known as the conducting airways. 
The lower respiratory region is responsible for the exchange of gases and 
comprises of the bronchioles and alveoli (Griesenbach et al., 2004). These are 
all illustrated in Figure 1.1 below.   






Figure 1.1 Structure of the lungs (Adapted from Griesenbach et al., 2004) 
 
The trachea is 10-12 cm in length and divides into the left and right main 
bronchi, which in turn connects to shorter bronchi, bronchiole and alveoli 
through a series of approximately 25 bifurcating airways. Of the first seven 
divisions, the bronchi have walls consisting of cartilage and smooth muscle, 
epithelial lining including cilia and goblet cells and endocrine cells. The next 16-
18 divisions contain bronchioles that have no cartilage, progressively thinner 
muscular layers with a single layer of ciliated cells and reduced goblet cells 
alongside Clara cells that produce a surfactant like liquid.  Connected to the 
bronchioles are the alveoli, of which their total surface area is in the region of 
40-80 m2 consisting of an epithelial lining containing attenuated cytoplasm 
(Malcolmson and Embleton, 1998).  
 
1.1.1.2 Defence Mechanisms of the Respiratory Tract 
The lungs receive around 10,000 L of air daily (Kumar, 2002) and have evolved 
to remove inhaled foreign particles including grass pollens, environmental 
particles, dander and prevent infection from invading bacteria, fungal spores 
and viruses. The continual branching and narrowing of the airways are 
responsible for filtering the inspired air and removal of particulate material by 
impaction against the respiratory tract. Mucous secretion enables the trapping 
of these materials while the beating cilia upon which this mucous rests, is 
continually moving this substance upwards towards the oropharynx where it is 
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swallowed (Hansel and Barnes, 2009). Within the nasal cavity, particles can be 
removed within 15 minutes due to faster ciliary movement and is responsible for 
the removal of 90% of particles greater that 10 µm inspired from this section 
(Kumar, 2002). This is in contrast to the relatively slower acting cilia of the 
bronchi where clearance can take up to an hour and delays of several days if 
particles are deposited further down within the respiratory bronchioles (Byron 
and Patton, 1994).    
  
1.1.2 Asthma 
Asthma is a common respiratory condition associated with broncho-constriction 
and airway inflammation for which an estimated 5.4 million people in the UK are 
receiving treatment (Murphy, 2010). In most instances, underlying 
pathophysiology of this disease is mediated in part, by immunoglobulin E (IgE) 
dependent mechanisms. These antibodies are produced in response to 
allergens such as pollen, dust mite or dander, inspired through the respiratory 
tract and cause sensitisation and produce allergen-specific IgE, increasing 
serum concentrations. Upon re-exposure, the binding of these triggers to IgE 
molecules results in the release of inflammatory mediators such as histamine, 
prostaglandins and leukotrienes from mast cells in a process known as 
degranulation (Tattersfield et al., 2002). These mediators cause the contraction 
of the smooth muscles of the airways and result in bronchospasm and patient 
wheezing, characteristic with the early (acute) phase of an asthma attack. 
 
If left untreated at this stage, degranulation of mast cells result in the local 
infiltration of further inflammatory molecules including eosinophils, T-
lymphocytes and additional mast cells. Release of cytokines by these 
lymphocytes recruit further pro-inflammatory cells while an increase of goblet 
cells produce mucus plugs that restrict airflow. This late phase response results 
in increased basal airway tone and airway responsiveness, causing hyper-
responsiveness associated with airway obstruction and sputum production 
(Murphy, 2010). If this condition is uncontrolled or poorly treated, chronic 
inflammation of the airway produces permanent structural changes to the 
airways, termed airway remodelling. Changes include subepithelial fibrosis 
(basement membrane thickening), airway smooth muscle hypertrophy and 
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hyperplasia, angiogenesis and increased mucus secretory cells (goblet-cell 
hyperplasia and submucosal-gland hyperplasia) (Barnes, 2004a).  
 
1.1.3 Chronic Obstructive Pulmonary Disease (COPD) 
For patients with COPD, airway restriction is usually progressive and not fully 
reversible. This umbrella term encompasses a range of different respiratory 
conditions with unique pathophysiology, including emphysema and chronic 
bronchitis, which in most cases is attributed to inhalation of noxious gases and 
particles (Ohri and Steiner, 2004).  
 
In chronic bronchitis, mucus hyper-secretion, often characteristic of cigarette 
smoking, promotes the activation of macrophages that secrete inflammatory 
proteins and mediators that attract inflammatory cells. Destruction of the 
alveolar regions follows whilst reactive oxygen species (ROS) found in cigarette 
smoke, alongside nitric oxide and peroxynitrate cause damage to host cells 
suppressing immuno-response and further reinforce pro-inflammatory 
responses (Hansel and Barnes, 2009). This is also thought to contribute to the 
resistance of steroid therapy in COPD (Barnes, 2004b).   
 
In addition to the progressive worsening of respiratory symptoms, COPD is 
associated with increased susceptibility to infections, disability and premature 
death (Murphy, 2010). Successful management of this disease is therefore, 
crucial in minimising and controlling the debilitating nature of this illness 
(Barnes, 2008).  
 
1.1.4 Differentiation Between Asthma and COPD 
Though there are many overlapping physiological features shared between 
asthma and COPD, a different response to treatment requires correct diagnosis 
for appropriate pharmacological management of each disease. A marked 
difference between the inflammatory mediators and pathways responsible for 
each disease state (Barnes, 2004b) requires the delivery of medicament to 
specific areas of the respiratory tract. For asthma, inflammation is located to a 
greater extent in the large conducting airways, while in COPD inflammation is 
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observed in the peripheral regions of the lung and the smaller conducting 
airways.  
 
1.1.5 Inhaled Pharmacological Treatment of Asthma and COPD 
Given the differences between asthma and COPD, the goals of asthma 
treatment are driven by the need to suppress chronic inflammation, whereas the 
drivers for COPD treatment are the reduction in symptoms (Buist, 2003). The 
first line of treatment in both cases is to promote airway dilation and reduce 
airway inflammation. Current British Thoracic Society (BTS) guidelines on 
asthma treatment and National Institute for Health and Clinical Excellence 
(NICE) indicate first-line treatment with bronchodilators (short and long acting) 
and anti-inflammatory therapy, following which a stepwise approach is taken.   
 
1.1.5.1 Bronchodilators 
Often termed reliever medicines, short-acting beta2 agonists (SABAs) are used 
to acutely treat the symptoms of asthma or can be administered just before 
exercise. These agents act on the β2 adrenoceptors found on the smooth 
muscles of the airways causing relaxation and bronchodilation. SABAs such as 
salbutamol and terbutaline, have an onset of action within five minutes and a 
peak effect within four to six hours (Buist, 2003).  
 
Bronchodilators also include long-acting beta2 agonists (LABAs) such as 
salmeterol xinafoate (SX) and formoterol fumarate dihydrate (FFD) are 
indicated for the chronic treatment of moderate asthma and COPD. Similarly to 
SABAs, these drugs have a rapid onset of action (between five to twenty 
minutes) and their effects can last for more than twelve hours. LABAs however, 
should only be used in combination with an appropriate inhaled corticosteroid 
(ICS) and discontinued in the absence of benefit due to LABA associated 
deaths in a small group of individuals (Nelson et al., 2006). 
 
Anticholinergic agents, such as ipratropium bromide (IB) and tiotropium bromide 
(TIO) also produce bronchodilation. These act by blocking vagal nerve 
stimulation on bronchial smooth muscles as a result of blocking muscarinic 
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cholinergic receptors (Brown et al., 1984). These drugs are less effective as 
reliever medicines in asthma and not recommended for the long-term 
management of this disease. In contrast, both drugs are indicated for the 
treatment of COPD with the newer and longer acting TIO having once daily 
dosing, compared to the shorter-acting IB (Vincken et al., 2002).  
 
1.1.5.2 Anti-Inflammatory Drugs 
Inhaled corticosteroids (ICSs) such as the glucocorticoids budesonide (BUD), 
fluticasone propionate (FP) and mometasone furoate are the most effective 
drugs used in controlling persistent asthma in adults and children (Murphy, 
2010) and additionally offer mainstay therapy for COPD patients. Increase in 
airway calibre is achieved by modifying airway inflammation response through a 
wide variety of pathways including the suppression of circulating cytokines and 
spasmogens known to cause inflammation (Rang, 2003). The full effect of ICS 
therapy is achieved after several days of therapy (Rang, 2003) (Neal, 2002) and 
when discontinued, deterioration of clinical control follows within weeks to 
months of most patients (Murphy, 2010). For patients with COPD, especially 
current or recent smokers, the full benefit of ICS treatment is less likely to be 
seen. Recently, it has been proposed that failure to suppress inflammation by 
ICS therapy in these patients may be related to decreased histone deacetlyase 
2 (HDAC2) expression in the peripheral regions of their lungs (Barnes, 2008).  
 
1.1.5.3 Combined Inhaled Therapy 
A wide range of inflammatory mediators are involved in the persistence of 
asthma and COPD.  Clinical studies identifying the benefits of multi-drug 
therapy in chronic respiratory disease have influenced current treatment 
guidelines and established best practice in this area.  
 
The addition of a LABA to ICS therapy has been shown to achieve better 
asthma control than ICS therapy alone (Matz et al., 2001) and has been 
demonstrated with the combination of SX and FP (Nelson et al., 2003). For 
patients with sever COPD, the combination of BUD and FFD has shown to 
improve exacerbation rates when compared to β2-agonists alone (Szafranski et 
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al., 2003) and improved 3-year survival rates for COPD patients receiving a 
combination of FP and SX (Calverley et al., 2003).  
 
Inhaled formulations containing ICS and LABA are available including the 
combination of FP with SX in Advair® (USA) and Seretide® (Europe) marketed 




1.2 Pulmonary Drug Delivery 
 
The delivery of medication via the inhaled route enables the direct access to 
drug targets for the treatment of patients with asthma and COPD, avoiding 
degradation within the gastrointestinal tract or first-pass effects (Byron and 
Patton, 1994). Moreover, the reduced dose required, when compared to oral 
administration, minimise side effects and provides rapid and predictable onset 
of action (Timsina et al., 1994a). Since the pulmonary epithelium provides a 
large surface area for deposition and slow mucocilary clearance, pulmonary 
delivery of therapeutic agents by inhalation has become established as the 
preferred method of treatment for respiratory conditions. 
 
1.2.1 Particle Deposition in the Lungs  
For a therapeutic effect to take place, inhaled drug particles must deposit on the 
site of action (Byron and Patton, 1994). Depending on the condition being 
treated, the target area will vary (Brain, 1985). Understanding the mechanisms 
in which particles deposit from air streams and the relationship between these 
properties and the physiological considerations of the lung, help determine the 
requirements for successful pulmonary drug delivery. While control of 
aerodynamic particle size is crucial, deposition by inertial impaction, 
sedimentation and diffusion (shown with reference to airway generation in 
Figure 1.2) highly influence lung deposition (Loalor, 1996) (Zeng, 2001). 
Additional mechanisms that contribute to the complex nature of respiratory drug 
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delivery include interception and electrostatic precipitation. These are all 
described below. 
 
Figure 1.2 The deposition profile of inhaled particles as a function of airway generation 
(Reproduced from Patton and Byron, 2007) 
 
1.2.2 Inertial Impaction 
The principle mode of deposition for larger particles in the upper airways of the 
lungs relies on inertial impaction (Hinds, 1982). For particles entrained in an air 
stream, inability to respond to the rapid changes in airflow directions associated 
with the bifurcations of the respiratory airways leads to impaction of the particle 
on to the respirable surface. This form of deposition is dependent on physical 
attributes of the suspended particle, notably size and density which is 
mathematically described by Stokes’ number (  
€ 
Stk ), a dimensionless parameter 











where is the particle density,  is the particle diameter,  is the air velocity, 
 is the air viscosity and  is the airway radius. The greater a particle’s Stokes’ 
number, the more likely it is to deposit by impaction (Crowder et al., 2002). 
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Increased density, particle diameter and air velocity will result in a greater 
impaction rate while reduced airway radius will also contribute to impaction.   
 
1.2.3 Sedimentation 
Sedimentation of particles within the respiratory tract occurs as a function of 
gravitational forces exerted on suspended particles (Brain, 1985). Stokes’ Law 
describes the terminal velocity ( ) at which particles between 1 and 40 µm 











where  is the density of air and  is the acceleration due to gravity. This 
process is also time dependent, since particles must be given sufficient 
residence time and therefore, dominates in the smaller airways of the lungs and 
alveoli where lower airflow velocities are found (Patton and Byron, 2007).   
  
1.2.4 Brownian Diffusion 
For particles of diameter less than 1 µm, the effect of gravity decreases and the 
influence of Brownian motion caused by the random bombardment of gas 
particles increases (Brain, 1985). Since the efficiency of this process is 
influenced by residence time, the diffusion and displacement of sub-micron 
sized particles can be greatly increased by breath-holding techniques when 
administering these materials to patients (Zeng, 2001).  
 
1.2.5 Interception 
If a particle is elongated, the centre of gravity may be some distance from one 
of the distal ends (Crowder et al., 2002). Interception is classed when a collision 
between an exposed area of a particle and an obstacle occurs, while that given 
particle maintains the centre of gravity within the air stream. It is most notable 
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for longer, needle shaped particles in the smaller airways and alveoli (Johnson, 
1994).    
 
1.2.6 Electrostatic Precipitation 
For particles that enter the airways charged, they may influence deposition by 
altering or inducing polarity to the airway walls. Though significance of this form 
of particle deposition is yet to be fully understood, ongoing research in this field 
has received interest (Young et al., 2007b) (Hickey et al., 2007b).  
 
1.3 Respiratory Drug Delivery Devices 
 
There are three main inhaler devices readily available for patient use in the 
pulmonary drug delivery market. These are nebulisers, pressurised metered 
dose inhalers (pMDIs) and dry powder inhalers (DPIs) (Daniher and Zhu, 2008) 
(Chow et al., 2007). All three can be used for the treatment of respiratory 
disorders such as asthma and COPD.  
 
1.3.1 Nebulisers 
Nebulisers generate an aerosol by converting aqueous solutions or aqueous 
suspensions into a respirable cloud through the use of compressed air or 
piezoelectric transducer (Mitchell and Nagel, 1997). Patients do not require the 
coordination between device and breathing to obtain therapeutic doses making 
nebulising systems suitable for all ages (Loffert et al., 1994). Limitations from 
these devices arise from the prolonged duration of administration, high 
operating costs and restricted portability of devices (Garcia-Contreras and 
Hickey, 2003). Though some of these restrictions are being overcome through 
newer technological developments, nebulisers are often reserved for geriatric, 
paediatric and hospitalised patients and administration of new chemical entities 
(NCE) in animal and man (Dalby and Suman, 2003).  
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1.3.2 Pressurised Metered Dose Inhalers (pMDIs) 
The first pressurised metered dose inhalers (pMDIs) appeared in the 
pharmaceutical drug delivery market in 1956 and has been established as the 
most prescribed inhaler device worldwide (Virchow et al., 2008). In comparison 
to other delivery modes, pMDIs are cheap, portable and easy to use for most 
patients (Mitchell and Nagel, 1997).  
 
These devices consist of an API in solution or suspended fine particles within a 
liquefied gas propellant, sealed into a canister. Connected to the canister is a 
metering valve which when actuated, releases a metered volume of solution or 
suspension through a narrow orifice, driven by high vapour pressures of the 
propellant, resulting in the emergence of a high velocity plume (Mitchell and 
Nagel, 1997). This process of liquid atomisation, combined with the evaporation 
of propellant, results in the creation of an aerosol of drug particles suitable for 
respiration and deposition within the respiratory tract.   
 
Traditional propellants in pMDIs were chlorofluorocarbon (CFC), though 
implementation of the 1987 Montreal Protocols phased out these ozone-
depleting gases for more environmentally friendly products. Hydrofluroalkanes 
(HFAs) were selected by the pharmaceutical industry to serve this purpose, 
however complexities in reformulation and long term issues related to the future 
of HFA-based propellants have in part, restricted the development of these 
formulations (Atkins, 2006). Moreover, addition of formulation excipients such 
as surfactants and co-solvents that improve solubility or reduce particle 
aggregation, increase the complexity of the resulting formulations (Traini et al., 
2007).  
 
Despite pMDIs being the most popular form of prescribed inhaled product, 
limitations on the efficacy of these devices are routinely attributed to poor or 
improper inhaler technique (Dalby and Suman, 2003) (Virchow et al., 2008).  
Coordination of actuation and patient inspiration, due to the high velocity of the 
emitted plume, often limits the efficiency of these devices and though 
spacer/chamber devices have been used to prevent these issues, pMDIs often 
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deliver less than one third of the emitted dose to lungs in the most trained of 
patients (Virchow et al., 2008).   
 
1.3.3 Dry Powder Inhalers (DPIs) 
The inconveniences associated with nebuliser use and the concerns related to 
pMDI drug delivery have spurred increasing interest in dry powder systems for 
inhalation (Son and McConville, 2008). Dry powder inhalers (DPIs) allow a 
metered dose of drug to be delivered to the airways as a dry powder aerosol 
without the need of propellant (Timsina et al., 1994a). Since the generation of a 
respirable aerosol is produced from a patient’s inspiration from DPIs, there is no 
longer an issue of coordination with the device (Hickey, 2004). Moreover, the 
slower velocities of the particles emitted from the device, compared to pMDI 
delivery, potentially avoids the excessive drug losses due to throat and upper 
airway impaction (Pauwels et al., 1997).  
 
Drug particles employed in DPI formulations have a mass median aerodynamic 
diameter (MMAD) less than 5 µm which enable deposition within the lung 
(Timsina et al., 1994a) (Prime et al., 1997) (Daniher and Zhu, 2008). To achieve 
this size, APIs formulated for DPI delivery are often comminuted by energy 
intensive processes such as air jet milling (Islam and Gladki, 2008) though other 
particle engineering techniques such as spray drying and supercritical fluid 
technologies exist (Telko and Hickey, 2005) (Chow et al., 2007). These 
respirable sized particles are intrinsically cohesive as a result of large surface 
areas and high surface energy, leading to particle aggregation, poor flow and 
entrainment complexities (Feeley et al., 1998).  
 
Metering and aerosolisation of respirable materials is therefore, a difficult 
process and is commonly overcome by blending these fine respirable particles 
with a larger, coarser inert excipient, notably lactose monohydrate (Bell et al., 
1971). This excipient, know traditionally as the carrier, has a particle size range 
of between 20 – 200 µm and is blended with the API to produce an ordered 
mixture (Ganderton, 1992) (Telko and Hickey, 2005). As a patient inspires, 
turbulent airflow generated within a device disperses and fluidises the 
formulation with sufficient force to deaggregate the drug particles from the 
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carrier particles (Malcolmson and Embleton, 1998) (Shur et al., 2008). These 
drug particles are then entrained within the inspired airstream and delivered to 
the lungs while the carrier particles are deposited within the oropharynxal 
regions of the patient. The integration of turbulent airflow within a DPI device 
leads to inhaler resistance that will therefore require a patient to provide greater 
inspiratory force to achieve a desired air flow (Islam and Gladki, 2008). 
Consequentially, a balance between device resistance and optimum flow rates 
for drug delivery needs to be engineered within a device (Timsina et al., 1994a).  
 
There are three different types of DPI available on the market; single dose, 
multidose and reservoir based inhalers (Prime et al., 1997) (Islam and Gladki, 
2008) (Daniher and Zhu, 2008). Illustrations of these approaches are shown in 
Figure 1.3. The early devices approved by regulatory bodies employed the 
delivery of medicament through individually metered hard gelatin capsules that 
required individual loading and triggering from the inhaler device (Prime et al., 
1997) (Dalby and Suman, 2003). Examples of which include the Spinhaler® 
and Rotahaler®, and even though these have been superseded by multi-dose 
and reservoir DPIs, both have gained increasing popularity in emerging 
economies due to robustness, ease of use and access to individual unit doses 
(Bhome, 2009).  
 
 
Figure 1.3 The three different types of unit dosing mechanisms employed in commonly 
used DPI devices; a – single unit-dose, b – multiple unit-dose, c – reservoir metered 
(Adapted from Daniher and Zhu, 2008)   
 
Pre-metered multidose inhalers include the successful GlaxoSmithKline 
Diskhaler® and Discus® devices. In the former, a pre-metered drug formulation 
is contained within a foil blister on a circular disk containing four or eight 
blisters. The device requires the patient to pierce through a foil blister, with an 
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in-built punch, prior to actuation.  Upon forced inspiration, the contained 
formulation is dispersed within that airstream and a fraction of the active 
ingredient contained in the inspired formulation is delivered to the lungs. Re-
priming of the device allows for rotation of the blister disk, exposing the piercing 
punch to the next blister (Newman and Busse, 2002). The Discus® 
(Accuhaler®) utilises a foil strip upon which formulation containing blisters are 
pre-filled. These devices follow the same principles of the Diskhaler® but due to 
the sophisticated coiling and blistering techniques employed, they contain 60 
individual doses within each device (Newman and Busse, 2002), improving the 
practical implications of using the inhaler.  
 
Reservoir DPIs dispense a single dose from a bulk reservoir contained within 
the device via an in-built metering chamber. The first device containing this 
mechanism was the Turbuhaler® (AstraZeneca), which employs a rotating base 
with a number of cavities of defined dimensions, permitting unit dosing of the 
formulation. Since the entire bulk is exposed to some extent to the surrounding 
atmosphere, a desiccant is required to maintain a dry powder throughout the 
shelf-life of the product (Prime et al., 1997). To achieve high powder dispersion 
efficiencies, the Turbuhaler® device relies on high resistance and helical 
airstreams to create the necessary turbulent airflow for particle delivery. More 
recent reservoir inhalers such as the Easyhaler® (Ranbaxy Ltd., UK) and 
Clickhaler® (Vectura Plc., UK) improve fine particle delivery by the use of 
changing airflow paths and by impaction plates, respectively (Son and 
McConville, 2008). 
 
It is well documented that for DPIs delivery efficiency is largely governed by the 
inspirational profile of the recipient patient (Timsina et al., 1994a) (Islam and 
Gladki, 2008). DPIs, therefore, must provide adequate internal resistance in 
order to deaggregate and fluidise the formulation, while considering the 
limitations and variability of inspiratory force a patient with respiratory conditions 
can achieve when using the device (Malcolmson and Embleton, 1998).  
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1.3.4 Summary of the Various Drug Delivery Options to the Lungs 
A brief overview on current forms of respiratory drug delivery has been 
described above. Though each form has significant advantages and 
disadvantages in the treatment of respiratory conditions, the delivery of 
therapeutic agents through a simple device that is independent to patient 
coordination or inspiration profiles appears to be the most favourable 
mechanism (Islam and Gladki, 2008). Developments within the DPI field in 
terms of device design and investigations into dry powder formulation strategies 
demonstrate the focus on optimising existing DPIs. Moreover, the exploration of 
novel approaches to this area demonstrates the relative merits of further 
investigation within this field. The rest of this chapter will concentrate on the 
pharmaceutical considerations of DPI formulations. Emphasis is placed on the 
crystallisation process, as the first process over which pharmaceutical 
formulators have any control. Consequently, this work will highlight how the 
crystallisation process may lead to materials that define future processability 
and functionality.    
      
1.4 Pharmaceutical Considerations in the Formulation of DPI 
Powders 
 
As discussed, DPI devices rely on the delivery of a unit dose of medication to a 
patient in one of three ways; single unit-dose, multiple unit-dose or reservoir 
metered dose. Traditional techniques in producing these formulations rely on 
blending the active pharmaceutical ingredients with an inert carrier, though 
other sophisticated formulation approaches are under investigation within the 
pharmaceutical industry.  
 
As shown in Figure 1.4, the production of most DPI formulations relies on a 
number of unit operations in order to produce a DPI formulation suitable for 
patient use. Key to this process is the isolation of active ingredients by the 
process of crystallisation whereby large crystals are produced and 
subsequently milled, following a  ‘top-down’ approach in order to produce fine 
particle with a median geometric diameter between 1 - 5 µm (Telko and Hickey, 
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2005). Blending of these particles with large carrier particles improves handling, 
dosing and fluidisation (Malcolmson and Embleton, 1998), yet the strong 
interparticluate forces between the active ingredients and carrier particles 
results in typical delivery efficiencies of only 10-30% (Timsina et al., 1994a). 
The balance of attractive and cohesive forces experienced between these 
formulation components therefore, greatly influences the entrainment and 
deposition profile of the active ingredients within DPI formulations (Begat et al., 
2004c) (Jones et al., 2008) in addition to influencing the blending dynamics 
(Pilcer and Amighi, 2010). Variability in the process history of these materials, 
such as changes in the crystallisation or micronisation operations, may 
consequentially lead to differences in formulation performance. Understanding 
and controlling the interfacial properties between APIs and excipient carrier 
particles, enables the formulation of DPI drug products of defined quality and 
functionality (Edge et al., 2008). Moreover, integration of appropriate analytical 
processes during the formulation process could reduce the reliance of QC and 
QA evaluation in the validation of DPI formulations. This section aims to 
introduce the concepts and complexity behind powder blending, the forces 
experiences between particles in the powder bulk and the issues resulting from 
micronised materials, in relation to DPI formulations.  




Figure 1.4 An overview of the various steps required in producing a formulated dry-
powder inhalation device and the possible implications of each process 
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1.4.1 Types of DPI formulations  
Carrier free formulations could comprise of engineered particles specifically 
produced for respirable drug delivery, which can be produced using techniques 
such as spray drying (Steckel and Brandes, 2004), supercritical fluid processing 
(Schiavone et al., 2004) and ultrasonically assisted crystallisation  (Dhumal et 
al., 2009). The use of pelletised drug only formulations in AstraZeneca’s 
Turbuhaler® comprise of softly aggregated particles which are then 
deaggregated in a turbulent airflow, highlighting the balance between device 
resistance and the tailoring of the interparticle forces of the formulation.    
 
In addition to drug only formulations, modifications of the forces between drug 
particles by the addition of an additive has been successfully shown to change 
the flow and aerosolisation behaviour of micron-sized particles. Coating of 
particles by mechanical means (Yokoyama et al., 1987) (Begat et al., 2008) or 
by the spray-drying a mixture of drug and additive (Seville et al., 2007) are two 
common examples. Modification of the interparticle forces, by the use of force-
controlling agents, has been proven to improve aerosolisation and formulation 
performance (Begat et al., 2008). Coatings such as magnesium stearate, which 
is commonly used as a die and punch lubricant in solid oral dosage forms, has 
been a subject of much interest within the inhalation field as a way of 
significantly improving the behaviour of DPI formulations and their 
aerosolisaiton efficiency (Beilmann et al., 2007) (Jones et al., 2008) (Shur et al., 
2008). 
 
The use of carrier based formulations remain the most popular method for DPI 
formulation preparation, where the forces generated within a device from a 
patient’s forced inspiration may detach fine drug particles from coarse carriers 
(Telko and Hickey, 2005) (Islam and Gladki, 2008). In order to produce a 
successful formulation, formulators require knowledge relating the mixing 
properties of multi-component mixtures, the interparticle forces that are involved 
in this process and the various factors that can modify the resulting 
performance. The following sections of this chapter aim to explore this area 
further.  
 




In order to improve the non-pharmacological attributes of a DPI formulation, a 
drug carrier is often blended with the active ingredient. This facilitates handling, 
dosing and metering of the drug (Timsina et al., 1994a) (Telko and Hickey, 
2005).  
 
Traditionally, a coarse fraction of lactose monohydrate is introduced to the 
formulation to act as a bulking agent and mixed with the API. With reference to 
early work in this field, many formulations include a size fraction of lactose of 63 
– 90 µm (Bell et al., 1971). In order to optimise the delivery of these 
formulations, selection of appropriate carrier attributes such as particle size, 
shape and surface topography requires a multifaceted approach. These include 
bulk physical, rheological and chemical characterisation techniques combined 
with knowledge of blending techniques and delivery device attributes (Jones et 
al., 2008).    
 
Processing history of the carrier can alter the blending efficiency and 
performance of DPI formulations (Chow et al., 2007). Milling and sieving of 
lactose monohydrate has been shown to affect the fine particle fraction of 
delivered drug and has been in part, attributed to the generation of fine lactose 
materials in the energy intensive processes altering the carrier surface (Steckel 
et al., 2006). The influence of fine excipient materials, such as added milled 
lactose or those intrinsically produced, has also been shown to modify the 
performance of DPI formulations (Zeng et al., 2001) (Shur et al., 2008).  
 
Successful blending of two or more components requires the use of blending 
equipment to produce an ordered, homogenous mixture. The use of mixing 
equipment such as co-shifting, convective turbula mixing and high sheer 
blending can however, lead to changes in bulk powder properties and has been 
investigated in the context of DPI performance (Dickhoff et al., 2005) (Bridson et 
al., 2007) (Shur et al., 2008). Predicting the required energy input to create 
ordered blends and the effect of these processes on the functionality of the 
resulting blends is however, poorly understood.  
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1.4.3 Interparticulate Forces 
The long-range interparticulate interactions experienced between particles of 
binding energies less than 40 kJ.mol-1 are considerably weaker than shorter-
range interactions, such as ionic and covalent bonding (Johnson, 1996).  These 
forces can either be cohesive, between particles of the same chemical 
structure, or adhesive, between particles and materials of different physical and 
chemical properties (Johnson et al., 1971). As the size of particles becomes 
smaller, the effect of gravity on these materials becomes increasingly negligible, 
especially for particles of size less than 10 µm (Deryaguin et al., 1978)  
 
Interactions between particles, such as those found in DPI formulations, are 
produced from a range of different mechanisms and forces and are therefore, 
important to understand and characterise. These include van der Waals, 
capillary and electrostatic interactions (Johnson et al., 1971) (Young et al., 
2003). Furthermore environmental conditions (temperature and relative 
humidity) and particle morphology may directly influence these particle 
interactions and resulting forces (Fuller and Tabor, 1975) (Zeng, 2001) (Hooton 
et al., 2004).   
 
1.4.3.1 Lifshitz - van der Waals Interactions 
The Lifshitz – van der Waals interactive forces are composed of three separate 
interactive forces known as Debye-induction force, Keesom-orientation force 
and dispersion force (Lifshitz, 1955).  These forces arise from the formation of 
dipole moments in surrounding electron clouds as particles become close. 
Debye-induction forces relate to the interaction forces between permanent and 
induced dipoles, while Keesom orientation forces represent the forces between 
two permanent dipoles (Lifshitz, 1955). Dispersion forces, also termed London 
dispersion force, result from the interaction between two induced dipoles, and 
are generally of greater magnitude than induction or orientation forces (Li et al., 
2006).  
 
The van der Waals forces (  
€ 
FVDW ) between two ideally smooth spheres in a 
vacuum is described by Hamaker (Hamaker, 1937) : 







where  is the Hamaker constant (Equation 1.4),  is the separation distance 
between the spheres and  and  are the diameters of the two spheres. The 








where  and  are the number of atoms per unit volumes of particle 1 and 2 











where  is Planck’s constant,   is the vibration frequency of the interacting 
electronic oscillators and  is the polarisability of the molecules. 
 
The adhesive force between a sphere (diameter ) and a plane composed of 










whereas the adhesion between a sphere (diameter ) and a plane composed 
of different materials and separated by distance  is expressed by: 
 











where  and  are the Hamaker constant for the particle and the plane 
surface, respectively.  
 
From the equations above the importance of the bulk separation distance, , 
for interacting bodies is critical in determining the van der Waals forces between 
two solid objects. The short-acting van der Waals forces retards rapidly as 
separation distance is increased. Therefore, van der Waals forces exert their 
influence only over a range of approximately 10 nm (Hamaker, 1937).  
 
1.4.3.2 Capillary Forces 
The attractive force related to the environmental effect of moisture on powders 
is termed capillary force and is related to the physico-chemcal properties of the 
contacting materials (Hiestand, 1966). Capillary forces arise from the partial 
water vapour pressure in the atmosphere, which may condense into the spaces 
between contiguous surfaces forming a meniscus at the point of contact (Fuller 
and Tabor, 1975). Its influence is related to the material properties such as gap 
geometry, surface free energy, wettability and surface roughness (Fuller and 
Tabor, 1975) and can have detrimental effects on powder flow and fluidisation 
(Hiestand, 1966) (Bérard et al., 2002) (Son and McConville, 2008).  
 
The magnitude of this capillary force ( ) between two identical smooth spheres 




Fc = 2πγwr cosα  
Equation 1.8 
 
where  is a surface tension of water and  is a contact angle between water 
and the spheres. For a sphere (radius ) adhering to a surface, the capillary 
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Fc = 2πγwr (cosα+ cosβ)  
Equation 1.9 
 
where  and  are the contact angles of the water with the surface and 
particle, respectively. 
 
For particles of the respirable size, control over the environmental relative 
humidity (RH) is therefore, essential throughout the formulation and storage 
period. As the RH exceeds 50%, it becomes the dominating force over other 
adhesional forces (Hiestand, 1966) and is known to effect particle interactions 
within DPI formulations (Bérard et al., 2002) (Zeng et al., 2007) (Young et al., 
2007b) introducing performance variability within the end drug-product.  
 
1.4.3.3 Electrostatic Forces 
Electrostatic forces are exemplified in daily life by dust attracted to various 
surfaces. During powder handling, particles can be charged by contact or 
friction with other particles or surfaces. This is termed triboelectrification 
(Staniforth and Rees, 1982) (Hickey et al., 2007b).  
 
When two charged particles are brought to close proximity, they will experience 
a net attractive or repulsive force, related to the charged state of each particle. 










where  is the electrostatic force,   and  are the electrical charges on the 
two particles,  is the permittivity and  is the separation distance between the 
particles. 




An uncharged particle may become charged if an image charge is induced 
upon it by the approach of a charged particle (Onsager and Samaras, 1934). 

















where  the separation distance between charged and uncharged particles. 
This equation may be modified to describe the adhesion of a charged particle to 
a flat, earthed conducting surface via the formation of an image charge by 












Contact between two uncharged particles with different work functions will 
appear in the flow of electrons from the particle with the lower work function to 
the particle with the higher work function until an equilibrium is established 










where  is the radius of the particles and   
€ 
ΔU  is the potential difference arising 
from the difference in work functions. 
 
These equations suggest that electrostatic forces are firstly dependent on the 
electrical properties of the particles involved and secondly, separation distance 
between these particles (Tabor, 1976). This leads to the dominance of van der 
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Waals forces, which are subsequently responsible to a greater extent, for the 
strength of the adhesional force, especially if the influence of electrostatic 
forces and capillary forces are low (Johnson, 1996). 
 
1.4.4 Factors Influencing the Degree of Interparticulate Forces 
In addition to the composite of interparticle forces outlined above, the physical 
nature of individual particles, the surfaces and surrounding environment they 
are exposed to can influence the magnitude of forces experienced. The most 
important of these factors are outlined below. 
 
1.4.4.1 Surface Free Energy  
For solid materials, the surface free energy represents the total energy from a 
solid surface in equivalence to the surface tension of a liquid (Johnson et al., 
1971) (Planinsek et al., 2001). However, unlike liquids, the molecules of a solid 
are unable to move, leading to an inhomogeneous distribution of energy over 
the solid surface. The levels and distribution of these energy changes are 
dependent in part, on the history of the material (Johnson, 1998) (Young et al., 
2007a). The quantity of work required to separate two surfaces is called the 
work of adhesion ( ) and is related to the surface free energy of the surfaces 




Wa = As (γ




where  is the area of surface produced by the separation,  and are the 
free energies per unit surface area of solids C and D in air, respectively; and 
 is the  free energy of the C-D interface per unit area. In addition, according 
to the geometric mean equation, the interfacial free energy between any two 
surfaces C and D can be expressed in its dispersion and polar components by: 
 





γCD = γC + γD −2(γC
LW .γD
LW )1/ 2 −2(γC
p .γD












p  are the polar contributions to the surface energy for solid C 
and D, respectively. Therefore, the work of cohesion ( ) (i.e. the work required 





As the above demonstrates, the thermodynamic work of adhesion and cohesion 
is directly related to the force of adhesion and cohesion. These two forces are 
therefore, dependent on the surface free energies of the interacting particles 
(Johnson et al., 1971).  
 
In order to investigate the work of adhesion between two particles, continuum 
contact mechanics are employed to model the interactive forces occurring as 
the result of two spheres coming into contact, in the absence of significant 
electrostatic force. Two models derived from Hertzian mechanics (Hertz, 1881) 
are used in this instance, the Johnson-Kendall-Roberts model (JKR) (Johnson 
et al., 1971) and the Deriaguin-Müller-Toporov model (DMT) (Derjaguin et al., 




Fadh = nπR *Wa  
Equation 1.17 
 
Where  is the force of adhesion,  is a predetermined constant related to 
the model in use (3/2 for JKR and 2 for DMT),  is the harmonic mean of the 
particle radii (contact radius) and  is the thermodynamic work of adhesion. 
The JKR model investigates the surface forces occurring within the contact 
region, while DMT theory models the effect of attractive forces outside the 
contact region. The choice of model used when investigating these forces is 
Chapter 1:  
 
 27 
dependent on the system being measured, the DMT model is found to be 
appropriate for small particles of low adhesion and the JKR model is suitable for 
larger radii particles of greater compliance (elasticity) and higher adhesional 
forces (Cappella and Dietler, 1999). These models are often used during 
colloidal probe based techniques, where the interactive forces between 
particles and substrate surfaces are used to quantify the adhesional forces 
experienced between particles and substrate surfaces. These measured pull-off 
forces are then used to derive the thermodynamic adhesive forces and are 
discussed in greater detail later in this section.     
 
1.4.4.2 Mechanical Interlocking 
The irregular nature of secondary processed drug particles for inhalation allows 
for greater propensity to the interlocking of particles through direct contact of 
asperities and microscopically rough surface topographies (Adolfsson et al., 
1997). If the direct contact between two particles is over a small surface area, it 
can in some instances, result in the increasing yield of the material and in turn 
increase the mechanical locking and van der Waals interactions (Fuller and 
Tabor, 1975).  
 
1.4.4.3 Particle Size and Shape 
The van der Waals forces have been shown to be proportional to the particle 
diameter ( ), while gravitational forces are proportional to the cube of the 
diameter ( ).  Consequently, as the particle size reduces, the adhesion force 
experienced becomes more significant (Johnson et al., 1971). For particles of 
size less than 10 µm, the adhesion force dominates over forces experienced by 
gravity (Hiestand, 1966).     
 
The effect of particle morphology on the forces experienced between particles 
can be understood when taking into account the ranges over which these forces 
exist. Any modification in particle size will have implication on the separation 
distance of particles and therefore, the electrostatic forces (influenced in the 
range of 10 nm) and longer ranging van der Waals forces (Johnson et al., 
1971). Ability for particles to pack in an ordered manner, for example needle-
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like particles, may increase adhesion forces, due to increased contact area 
between the surfaces (Zeng, 2001). Furthermore, processing these materials 
can alter packing properties, modifying the interparticle forces and thereby 
changing powder properties (Steckel et al., 2006).       
 
1.4.4.4 Surface Roughness 
Since the separation distance between particles can affect the adhesion forces, 
roughness of a particle surface or the substrate it comes into contact with will 
affect adhesion forces. This is due to the change in contact geometry between 
the adhering particle and the substrate (Fuller and Tabor, 1975). For a smooth 
surface, a particle adhering to this surface would have greater contact area and 
decreased separation distance (Fuller and Tabor, 1975) (Johnson, 1998). In 
contrast, for the same particle in contact with a surface with a roughness at a 
smaller scale than that of the particle, the separation distance will increase and 
contact area decrease, leading to reduced adhesion. If the contact surface has 
a roughness greater that that of the adhering particle, mechanical interlocking is 
possible, and contact area is therefore increased, increasing the adhesion force 
experienced by that particle (Johnson et al., 1971).    
 
1.4.4.5 Particle Deformation 
The mechanical nature of particulate materials will influence the propensity of 
deformation at the contact site between particles. The attractive forces 
experienced by particles can cause this deformation and thereby alter the 
contact area and magnitude of interparticle forces (Li et al., 2006). Within the 
context of DPI formulations however, these forces are only recognised as 
significant modifiers of particle re-entrainment following aerosolisation 
(Johnson, 1998).    
 
1.4.4.6 Relative Humidity 
Two different mechanisms related to relative humidity can influence 
interparticulate forces. As discussed previously, environmental RH can induce 
the sorption and condensation of water on the surfaces of particles and the 
surfaces in which they are in contact. This can cause the formation of liquid 
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bridges and increased capillary forces (Young et al., 2003). Additionally, the 
conductivity and dissipation of charge will increase for particles in a humid 
environment. This is of interest in the field of respiratory drug delivery, since the 
humidification of the airways can alter the electrostatic nature of the entrained 
particles (Byron et al., 1997).  
 
1.4.5 The Impact of Particle Size Reduction on the Physico-Chemical 
Behaviour of APIs 
The production of inhaled formulations for DPIs requires active drug particles of 
the respirable size. Traditional methods of crystallisation used in the large-scale 
production of these APIs fail to provide adequate control over particle size and 
engineer particles suitable for pulmonary delivery (Shekunov and York, 2000). 
Particle size reduction is therefore, an essential process in producing these 
materials, as shown in Figure 1.4, upon primary crystallisation process and prior 
to blending. The resulting particles from this technique are adversely affected 
by the high-energy input and relatively uncontrolled nature of the process and 
can lead to detrimental effects in formulating orally inhaled drug products 
(OIDPs) of defined specification (Steckel et al., 2006).   
 
The comminution process of reducing primary drug crystals to a respirable size 
can be achieved by a wide variety of techniques. Commonly used processes in 
DPI production include ball milling, vibration milling and air jet milling (Chow et 
al., 2007).  
 
Jet milling has emerged as the most popular method of particle size reduction in 
the context of DPI formulation (Chow et al., 2007), attributed to its simplicity and 
minimal contamination of processed materials (Katz and Kalman, 2007). These 
mills produce super and ultra-fine materials by particle impaction and attrition, 
using a feed gas pass through a venturi and micronisation chamber at 
supersonic speeds (Brodka-Pfeiffer et al., 2003). Successive collisions between 
particles and the walls of the micronisation system result in the fracture, 
chipping and overall loss of size of the feed material, which then loose inertia 
and pass from the circulating gas into a collecting hopper (Midoux et al., 1999). 
The most important parameters of these systems which can be controlled are 
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the feed rate, feed pressure and grinding pressure (Brodka-Pfeiffer et al., 2003) 
(Katz and Kalman, 2007). The extent of comminution will largely be determined 
by the particle size and mechanical properties of the input material (Kwan et al., 
2004), including pre-existing crystal flaws and material ductility (de Vegt et al., 
2008). 
 
Since the number of collision events taking place for each individual particle is 
uncontrolled, output product characteristics such as shape, morphology, 
surface properties and electrostatic charge are largely unpredictable (Steckel et 
al., 2003) (de Vegt et al., 2005). Moreover, the relatively high input energies 
subjected to the material can induce a loss of crystallinity (Ogura and Sobue, 
1970) and lead to chemical and physical changes within the product (Begat et 
al., 2003) (De Gusseme et al., 2008).  
 
The micronisation process can lead to disordered, metastable regions on the 
crystal surface, inducing mechanical or surface activation of crystalline 
materials (Begat et al., 2003) (Brodka-Pfeiffer et al., 2003). These changes 
have been associated with agglomeration and particle size changes (Ng et al., 
2008) and have been show to lead to changes in the in vitro and in vivo 
performance of the formulation  (Steckel et al., 2006).    
 
1.5 Characterisation of Pharmaceutically Processed Materials  
 
From the previous sections, it is evident that the processing of active 
pharmaceutical ingredients and excipients by micronisation or blending can 
result in changes to the physical and chemical nature of these materials. With 
reference to Figure 1.4 we can see that the quality control and quality 
assurance testing is only performed once a product is formulated. After this 
process, the product is either rejected or accepted against pre-determined 
parameters (Tougas et al., 2009). To date, in vitro cascade impaction testing is 
the only QC tool used in relating pharmaceutical formulation development, 
production and batch release (Chow et al., 2007). However, a number of 
analytical techniques of bulk powders and individual particles aim to relate one 
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or more properties to the final performance of the DPI formulation and may 
provide information a priori relating the functionality of the final product prior to 
formulation. This section aims to review some of the commonly employed 
methods in evaluating the differences found in the crystallinity, interfacial 
energy and interactive forces of particulate systems in order to relate those 
findings to DPI performance.  
 
1.5.1 Crystallinity 
The stresses placed on crystalline materials during processing can lead to 
disorders and defects within the crystal lattice and may lead to thermodynamic 
changes to the crystalline form in addition to stability and performance 
modifications to formulated products. The use of appropriate analytical methods 
in detecting these changes is evident in regulatory interest in controlling and 
defining acceptable limits of these changes throughout the development and 
manufacturing process (Yu, 2008). This section highlights some of the key 
analytical approaches in detecting the changes in crystallinity of bulk 
pharmaceutical samples.        
 
1.5.1.1 Thermal Analysis 
The thermal analysis of materials using techniques such as differential scanning 
calorimetry (DSC) are most often used as a tool in evaluating a material’s 
response to heat and can be used to accurately quantify enthalpic transitions of 
small quantities of material (Clas et al., 1999), including those used within DPI 
formulations. DSC is often used to investigate the physico-chemical changes 
that result as a function of processing, for example the loss of crystallinity by 
milling (Wildfong et al., 2006). While studies have aimed to investigate the 
correlation between measurements of amorphous content via thermal analysis 
and aerosolisation performance (Velaga et al., 2004), the relative insensitivity in 
detecting non-crystalline domains of bulk samples lower than 5% (Lappalainen 
and Karppinen, 2010), limits the use of DSC for the quantification of discrete 
changes to a material (Saunders et al., 2004).  
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Isothermal microcalorimetry is another such technique used to investigate 
formulation components. The continual monitoring of thermal events occurring 
within a sample held under constant temperature can be used to assess 
enthalpic transitions with greater sensitivity compared to DSC (Dilworth et al., 
2004). A thermal activity monitor was used to perform analysis on salbutamol 
sulphate samples micronised at different grinding pressures (Brodka-Pfeiffer et 
al., 2003). The group found that increasing pressures resulted in detection of a 
greater amount of non-crystallinity and that after 6 bar, increasing the pressure 
resulted in non-crystalline response, with no change in particle size.  
 
1.5.1.2 Dynamic Vapour Sorption (DVS) 
Highlighted previously in this section, the external environment, namely the 
relative humidity that a DPI formulation is exposed to, can alter the 
interparticulate forces within a blend and has previously been shown to affect 
aerosolisation efficiency of binary formulations (Das et al., 2009). Dynamic 
vapour sorption enables the accurate measurement of the tendency of solids to 
take up water vapour from the atmosphere at a constant temperature during 
changes in relative humidity (RH) (Newman et al., 2008). This uptake of water, 
termed hygroscopicity, is often investigated during the preformulation process in 
order to assess physical and chemical stability of materials, including those that 
have been processed (Newman et al., 2008). The change in mass associated 
with water sorption can be characteristic of a recrystallisation process for 
crystalline materials with a degree of disorder, often as a result of processing or 
the crystallisation process. Dynamic vapour sorption is therefore, often used in 
the detection of non-crystallinity (amorphous content) within bulk samples and 
has been shown to resolve levels down to 0.5 % in lactose samples (Steckel et 
al., 2006). In the context of the DPI formulation process, investigation into 
lactose blending highlighted differences in moisture uptake of blends directly 
after processing and after storage (Bridson et al., 2007) indicating that the 
power input associated with shear blending can result in functional changes to 
the formulation. Additionally, detection of recrystallisation of salbutamol 
sulphate after milling revealed process-induced disorder of this API by DVS 
analysis, indicating that stresses placed onto the material during micronisation 
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had resulted in measurable disruption to the crystallinity of the subsequent 
material (Brodka-Pfeiffer et al., 2003). 
 
1.5.1.3 X-Ray Powder Diffraction 
Identification of the crystal structure of APIs produced by different crystallisation 
process is vital in identification of the physical structure of the crystal lattice. 
Inclusion of solvates, hydrates or the crystallisation of different polymorphs 
require detection as these changes can lead to physico-chemical differences in 
the material (Datta and Grant, 2004). This technique has been shown to identify 
differences in the diffraction profiles of a non-steroidal anti-inflammatory 
crystallised using different organic solvents (Di Martino et al., 2007) and the 
identification of different polymorphic forms of API (Jarring et al., 2006) (Perkins 
et al., 2009). Additionally, XRPD has been used to identify the presence of two 
APIs in crystals engineered for inhaled delivery (Westmeier and Steckel, 2008) 
(Pitchayajittipong et al., 2009). The effect of milling on APIs has also been 
investigated using XRPD to identify the polymorphic transition of fananserine 
during the mechanical process (De Gusseme et al., 2008). The use of this 
technique however, is not sensitive enough to quantify the relative changes in 
crystallinity.  
 
1.5.2 Methods of Surface Energy Determination 
The detection of changes in material crystallinity provides information relating to 
the impact of processing operations in the changes to thermodynamic 
properties of materials but does not directly asses the impact on interparticle 
forces. Therefore, techniques that quantify the interactive forces of processed 
materials may offer additional understanding on how these materials may 
behave in a DPI formulation, where the interparticle forces underpin the 
aerosolisation and efficiency of drug delivery.  
 
1.5.2.1 Contact Angle Measurement 
This technique encompasses the measurement of contact angles between 
liquids and solid surfaces. In many cases, the compaction of a powder sample 
is used as the investigational material and the measurement of the resulting 
Chapter 1:  
 
 34 
droplet angle for several liquids of known polar and dispersive components is 
performed (Planinsek et al., 2001). Using the method of Good and van Oss, 
three different liquids of known nonpolar, acid (electron acceptor) and base 
(electron donor) components are measured to quantify surface free energy as a 
function of Lifshitz-van der Waals (nonpolar) and acid-base (polar) components 
(Van Oss et al., 1988). The use of such a technique has been shown to be 
beneficial in the general physico-chemical assessment of material wettability 
(Good, 1992) and differences in material free energy, for relation to adhesion 
against various surfaces (Podczeck et al., 1996). Limitations on the value of 
bulk compact measurements arise from the deformative stress placed on the 
specimens during compaction and the resulting changes in roughness and 
porosity of material as a result (Duncan-Hewitt and Nisman, 1993) and 
therefore, examples of use of this technique alone in the pharmaceutical 
literature are sparse.       
 
1.5.2.2 Inverse Gas Chromatography (IGC) 
A commonly employed approach in determining the interfacial properties of 
pharmaceutically relevant materials is the use of inverse gas chromatography 
(IGC). In this technique, the material of interest is packed into a column and the 
time required for a gas probe to pass through is determined. By measuring the 
retention times of a series of probes of different polarity, the surface free energy 
as well as other parameters can be qualitatively determined (Grimsey et al., 
2002).  
 
IGC has routinely been used to investigate differences in interfacial properties 
of milled materials and supercritically engineered particles (Tong et al., 2002) 
(Schiavone et al., 2004), where stable samples produced supercritically were 
found to have a lower surface energy than those that were crystallised and then 
milled. More recently, work by Das et al. investigated the effect of humidity on 
the surface free energy of coarse lactose and milled salmeterol xinafoate. They 
found an increase of surface energy related directly to increases of relative 
humidity, leading to increases in capillary forces. Furthermore, these change 
also led to increases in the emitted fraction of powder formulations from a DPI 
device, attributing the agglomerative nature of capillary forces on powders, to 
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better flow properties and therefore improved device emptying (Das et al., 
2009). A combined approach of atomic force microscopy (AFM) and IGC 
measurements have highlighted the different surface free energies of different 
forms of carbamazepine (Perkins et al., 2009), while investigations into bovine 
serum albumin spray-dried into two forms showed no difference in IGC, the use 
of AFM imaging has revealed differences in surface roughness  leading to 
differences in DPI performance (Adi et al., 2008). 
 
      
1.5.3 Measuring particle removal efficiency  
Key to the delivery of active ingredients by DPI formulations is the effective 
removal of drug particles from the carrier surface. Approaches that enable the 
measurement of particle forces against other surfaces are routinely used to 
evaluate the particle removal efficiency. This section addresses the use of 
these methodologies in developing tools to predict the entrainment and delivery 
profile of DPI products.  
 
1.5.3.1 Centrifugal Techniques  
Though classed as a bulk technique, the use of centrifuge measurements 
enables the investigation of adhesional forces between particles and 
investigational surfaces (Podczeck et al., 1996). Briefly, samples are placed 
onto a disk located on a centrifuge and a given load (press-on force) is applied 
to the particles by rotating the disk facing inwards. Subsequently, particles are 
counted and then mounted facing away from the centre and samples are 
rotated in a series of progressively increasing speeds, recording the number of 
particles remaining after each speed. While this process is relatively cheap and 
requires low quantities of sample, single particle measurements cannot be 
performed and generation of data relating to particle-particle interactions is 
limited.  
 
1.5.4 Single Particle Investigations of Interfacial Forces 
Bulk measurement techniques of pharmaceutical materials provide a useful 
means of investigating a broad population of particles. However, results are 
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often limited in providing in-depth understanding, due to the heterogeneous 
nature of the materials under investigation. Single particle investigations 
therefore, enable the measurement of properties independently from the 
influences of the bulk and are useful in quantifying interfacial properties of 
materials by the use of multiple measurements of different individual particles.   
 
1.5.4.1 Colloidal Probe Atomic Force Microscopy 
The atomic force microscope enables the investigation of interactive forces 
between a cantilever based probe and interacting surface at a nano-Newton 
resolution (Cappella and Dietler, 1999). By replacing the cantilever tip with a 
colloidal probe, interactions between a substrate sample and micrometer sized 
particles can be investigated. Unsurprisingly, this form of measurement has had 
significant implications to the field of DPI formulation, as the interactive forces 
between inter-particle components play a critical role in the behaviour of these 
mixtures (Roberts, 2005). Initial work in this area was limited, due to the 
irregular nature of particles attached leading to significant variations in contact 
area between the probe and substrate surface. Two refined approaches have 
overcome this issue by either quantifying the contact area directly or interacting 
the same colloidal probes with smooth surfaces of interest.  
 
Using a test grating containing a uniform series of sharp spikes of defined size 
and geometry, a raster-scanned image of an interacting probe can be reverse 
imaged and deconvoluted to quantify a 3D image of the tip (Hubner et al., 2003) 
(Clifford and Seah, 2005a). These data can then be used to determine tip 
sharpness parameters and effective contact areas for particles attached to 
modified cantilevers. Once these parameters have been determined, interactive 
forces can be calculated between these particles and investigational materials 
by interactive measurements between the two materials. Using JKR theory, 
which accounts for surface forces occurring within the contact area only 
(Johnson et al., 1971), or DMT theory whereby adhesion forces are deemed to 
occur outside the contact area (Deryaguin et al., 1978), this technique can 
quantify surface energies and work of adhesion. Work by Hooton et al. using 
this approach has demonstrated the possibility of normalising particle adhesion 
data from different particles by calculating force per unit area in order to show 
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differences of adhesional forces for salbutamol sulphate prepared in two very 
different manners (Hooton et al., 2004). Further work demonstrated the use of 
this approach alongside bulk IGC measurements for milled and unmilled 
budesonide (Davies et al., 2005). The group found variability in values obtained 
from AFM measurements, attributing these to orientational differences between 
the different particles fixed onto the cantilevers, drawing attention to the 
limitations and complexity arising from individual particle measurements. The 
values obtained for IGC measurements of micronised materials, though 
different to AFM measurement, did highlight the complimentary nature of each 
technique in understanding the physico-chemical interactions between 
materials of DPI formulation interest.    
 
Another approach using colloidal AFM is to interact individual particles of 
interest to two smooth surfaces of substrate crystals, one of the same material 
and another of the excipient. Without the need of quantifying the true contact 
area of the investigational probe, AFM measurements of interparticle forces 
using this methodology provides a ratio of the thermodynamic work of cohesion 
to adhesion. From these measurements, the force of cohesion (drug-drug) and 
force of adhesion (drug-excipient) can be obtained and by dividing the cohesive 
force over the adhesive force, a cohesive-adhesive balance (CAB) value is 

















Figure 1.5 A representative graphical description of a CAB-graph for a binary system 
(Adapted from Begat et al., 2004) 
 
where Fcoh and Fadh are the cohesive and adhesive forces measured by AFM, 
and Wcoh and Wadh are the thermodynamic work of cohesion and adhesion, 
respectively (Traini et al., 2005). The use of multiple colloidal probes in this 
approach negates the need to quantify the spring-constant for each cantilever, 
as the thermodynamic ratio of the work of cohesion and adhesion interactions 
extrapolated from surface interaction measurement are assumed to follow the 
same theoretical model of contact mechanics.   
 
The CAB approach has been demonstrated to observe differences in interactive 
forces with lactose for salbutamol sulphate and budesonide (Begat et al., 
2004b) and the interactions of salbutamol sulphate with different sugar excipient 
crystals (Hooton et al., 2006). Moreover the technique has shown applications 
within a liquid environment, investigating interactions within model liquid 
propellants (Traini et al., 2005) and shown to relate to dry powder inhalation 
delivery (Begat et al., 2004c); whereby micronised budesonide was found to be 
cohesively led in comparison to the adhesively led salbutamol sulphate, 
affecting both the mixing and fluidisation behaviour of each material. 
Additionally, further work found that fluticasone propionate has an adhesion to 
lactose monohydrate 4.55 times greater than the force of cohesion (Jones et 
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al., 2008) and that the performance of these carrier-based formulations could 
be altered by the inclusion of fine particles of tertiary excipient materials.  
 
1.6 Primary Crystallisation of APIs  
 
The process of crystallisation is fundamental to the isolation and purification 
active pharmaceutical ingredients and excipients (Fujiwara et al., 2005) and 
therefore receives significant attention in order to produce a product of defined 
quality standards (Variankaval et al., 2008). As a consequence, this is often the 
final process that determines the physico-chemical nature of primary materials 
for secondary processing. From Figure 1.4 we can see how this step may have 
significant downstream implications in the handling, processing and functionality 
of these materials (Shekunov and York, 2000) (Datta and Grant, 2004). By 
understanding the crystallisation process and its possible impact on the 
physical properties of the resultant crystals, the effects of micronisation and 
subsequent performance of DPI formulations may be better understood.   
 
1.6.1 Background Theory of Crystallisation 
A crystalline solid is defined as being comprised of a rigid lattice of molecules, 
atoms or ions, in a thermodynamically stable order, characteristic of the 
substance (Mullin, 2001). This repeating pattern extends in three dimensions, 
defining internal crystal structure and external crystal morphology for organic 
molecular crystals, which retain this structure by a combination of forces 
including van der Waals, hydrogen bonding, ionic and electrostatic interactions 
(Sheth and Grant, 2005). These can be attractive or repulsive in nature, ranging 
from 0.5 – 150 kJ.mol-1 depending on the type of intermolecular interaction, 
though in the case of most organic crystals, van der Waals and hydrogen bond 
interactions dominate (Datta and Grant, 2004). In many cases the molecules 
being crystallised can be prepared by the careful selection and control of 
crystallisation conditions. In turn, the product can be recovered as native free 
bases (or acids), they can be hydrated, anhydrous or solvated. Each will have 
differences on the pharmaceutical and pharmacokinetic properties of the 
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resulting material and therefore, this process must be optimised to produce 
material of the greatest quality (Variankaval et al., 2008).    
 
1.6.1.1 Nucleation 
The driving force for the nucleation involves the creation of a supersaturated 
solution or the supercooling of a solid melt (Mullin, 2001) (Fujiwara et al., 2005). 
For a solution, this can be created by cooling, evaporation and/or addition of an 
antisolvent, including the addition of an acid or base to change the pH 
(Rodriguez-Hornedo and Murphy, 1999).  Supersaturation is referred to as a 
state in which the concentration of a substance in a solvent at a certain 
temperature and pressure, is greater than the saturated solubility of that 
substance under controlled conditions (Myerson, 1993) and is routinely defined 








where  is the relative supersaturation,  is the concentration of the 
crystallising substance in the supersaturated solution and  is the solubility 
(Rodriguez-Hornedo and Murphy, 1999). 
 
At the point of supersaturation, the solution is not in equilibrium and nucleation 
can occur if a sufficient level of supersaturation can be generated. Prior to the 
point of nucleation the solution is termed metastable, wherein a metastable 
zone exists whereby crystals can grow without nucleation (Myerson, 1993). The 
formation of nuclei from solution, which act as a growth centres for crystals can 
occur in two ways. Primary crystallisation occurs in the absence of crystalline 
surfaces and can be homogeneous, whereby local concentration fluctuations 
give rise to regions of ordered or clustered molecules forming nuclei that grow. 
Primary heterogeneous nucleation occurs where foreign materials in the 
solution or equipment, reduce energy barriers for nucleation, and therefore 
require lower levels of supersaturation for nucleation and crystal growth (Mullin, 
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2001). The nucleation process can be further induced by agitation, changes in 
pressure and ultrasound radiation (Myerson, 1993) (Ruecroft et al., 2005).  
 
The thermodynamic investigations of homogeneous nucleation are based on 
work by Gibbs (Gibbs, 1948) and Volmer (Volmer, 1939), describing the overall 
Gibbs free energy for an aggregate undergoing a phase transition (  
€ 




ΔG = ΔGV + ΔGS  
Equation 1.20 
 
where  is the volume free energy (negative value) and  is the surface 
free energy associated with the with the formation of an aggregate (positive 





ΔG = 4πr 2γ + πr 3ΔGv  
Equation 1.21 
 
when modelling for spherical nuclei of radius  and  denotes surface tension. 
As the value of  is dependent on  and  increases proportionally to , 
upon reaching a critical radius ( ),  increases faster than  enabling the 
growth of the nucleus thermodynamically more favourable than re-dissolution 
(Myerson, 1993). At this point, nucleation is replaced by crystal growth and can 





The rate of nucleus formation is given by the Arrhenius expression  
 






where  is a pre-exponential factor (1030 nuclei.cm-3.s-1) and k is the Boltzmann 
constant (Myerson, 1993). Using the Gibbs-Thompson equation to relate 










By combining Equation 1.22, Equation 1.23 and Equation 1.24, the rate of 
















From Equation 1.25, the rate of nucleation is seen to be dependent on the 
temperature, supersaturation and surface energy. Additionally, surface tension 
increases would lead to decrease of nucleation, promoting the formation of 
nuclei of the lowest possible surface free energy (Myerson, 1993) (Rodriguez-
Hornedo and Murphy, 1999). 
  
1.6.1.2 Crystal Growth  
Once the barriers to nucleation are overcome, nuclei are able to grow into 
macroscopic crystals and this is termed crystal growth. Single molecular units 
are incorporated to a crystal surface over a number of steps including the 
transport of units from the bulk solution to the crystal surface, adsorption of the 
growth unit to the impingement site, diffusion from the impingement site to a 
growth site and incorporation of the growth unit into the crystal lattice 
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From a thermodynamic standpoint, the attachment of units would be favourable 
at point where the greatest surface free energy is found on the crystal surface 
(Nyvlt et al., 1985) and tend to be found in regions where growth units can be 
incorporated to the maximum number of nearest neighbours (Myerson, 1993). 
From Figure 1.6 it can be seen that incorporation at a kink site on a ledge will 
result in the formation of three-unsaturated bonds, a ledge without a kink site 
will result in two bonds and the attachment of a unit to a surface alone will result 
in only one bond (Kossel, 1934). This theory goes some way to explain the 
layer-by-layer nature of crystal growth but fails to incroporate in the model for 




Figure 1.6 The surface structure of a growing crystal (Adapted from Myerson, 1993) 
 
The growth of crystals is a process governed by internal and external factors 
(Rodriguez-Hornedo and Murphy, 1999). A range of growth mechanisms have 
been proposed in the literature (Nyvlt et al., 1985) (Myerson, 1993) (Mullin, 
2001), taking into account the diffusion of molecules, integration of molecules 
within the lattice and the formation of nucleating clusters on crystal surfaces. 
Discriminating between these models, which take into account supersaturation, 
temperature and growth faces, is often difficult in identifying the correct model 
responsible for growth and requires a combined approach of growth theory and 
topographical observations (Rodriguez-Hornedo and Murphy, 1999). 
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The growth rate of different crystal faces was shown by Wulff to grow at rates 
proportional to surface energy, leading to an observed crystal habit – the 
external appearance of the crystal. The crystal habit can vary, largely based on 
the rate of nucleation and crystal growth (Abu Bakar et al., 2009). External 
factors surrounding solvent environment, presence of impurities and 
temperature can modify the rate of growth on specific faces. This can lead to a 
change in the rates of growth on various faces and in turn, affect the crystal size 
distribution (Mullin, 2001).  
 
1.6.2 Effect of Solvents and Impurities on Crystallisation  
A crystal is internally composed of a repeating series of molecules or atoms that 
then form the building blocks of a solid crystal. The ability of each unit molecule 
to pack in a different manner will result in the formation of polymorphic forms of 
the same compound, which in many cases can result in serious differences in 
the physico-chemical properties of the material (Gardner et al., 2004). 
Moreover, if the repeating internal structure is disrupted in any way, the 
imperfection can lead to displacements within the structure and strain placed on 
the lattice structure. These imperfections can be substitutional, whereby a 
foreign particle occupies the area in which the unit cell was to be incorporated, 
or the space between unit molecules/atoms can be occupied a foreign element 
and is termed interstitial impurity. Where a unit has failed to be incorporated 
and a void exists, it is termed a vacancy. These three imperfections are classed 
as point defects since they involve a single point within a lattice (Myerson, 
1993). Other defects termed line dislocations and screw dislocations represent 
line defects, which are found in most crystals (Mullin, 2001). These arise due to 
miss-alignment of molecules within the lattice, resulting in spiral growth and 
miss matching of boundaries, producing crystals of varying physical, thermal 
and mechanical properties (Mullin, 2001). 
 
The crystallisation of organic materials from solution can be greatly affected by 
the solvent used. Solvent-solute interactions can influence the mass transfer of 
solute to the crystal surface while the degree of solute solubility will determine 
the resulting mass (yield) of crystals obtained (Myerson, 1993). Moreover, 
altering the kinetics of crystal growth is known to change the crystal habit 
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(Garekani et al., 2001) (Banga et al., 2007) and alter the polymorph formed 
(Parmar et al., 2007). In the screening of solid forms, solvent selection is based 
on a wide range of parameters including a broad distribution of solution 
properties (density, viscosity, polarity), purity, solvent toxicity, chemical 
reactivity and environmental impact (Myerson, 1993) (Camarasu et al., 2006) 
(Aaltonen et al., 2009). Often, mixtures of solvents are tested, with water-
solvent mixtures favoured in the screen for hydrates of desired pharmacokinetic 
properties (Aaltonen et al., 2009). 
 
Impurities, either from the solvent or introduced by other means, can have a 
significant effect on the growth of crystals and the strength of the resulting 
intermolecular bonds, leading to further changes in crystal habit and 
consequential impact on future processing (Wood, 2001). Apart from changes 
in solution properties, for example metastable zone width and solubility 
parameters, impurities can lead to preferential adsorption of solute molecules to 
different faces (Mullin, 2001) (Fiebig et al., 2007). These effects can occur as a 
result of impurities being adsorbed to an immobile position on the crystal 
surface, reducing or blocking the advancement of growing crystal layers. In 
contrast, mobile impurities may adsorb to the surface of a growing crystal and 
relocate by diffusion, in two dimensions over the surface. The relative effect this 
type of impurity will have on the growth kinetics of a crystal will be determined 
by the relative mobility of the impurity. Specific studies investigating the kinetics 
of both types of impurities were postulated by Cabrera and Vermilyea (1958) 
and the reader is directed to that reference e literature for further details 
regarding this topic.     
 
1.6.3 The Mechanical Properties of Crystalline Materials  
The crystallisation of pharmaceutical materials is known to influence a variety of 
processing factors that may then lead to changes in the functionality of the 
resultant product (Edge et al., 2008). One key process mentioned previously, is 
the milling of crystals into the respirable size range. Mechanical properties of 
these materials, processing conditions of the mill and pre-existing flaws and 
imperfections in the crystalline material are known to affect particle fracture 
(Rumpf, 1973). The size reduction efficiency therefore, is largely a function of 
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the material properties (material function) and the ability of loads exerted from 
the milling process or particle-particle collision being transformed into the 
propagation of fractures within the solid materials (Teipel, 2004). It has been 
shown that three material functions are highly influential on the breakage of 
solid materials; Young’s modulus ( ), hardness (H) and critical stress intensity 
factor (Kc) (Ghadiri and Zhang, 2002) (Kwan et al., 2004), representing the 
resistance of a material to elastic deformation, plastic deformation and crack 
propagation, respectively.  
 
Solid material behaviour within the mill can be described as linearly elastic, 
plastic or viscoelastic (Ward and Hadley, 1995) (de Vegt et al., 2006). For a 
linearly elastic material, stress applied to the material is proportional to the 
deformation that occurs and is independent of loading rate (Clifford and Seah, 
2005a). This proportionality factor is a characteristic of one mechanical property 
of a material and is called the Young’s modulus, (also known as elastic 




σ = E.ε  
Equation 1.26 
 
where  is the tensile stress and  is the extensional deformation (Rowe and 
Roberts, 1995) (Teipel, 2004). These elastic-plastic properties determine the 
breaking resistance as well as the formation and propagation of cracks and 
therefore, define the degree of size reduction (Zugner et al., 2006). Moreover, 
as the particle size reduces, materials show a transition from elastic to plastic 
behaviour resulting in increased deformity of the material alongside reduced 
probability of breaking (Shekunov and York, 2000) (Teipel, 2004).  
 
1.7 Methods of Measuring the Young’s Modulus of Organic 
Materials 
 
The elasticity of a material has significant implications for a wide variety of 
pharmaceutical preparations, notably in the production of tablets (Bassam et al., 
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1990) and the milling behaviour of pharmaceutical ingredients (Zugner et al., 
2006). Understanding the compaction behaviour of excipients and APIs used in 
the production of solid oral dosage forms has relied heavily on various bulk 
techniques such as flexure testing (Roberts et al., 1991) and compression 
testing. These ideas have influenced the understanding of comminution 
behaviour of pharmaceutical materials, relating to the processing of inhaled 
formulations, though limitations of these methods have led to advances in 
newer techniques such as the indentation of single crystals. The use of acoustic 
pulse monitoring has also evolved in determining the elastic modulus of 
compacts (Akseli et al., 2009) but will not be discussed in this work.   
 
1.7.1 Flexure Testing (Beam Bending) 
A traditional method of measuring the Young’s modulus using a bulk approach 
involves the creation of a beam of test material within a special punch and die 
at different compression pressures to achieve a range of porosities (Rowe and 
Roberts, 1995). This rectangular beam is then subjected to a transverse load 
and the deflection caused by bending of the beam is measured. If the beam is 
supported at two points and loaded at two, it undergoes a four-point beam 
bending (Bassam et al., 1990), while if it supported at two points but loaded at 
one, it is known as three-point beam bending (Roberts et al., 1991). Initial tests 
using these methods required 15-20 g of material for four-point bending 
experiments and although modification of the three-point bending method 
required approximately 200 mg, this technique is often considered as expensive 
and time consuming (Masterson and Cao, 2008).  
 
1.7.2 Compression Testing 
This method relies on applying a compressive stress onto a compact or single 
crystal and measuring the corresponding strain to calculate the compressive 
Young’s modulus of elasticity (Leigh et al., 1967) (Leuenberger and Rohera, 
1986). Compression testing of compacts similarly requires repeated 
measurements of specimens of various porosities while single crystal 
techniques can be influenced by crack propagation of the material (Rowe and 
Roberts, 1995), again limiting its use for accurate characterisation.  




1.7.3 Nanoindentation Measurements 
Indentation tests rely on applying a given load to the surface of a sample with 
an indenter of defined geometry, recording the penetration depth of the probe 
and in many cases, the material response after loading. The most common 
probes used in this technique are square-based pyramid (Vickers indenter), 
three-sided pyramid (Berkovich indenter) and spherical ball (Brinell indenter) 
(Meier et al., 2008). These indenters are produced from hard materials such as 
diamond, sapphire, steel or silicon and are chosen based on the samples being 
investigated and the operating parameters while taking into account the 
measurements required from the instrument.  
 
As techniques of fabricating various instrumental components have developed, 
increasing resolution and control over loading forces and penetration depths 
have enabled the application of loads ranging between 10-5 and 10-2 N resulting 
in recorded penetration depths in the nanometre range (Fraxedas et al., 2002). 
Many instruments are now commercially available to perform nanoindentation 
tests using a rigid probe placed on a pendulum (Nanotester, Micromaterials, 
UK) or by application of a voltage over capacitive plates resulting in probe 
movement (Triboindenter, Hysitron Inc., USA). These approaches rely on the 
elastic recovery of a sample after a set load is placed at a given loading rate 
and then withdrawn. Marked hysteresis between the loading and unloading 
portion of the curves are seen (Figure 1.7) and data from such plots can be 
extrapolated to obtain the elastic modulus and hardness of a material (Oliver 
and Pharr, 1992). Moreover, if the cracks formed from the indentation can be 
measured, the fracture toughness (Kc) can also be determined (Ponton and 
Rawlings, 1989).  
 
Work by Liao and Wiedmann (2005) used this technique to observe differences 
in the mechanical properties of acetaminophen (paracetamol) and potassium 
chloride produced by rapid (quenched) or slow recrystallisation methods. For 
the quenched samples, where crystallisation occurs rapidly and in a relatively 
uncontrolled manner, the measured Young’s modulus for each sample was 
higher that those recrystallised slowly. These results were attributed to 
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differences to the dislocation propensity of each of the materials (Liao and 
Wiedmann, 2005). The effect of crystal face was also investigated by Ramos 
and Bahr on slowly grown sucrose crystals, highlighting the different elastic 
limits of each face (Ramos and Bahr, 2007). Additionally, work by Taylor et al., 
identified the use of nanoindentation in determining differences in the 
mechanical properties of a wide range of pharmaceutical ingredients (Taylor et 
al., 2004b), aiming to relate differences to milling behaviour of these materials 
(Taylor et al., 2004a). 
 
 
Figure 1.7 A representational load versus displacement graph obtained from a single 
nanoindentation experiment (Reproduced from Taylor et al., 2004) 
 
 
Atomic force microscopy has emerged as another important tool in the 
assessment of nanoscale properties of a wide variety of materials (Cappella 
and Dietler, 1999). Force-distance curves, whereby a cantilever and probe of 
defined stiffness and contact area can be loaded perpendicularly (z-axis) upon 
a sample, enable the investigation of indentation depths of single crystals. From 
these experiments and use of contact mechanics, various mechanical 
parameters, including the Young’s modulus can be determined.  
 
The Hertzian model of deformation (Hertz, 1881) takes into account the 
deformation of an elastic sphere on a flat surface, neglecting the surface forces 
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or adhesion of the tip on the sample modelled in  Johnson-Kendall-Roberts  
theory (JKR) and Derjaguin-Müller-Toprov Theory (DMT). It can be used when 
indentation takes place under low loads and surface interactions are to a 
greater extent, negligible (Cappella and Dietler, 1999). This approach can use a 
hemispherical probe and models the loading curve to extrapolate the elastic 
modulus of a material. Work by Perkins et al. (2007) demonstrated the use of 
AFM nanoindentation on lactose monohydrate crystals and compared these 
results to previously established nanoindentation instruments, using a sharp 
indenter and extrapolation of the unloading curve using the Oliver and Pharr 
approach. The group concluded that AFM, due to its superior resolution and 
non-destructive approach, has significant advantages over the larger indenters 
used and provides a means of accurately measuring the elastic modulus of 
pharmaceutical materials. 
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1.8 Aim of Study 
 
The primary crystallisation of APIs is known to directly influence the physical 
and chemical nature of the resulting material. This thesis aims to investigate 
these differences and in addition to evaluating the effect on the mechanical 
properties of primary sources of APIs. Furthermore, the work aims to highlight 
the possible relationship of the physico-mechanical properties of APIs in 
relation to primary crystallisation with secondary processing of these APIs and 
influence on formulations for carrier-based dry powder inhalation delivery.  
 
The outline of this thesis in relation to the aims is shown in the flow diagram in 
Figure 1.8 below. Chapter 3 will outline the development of an atomic force 
microscope approach in determining the Young’s modulus of different organic 
materials used within the pharmaceutical formulation of orally inhaled drug 
products. In Chapter 4, the role of solvents in determining the elastic modulus of 
primary crystals of fluticasone propionate will be investigated and the effects 
this has on the processing of DPI formulations. Subsequently, Chapter 5 will 
explore the relationship between crystal habit and the mechanical nature of 
budesonide – specifically the affect of crystal habit on the formulation properties 
of a DPI formulation. The final experimental chapter, Chapter 6, assesses the 
implications of the crystal hydrate of ipratropium bromide compared to a 
relatively novel technique of producing anhydrous ipratropium bromide for DPI 
formulation. The general conclusions of this thesis will be presented in Chapter 








Figure 1.8 A flow diagram illustrating the structure of this thesis in relation to the primary 
hypothesis.  
    
Hypotheis: The primary crystallisation of APIs has an 
effect on the secondary processing and functionality of 
these materials formulated for dry powder inhalation 
Chapter 3: Development of a technique to 
determine the elastic modulus of primary crystalline 
APIs used in pharmaceutical DPI formulation 
Chapter 4: Investigation into the role of solvents in 
the primary crystallisation and secondary processing 
of Fluticasone Propionate formulated for DPI 
delivery 
Chapter 5: The influence of crystal morphology on 
the primary crystallisation and secondary processing 
of Budesonide for DPI delivery 
Chapter 6: The effect of crystal hydrate on the 
mechanical properties and  secondary processing of 
Ipratropium Bromide for DPI delivery 
Chapter 7: General conclusions 
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Chapter 2: General Methods and Materials 
2.1 General Physicochemical Characterisation  
2.1.1 Overview 
Dry powder inhalation formulations contain drug particles of respirable size 
blended with coarser carrier particles. The physical and chemical properties of 
these materials are known to affect the quality and performance of the resulting 
formulation. Characterisation of the primary crystals and processed materials is 
therefore, essential in developing efficient processes and effective DPI 
products. This section provides details relating to the specific techniques used 
to comprehensively test components of DPI formulations, including the 
topographical, morphological, thermal and crystal properties. Additionally, in 
order to measure the effect these variables have on the final product, the in 
vitro testing of DPI performance is also detailed.    
  
2.1.2 Scanning Electron Microscopy  
The shape and size of materials used in the formulation of inhaled products is 
known to influence the resulting performance (Timsina et al., 1994a). Scanning 
electron microscopy (SEM) provides high-resolution images from 20-100,000 
times magnification enabling the visualisation of individual particles and their 
surfaces (Hickey et al., 2007a).  
 
Images are produced by the use of electrons generated by an electron gun and 
focused on to a spot on the specimen through a series of magnetic lenses. This 
collimated beam of electrons is raster scanned across the sample and the 
secondary electrons produced on each spot are detected and amplified. These 
signals are then processed to produce a final image. To prevent divergence of 
the electron beam and because of the high acceleration voltages required, 
usually between 0.5 – 50 kV, SEM is carried out under vacuum. Moreover, 
since the surface of the sample must be conductive, a thin layer of gold is 
coated upon an electrically grounded specimen. 
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Though various image analysis software platforms exist that quantify geometric 
parameters of materials imaged in this manner, SEM has widely remained as a 
qualitative approach in pharmaceutical material size analysis. This is partly due 
to the large number of particles required to be measured for statistical 
significance, operator related bias in sampling or dispersion of materials and the 
complex process of distinguishing between agglomerates within a given image.     
  
2.1.3 Particle Size Analysis 
The particle size of APIs and excipients used in pharmaceutical formulation is 
known to affect various rheological and pharmacokinetic parameters and will 
largely influence the safety and efficacy of formulated drug products (Shekunov 
et al., 2007).  For DPIs, the determination of particle size distribution (PSD) is 
critical since any changes may result in significant variations in the blending 
properties, fluidisation, aerosolisation and performance of the inhaled 
formulation (Timsina et al., 1994a) (Shur et al., 2008). Techniques such as 
sieving, sedimentation, electrozone sensing, microscopy and cascade 
impaction can be used in obtaining the PSD of particulate material.  
 
Laser diffraction (low angle laser light scattering (LALLS)) is routinely used in 
the rapid and accurate measurement of particle size for components of inhaled 
formulations (de Boer et al., 2002) (Zeng et al., 2007) and can be used in the 
wet or dry dispersion state. When particles pass thought light, a diffraction 
pattern is scattered, with smaller particles scattering at larger angles. 
Furthermore, in certain materials, light is also reflected, refracted and absorbed, 
depending on the light source, particle size and optical properties of the 
material being investigated (Keck and Mueller, 2008). In the most popular 
LLALS systems, a monochromatic laser is scattered by particles dispersed in its 
path, as shown in Figure 2.1. The incidental light that has been diffracted is 
then focused onto a multi-element detector from which these patterns are then 
integrated to derive a volume-weighted distribution of volume equivalent 
diameters (Shekunov et al., 2007 (Keck and Mueller, 2008).       
 




Figure 2.1 Scattering phenomena that occur when particles are illuminated with light 
(Reproduced from Keck and Mueller 2008) 
 
Two models are used in LALLS in derivation of the complex diffraction patterns 
of light scattering by particles, Mie theory and Fraunhoffer diffraction. The first 
requires knowledge of the refractive index (RI) of the materials being 
investigated and makes the assumption that all particles are smooth spheres, 
calculating the particle size from the measured angle of scatter combined with 
the optical properties of these materials (Mie, 1908 (Keck and Mueller, 2008). 
For materials of unknown RI, variable shape and particle size greater than the 
wavelength of the operating system, Fraunhoffer approximation can be applied 
to the diffracted light patterns to derive particle size.  
 
2.1.4 Differential Scanning Calorimetry 
Understanding the response of materials to thermal stress has been central to 
the characterisation of pharmaceutical materials. Routinely, differential 
scanning calorimetry (DSC) is employed within the pharmaceutical industry to 
provide detailed information to relating the physical and energetic properties of 
a sample that include, but are not limited to crystallisation, melting, and 
decomposition (Clas et al., 1999). This is achieved by measuring the heat flow 
required to heat and cool a reference and sample at the same rate. Differences 
in this energy required is charted and subsequently provides a thermal 
fingerprint of that sample, a representative example is shown in Figure 2.2. 
Quantitative information relating the endothermic and exothermic properties as 
well as the heat capacity of the sample has been used to identify different 
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polymorphs of the same API (Tong et al., 2001), assess the influence of 
mechanical activation on the physical stability of salbutamol suphate (Brodka-
Pfeiffer et al., 2003) and identify thermal differences between anhydrous and 
solvated forms of the same API (Caira et al., 2007).  
 
Figure 2.2 A representative DSC trace showing the glass transition temperature (Tg), 
recrystallisation exotherm temperature (TC) and enthalpy (ΔHC), melting endotherm 
temperature (Tm) and enthalpy (ΔHf) and onset of degradation. Endothermic transitions 
are down (Reproduced from Class et al., 1999) 
 
2.1.5 X-Ray Powder Diffraction 
X-ray diffraction is commonly employed in the routine solid crystal form 
screening of organic crystalline materials (Aaltonen et al., 2009). It can be used 
to determine the crystal structure and in many cases, used to confirm the 
presence of molecular adducts such as solvates and hydrates introduced by the 
crystallisation process (Datta and Grant, 2004). Development of single crystal 
X-ray diffraction techniques led to the analysis of powder materials using X-ray 
powder diffraction (XRPD), enabling the evaluation of processed materials 
(Harris et al., 2001). Diffraction patterns are obtained by directing a 
monochromatic X-ray beam at a sample and measuring the scattered radiation 
on a detector. By changing the angle between the radiation source, and the 
detector plate, the intensity of detected radiation from the sample can be plotted 
against the angle of incidence. Since crystalline materials are composed of a 
regular lattice, the detected X-rays will correspond to the repeated properties of 
the material, while areas containing disordered regions of reduced crystallinity 
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will produce peaks of little or no definition. These peaks occur only when 




nλ = 2dp sinθ  
Equation 2.1 
 
where n is an integer (the order of reflection), 
€ 
λ is the wavelength of the X-ray, 
dp is the distance between planes of the crystal and 
€ 
θ is the angle between the 
incident X-rays and the crystal surface (Bragg, 1913).  
 




θ are recorded, the crystal structure can be solved 
using the Bragg equation, thereby identifying different polymorphic and solvated 
forms of the same material (Datta and Grant, 2004). 
 
2.2 Atomic Force Microscopy 
2.2.1 Overview 
The atomic force microscope (AFM) was developed by Binnig, Quate and 
Gerber in 1986 from its predecessor, the scanning tunnel microscope (STM) 
and has found uses in varying applications ranging from biophysics to 
particulate science (Cappella and Dietler, 1999). Most AFM systems comprise 
of a microfabricated cantilever probe upon which a laser is focused on the apex. 
With reference to Figure 2.3, reflected laser light is then detected onto a four-
quadrant photodiode detector. A scanner containing a piezoelectric ceramic 
enables the precise (sub-Angstrom (Å)) positioning of samples mounted upon it 
by applying a known voltage against electrodes responsible for x, y and z 
movement resulting in a proportional expansion or contraction of the scanner. In 
the case of a multimode AFM (Bruker Nano AFM,Santa Barbara, CA, USA), the 
sample is moved relative to a stationary cantilever. To ensure that continual 
contact between the probe and the sample is maintained, a feedback loop 
controller can be integrated between the photodiode analyser and the 
movement controller of the piezo scanner. Continual monitoring of a defined 
parameter (cantilever deflection, amplitude, height, etc…) will alter the position 
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of the sample relative to the probe by optimising the piezo scanner position 




Figure 2.3 A schematic representation of an AFM (a) and a photograph of a multimode™ 
AFM (b)    
 
2.2.2 Topographical Surface Analysis 
By raster scanning an AFM probe over a sample surface, deflection of the 
cantilever caused by surface irregularities such as protrusions, dislocations or 
other defects will be recorded on the photodiode detector. These data are then 
processed by dedicated software to provide a 3D image of the substrate 
surface that can subsequently be analysed to provide topographical detail 
relating to the surface parameters such as roughness. There are three 
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fundamental operating modes that can be used to acquire images of substrate 
surfaces. An illustration of each mode is provided in Figure 2.4.  
 
Contact mode AFM was the first surface profiling method whereby an image is 
obtained by keeping the probe at either a constant height or force upon the 
sample. This method has potentially destructive implications for the tip from 
irregular samples or can result in possible damage to soft samples from the 
shear forces produced by lateral movements of the investigational probe (Jalili 
and Laxminarayana, 2004).    
 
With non-contact AFM, the stiff cantilever is resonated at its resonant frequency 
50-150 Å above the sample surface and topographical images are constructed 
by detecting changes in the oscillating frequency, amplitude of phase of the 
probe caused by van der Waals interactions between the probe and the 
substrate surface. Though this technique has been extensively used in the 
tribological investigation of a wide range of materials, drawbacks include loss of 
detail to images as a result of surface water interaction with probe tips (Jalili and 
Laxminarayana, 2004). 
 
The third mode of operation is tapping mode. This technique relies on a fixed 
continual oscillation of the cantilever probe at the resonant frequency, allowing 
intermittent contact of the tip to the substrate surface. The feedback loop 
adjusts for and changes between the tip and the surfaces that are observed by 
the photodiode detector and a topographic image is then constructed from this 
processed data. Tapping mode overcomes the limitations of both non-contact 
and contact modes of AFM imaging and has been developed into a useful tool 
in not only obtaining topographical images, but also mapping the different 
physico-mechanical properties of crystal substrates (Begat et al., 2003). 
 




Figure 2.4 An illustration of different imaging modes with tip and deflection showing 
contact (a), non-contact (b) and tapping-mode (c) tip interactions with a substrate 
 
2.3 Force Interaction Microscopy  
2.3.1 Overview 
Alongside the development of imaging modes, AFM has enabled the 
investigation of cantilever probe and substrate interactions at a given X,Y 
coordinate. If the stiffness of the cantilever is known, the deflection of the 




F = −kx  
     
Equation 2.2 
 
where F is the force acting on the cantilever tip (N), k is the spring constant of 
the cantilever (N.m-1) and x is the cantilever deflection (Colton, 2004). For 
reliable force measurements, the accurate determination of the spring constant 
should be obtained for each individual probe. While this value is often quoted by 
the manufacturer, this nominal value can be up to a factor of two or more in 
error (Clifford and Seah, 2005b) and therefore, true determination of individual 
spring constants are crucial for quantitative analysis. Furthermore, converting 
the deflection signal and the piezo displacement into force and distance values 
requires a conversion factor obtained from a linear fit of the constant 
compliance region. Additional sensitivity is also obtained by calibration of the 
interacting tip on a non-indenting surface such as glass, silica or mica.     
 
A range of forces are experienced by an interacting probe as it comes into 
contact,then withdrawn from the substrate surface and are represented in 
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Figure 2.5. Initially the probe is a large distance from the sample surface and no 
deflection is recorded. As the substrate is brought closer to the probe, long-
range electrostatic forces often provide a repulsive force against the probe, 
recording a cantilever deflection away from the sample. When this distance is 
further decreased, attractive short-ranging van der Waals interactions overcome 
the repulsive forces and, depending on the stiffness of the cantilever, the probe 
jumps to contact with the substrate surface. Once contact is made, the probe 
can be pressed onto the surface with a pre-determined loading force prior to 
withdrawal. Upon retraction of the probe, sufficient force must be given in order 
to overcome the adhesive forces experienced between the probe and the 
substrate surface. Integration of the net difference between the adhesion force 
at the point of pull-off and zero interaction state can then be used to 
determining the energy of adhesion.     
 
 
Figure 2.5 A schematic force-distance curve obtained from AFM using a colloidal probe 
technique. Adapted from (Turner et al., 2007) 
 
These measurements can be performed individually, or similarly to imaging 
modes, within a raster-scan across a substrate surface at a pre-defined X and Y 
interval, providing a force map, highlighting variations of surface adhesion over 
a given area. Modifications of the functional probes used at the apex of AFM 
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cantilevers have resulted in wide application of this technique, replacing the 
nominally sharp probes with materials of interest.    
 
2.3.2 Colloidal Probe Microscopy 
If the integrity of the colloidal probe can be maintained throughout the 
experiment, an approach relating to the cohesive and adhesive properties of the 
interacting particle can be used to provide quantitative measurements.  Known 
as cohesive-adhesive balance (CAB) measurements, individual drug particles 
are interacted with the dominant face of extremely smooth crystals of the same 
drug and excipient, to provide relative forces of cohesion and adhesion 
respectively. By performing these measurements in a force-volume mode, 
whereby a series of measurements are performed with the same cantilever and 
particle over a set area of the substrate crystal, a large number of force-stance 
curves can be extrapolated to quantify the appropriate forces. Using JKR and 
DMT models of deformation, the resulting van der Waals force of adhesion 




FVDW = nπR *Wad  
Equation 2.3 
   
where   
€ 
R * is the harmonic mean of the particle radii (contact radius),  is the 
thermodynamic work of adhesion (mJ.m-2) and  is a predetermined constant 
depending on the selected model (  = 3/2 for JKR and  = 2 for DMT) (Begat 
et al., 2004b). The cohesive-adhesive balance can be calculated by dividing the 
relative forces of cohesion by the relative forces of adhesion and is expressed 
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where  and are the cohesive and adhesive forces measured by AFM, 
and  and  are the thermodynamic work of cohesion and adhesion, 
respectively. When a number of probes are plotted on a graph of cohesion 
versus adhesion, a linear relationship from the ratio of cohesion and adhesion 
by different probes forms a straight line, from which gradient is used to obtain 
the CAB value for that material.  
    
2.3.3 AFM Nanoindentation  
Indentation experiments provide information relating to the elastic, plastic and 
viscoelastic properties of materials (Lee, 2007). The ability of obtaining force-
distance curves using AFM has enabled the investigation of every kind of 
surface under various environments providing high lateral (25 nm), vertical (0.1 
Å) and force (1 pN) resolution (Cappella and Dietler, 1999).  
 
For AFM indentation experiments, the Young’s modulus of a material (E) can be 
obtained by knowledge of the indentation occurring after applying a load to a 
given material. If elastic conditions are maintained, Hertzian mechanics can be 
applied to model the loading curve and extract the elastic modulus. This 
process requires a non-destructive technique in which deformations are 
reversible. Therefore, appropriate choice of operating parameters is crucial for 
the accurate determination of this modulus (Perkins et al., 2007).  
 
As previously mentioned, the Hertz model of deformation operates within the model of 
an elastic sphere deforming a spherical surface ( 
Equation 2.5). In context of an AFM instrument, the radius of the sphere is 
based on the radius of the indenting tip (R) and the loading force determined by 
Hooke’s Law, where   
€ 
k is the spring constant of the indenting cantilever and   
€ 
Δz 
is the relative piezo displacement. The Poisson ratio of the indented material (
€ 
ν












4δ3 / 2R1/ 2
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From this model, it can be seen that the controllable parameters are the loading 
force applied to the material and the radius of the indenting probe. Work by 
Perkins et al. (2007) demonstrated the destructive effect of a smaller radius 
probe on the surface of lactose, showing that Hertzian conditions were not met. 
Moreover, their work demonstrated that loading force, related to cantilever 
stiffness, must only provide enough for indentation within the elastic limits of a 
material. Accurate determination of the spring constant and indenter geometry 
are therefore, vital in quantitative measurement of the Young’s modulus in this 
manner.  
 
2.3.3.1 Data Handling    
The AFM produces a force-distance curve containing data relating to the 
deflection of the cantilever and piezo displacement. These data are required to 
be processed in order to produce two values that can then be used to calculate 
the Young’s modulus, the force placed on the sample by the tip and indentation 
depth of the tip. The following method has been developed from the principles 
based in previously published work (Salerno and Bykov, 2006) (Perkins et al., 
2007) and are outlined in detail below. 
 
During the indentation process, the cantilever deflection is recorded on a 
photodetector and output as a voltage, representing deflection (A-B), which 






(A −B)voltage x instrument sensitivity x attenuation
detector sensitivity  
Equation 2.6 
 
whereby the four-quadrant AFM detector is calibrated to obtain instrument 
sensitivity, attenuation is defined by the operator and detector sensitivity is 
measured from the gradient of deflection versus z-voltage, when in constant  
compliance.    
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The substrate is brought into contact in the z direction to the cantilever as a 
series of stepped movements by the piezo, this z-step size needs to be 




z −step size =
scan size




Both scan size and the number of steps in a scan are assigned by the operator. 
 
The deflection of a cantilever versus the cumulative z-step are charted to 
produce a plot similar to Figure 2.6 
 
Figure 2.6 A representative deflection versus cumulative z-step for a single 
nanoindentation experiment performed using AFM  
 
From the plot of cantilever deflection versus cumulative z-step the point of 
contact is determined. From here, the deflection and z-step are set as the origin 
and the points proceeding from contact to end of indentation are adjusted using 
the change in deflection and calculated z-step size from the y and x axis 
respectively.  
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The values of the zeroed z-step and deflection for the sample are compared to 
the indentation profile of the reference material. Since the reference (non-
indenting) material provides greater elastic resistance to the probe, it should be 
higher, since the probe will indent the sample in situations where operating 
parameters are optimal. If there is no difference at this point, the measurement 
is discarded, as there may be false engagement of the probe, incorrect 
operating parameters or other irregularity.  
 
Next, the loading force of the tip on the sample is calculated using Hooke’s Law 
(Equation 2.2). This requires the spring constant of the cantilever, the distance 
travelled by the piezo (cumulative z-step) and the constant compliance value 




loading force (N) = z −step x spring constant x constant compliance  
Equation 2.8 
  
The indentation of the probe with the sample is obtained by the difference 
between the deflection of the probe recorded for the reference and sample 
under the same load. This value is then converted to metres, raised to the 
power of 3/2 and plotted on the x-axis against the loading force to produce 








Figure 2.7 A representative nanoindentation plot of loading force versus indentation 
obtained from an AFM experiment 
 
From the plot of loading force versus indentation3/2 a gradient is obtained. Alongside this 
value and the other parameters that include tip radius and Poisson ratio, the Young’s 
modulus is calculated using the Hertzian model of deformation ( 
Equation 2.5).  
 
2.4 In vitro Testing of Inhaled Drug products 
 
In order to assess the performance of inhaled drug products, in vitro techniques 
utilise the principles of particle impaction and impingement (de Boer et al., 
2002). The US and European Pharmacopeia describe five different cascade 
impactors/impingers suitable for the characterisation of fine particles and 
selection of appropriate technique is based on the product being tested and the 
detail of particle size required from the assay. These techniques provide 
measurements based on the aerodynamic particle size of the materials being 
tested, taking into account particle shape, size density and viscosity. Moreover, 
they provide a means of recovering and quantifying the amount of active 
Chapter 2:  
 
 68 
pharmaceutical ingredient contained in the aerosol cloud, separate from the 
particle size distribution of other excipients. For these reasons, these 
techniques are routinely used in the development and quality control of DPIs. 
 
2.4.1 Next Generation Impactor (NGI) Testing   
The principle mode of operation for cascade impactors, with respect to DPIs, 
relies on the aerosolisation of a unit dose that is drawn through an impactor by 
means of a laminar air stream. The aerosol stream passes through a series of 
stages within which nozzles or jets are directed towards plates of impaction. 
Particle deposition on each stage is dependent on its aerodynamic size and as 
each stage becomes progressively smaller as a function of jet/nozzle size, 
particle deposition becomes finer until all remaining particles are collected on a 
filter stage (Mitchell et al., 2007).  
 
 
Figure 2.8 Next Generation Impactor (NGI) (Adapted from http://www.mspcorp.com) 
 
The Next Generation Pharmaceutical Impactor (NGI), shown in Figure 2.8, was 
launched in 2000 as a result of developments by a group of prominent 
pharmaceutical companies to produce a device specific for pharmaceutical 
inhaler testing. It comprises of seven stages, plus a micro-orifice collector 
(MOC) and operates by vacuum pump at a range of 15 – 100 L.min-1.   A 
standardised induction port containing a 90° bend is connected to the inhaler 
device via a mouthpiece adapter and entrance of the NGI in order to mimic the 
human throat. A vacuum pump is then set to a desired flow rate in order to 
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produce a reproducible pressure drop across the inhaler and actuated to draw a 
specific volume of air under sonic conditions.  
 
 
Figure 2.9 A schematic representation of particle impaction through a NGI nozzle 
(Adapted from http://www.copleyscientific.com) 
 
Within the NGI, particle deposition (illustrated in Figure 2.9) occurs as a result of 
two forces; hydrodynamic forces caused by airflow changes and particle 
momentum. For a set nozzle diameter and flow rate, particles will impact on a 
collection plate. The efficiency with which particles of varying size impact onto a 
given stage follows a sigmoidal function and the cut-off diameter give for each 
stage is described as the aerodynamic diameter for which 50% of particles 
impact (Marple et al., 2003). The cut-off diameter of each stage can be 














µ is the air viscosity,   
€ 
nn is the number of nozzles on the stage,   
€ 
ρae  is unit 
density (i.e., 1 g.cm3),   
€ 
Q  is the total volumetric flow rate through an impactor 
stage and   
€ 
St50 is the Stokes number at 50% collection efficiency.  
 
When operated at a flow rate of 60 L.min-1, the cut-off diameters of each NGI 
stage exhibit as follows: 
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• Throat and pre-separator:  >12.8 µm 
• Stage 1:    8.06 – 12.8 µm 
• Stage 2:    4.46 – 8.06 µm 
• Stage 3:    2.82 – 4.46 µm 
• Stage 4:    1.66 – 2.82 µm 
• Stage 5:    0.94 – 1.66 µm 
• Stage 6:    0.55 – 0.94 µm 
• Stage 7:    0.34 – 0.55 µm 
• MOC     0.14 – 0.34 µm 
 
The fine particle dose (FPD) can, therefore, be defined as the mass of drug 
deposited on stage 3 and below (<4.46 µm). 
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Chapter 3: Investigation of the Mechanical and Surface 





Successful delivery of active pharmaceutical ingredients (APIs) to the lung 
using dry powder inhalers (DPI) requires particles to be less than 5 µm.  As a 
result, APIs intended for delivery to the lungs usually undergo intense 
processing using air-jet mills to reduce the particle size of the primary API 
crystals to enable delivery of the therapeutic agent to this region. These 
micronised particles of the API are then blended with large carrier particles of 
lactose monohydrate to form an adhesive mixture, which enables accurate 
metering of the dose and improves flow properties to aid device filling. The 
force generated upon the patient’s inspiration then aids the fluidisation and de-
aggregation of the fine API particles from the lactose.  
 
The complex nature of the surface interfacial interactions between drug and 
excipient within a DPI blend governs the overall relationship between device 
and de-aggregation efficiency of the formulation and therefore, directly 
influences the functionality and therapeutic effectiveness of the drug product. 
Subtle variations in the processing of materials for inclusion in DPI drug 
products will impact the surface interfacial free energy of the components, 
which may affect the performance and efficacy of the final drug product. It is, 
therefore, important to understand the relationship between material processing 
and material physicochemical properties to produce DPI drug products with the 
desired performance and stability attributes. 
 
Current pharmaceutical manufacturing processes of APIs for use in DPI drug 
products remains empirical and are not designed efficiently with the desired 
functionalities. The future of pharmaceutical manufacturing of APIs for DPIs, 
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therefore, is the generation of products with well-defined properties and 
functionality. This is the primary goal of pharmaceutical product engineering, 
which is achieved through control of the ‘property function’ of a product. 
 
The ‘property function’ was initially defined by Rumpf and further developed by 
Peukert (Vogel and Peukert, 2005) as the relationship between the 
physicochemical properties of particulate systems (i.e., particle size, 
morphology, surface properties) and product properties.  A further consideration 
in producing products with well-defined properties is the ‘process function’, 
which relates specific process parameters (e.g. air-jet micronisation) to the 
physicochemical properties of the product (Vogel and Peukert, 2005). Hence, 
both the process and property functions must be known, understood and 
controlled in order to achieve products with defined functionality and properties 
that have been built in by design (Vogel and Peukert, 2005). 
 
Current pharmaceutical manufacturing strategies for DPI dosage forms, 
generally involve the engineering of the API into specific crystalline forms. The 
API crystals are then processed into particles to the required particle size range 
using destructive ‘top-down’ strategies such as air-jet milling and then 
formulated into dosage forms. Although it is possible to control particle size of 
materials using such processes, the control of particle surface properties and 
morphology is extremely difficult. The inability to control surface properties of 
micronised materials is directly related to variability in the performance of the 
drug product, because small differences in batch-to-batch preparations can 
result in extreme variations in surface properties of processed materials and 
therefore, equivalent batches may possess varying property function (Feeley et 
al., 1998).  
 
Furthermore, there is a paucity of data relating the physicochemical properties 
of the primary API crystals on downstream secondary processing of the 
materials by air-jet milling and the resultant affect on formulation structure and 
product functionality. Hence, to control the specific performance and stability 
properties of DPI dosage forms, the central product design principle in DPI 
manufacturing must focus on tailoring the physicochemical and mechanical 
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properties of the primary API crystals to enable careful control of property 
function of the secondary processed API particles and therefore, drug product 
performance and stability.  
 
Crystallisation processes are routinely used in the isolation and purification of 
APIs, governing the physicochemical properties of the resulting crystalline 
material. APIs produced in this manner are significantly larger than those 
required for respiratory drug delivery and therefore, require comminution of the 
primary crystals in order to produce a particle size distribution (PSD) required 
for respiratory drug delivery. Suitable techniques such as fluid air-jet-milling rely 
on overcoming the material function of individual particles in order to fracture 
and break up larger material into smaller particles within a turbulent airflow. The 
high levels of stress placed on the feed materials, combined with the relative 
inefficiency of this unit process leads to an inhomogeneous power input 
throughout the bulk, often resulting in reduced crystallinity of the output 
material. These energy differences, often found at the surface of individual 
particles contribute to instability of micronised formulations over time.  
Characterisation of key mechanical properties of crystalline product is therefore, 
essential in understanding the milling behaviour of different materials, reducing 
the time and cost of milling studies and aiding the transferability of processes 
and equipment. Understanding the differences between the mechanical 
properties of APIs therefore, aids fundamental understanding relating to the 
variability of this property and possible future processing parameters of these 
materials.   
 
Three key parameters have previously been reported to determine the milling 
efficiency of organic crystalline materials; Young’s modulus (E), Hardness (H) 
and critical stress intensity factor (Kc).  The hardness of a material represents 
resistance to plastic deformation and has been investigated closely alongside 
the critical stress intensity factor and has been shown to empirically differentiate 
between samples, but not directly represent milling behaviour. The resistance to 
elastic deformation of a given material is represented by the Young’s modulus 
and has been reported to vary significantly between different APIs and different 
polymorphs. Moreover, the Young’s modulus of a material affects the 
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absorption and dissipation of energy transferred to it from a given process, such 
as communition. For effective milling of these materials, formation and 
propagation of cracks, and therefore the reduction of particle size, will occur as 
a result of overcoming the elastic properties of individual particles. A low 
Young’s modulus will represent a highly elastic material that in theory will have 
greater resistance to particle size reduction by milling.      
 
Early methods of Young’s modulus analysis relied on bulk testing of powder 
samples using three and four point beam bending where compacts of materials 
being investigated are produced to different porosities. Flexure measurements 
extrapolated to zero porosity can be used to calculate Young’s modulus value 
but neglect the effects of work hardening during compaction and fragmentation 
or bonding mechanisms, often making results unusable or unreliable. This 
destructive process requiring large quantities of material and the time-
consuming nature of these experiments led to a need to develop better 
techniques in determining the elastic properties of crystalline material with 
minimal sample preparation or product loss. 
 
Development of micro and nano indentation techniques using single crystals 
enables direct investigation of individual particles selected from a powder bulk. 
Microindentation relies on placing loading forces onto individual crystals using 
sharp indenters followed by investigation of the indentation using microscopy in 
order to characterise mechanical properties. Limited by use of large crystals 
grown specifically for the test, often non-representative of the test sample, and 
the inability to accurately determine the elastic response of a material from 
unloading, specific indentation instrumentation devices were developed. These 
systems enable higher load sensitivity using smaller indenters – resulting in 
reduced loading forces and the direct testing of batch material relevant to the 
pharmaceutical product. In a typical experiment, a sharp tip of known geometry, 
is loaded and unloaded onto a sample at a controlled rate and force while 
constantly measuring the mechanical response of the sample. Extrapolation of 
the unloading curve is performed using parameters deduced by Sneddon or use 
of Oliver and Pharr methods (Jalili and Laxminarayana, 2004). Though these 
indentation methods require the use of sharp indenting probes in a small area, 
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the pressure placed on samples results in plastic deformation and can be seen 
by the dissimilar load and unloading profile recorded by these instruments. 
Extraction of the Young’s modulus from a loading profile may not therefore, be 
representative of the original material.  
 
The atomic force microscope (AFM) has emerged as a useful tool in high-
resolution characterisation of micro and nano-scale interactions between 
cantilever probes and sample substrates. Atomic force microscopy has allowed 
the investigation of nanoNewton forces at nanometre indentation depth of 
organic crystalline material, revealing the nanomechancial properties of 
materials.  
 
The aim of this study was to determine the Young’s modulus of API and 
excipient crystals utilised in inhaled drug delivery. Furthermore, the cohesive-
adhesive surface interfacial properties of the secondary processed micronised 
form of the APIs were determined against an inert highly orientated pyrolytic 
graphite (HOPG) surface.  
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3.2 METHODS AND MATERIALS 
 
Materials  
Salmeterol xinafoate and fluticasone propionate were supplied by Merck 
Generics (Potters Bar, UK). The formoterol dihydrate and budesonide was 
supplied by (Sicor, Santhia, Italy). Lactose monohydrate was obtained from 
(DOMO, Borculo, Netherlands). All solvents used were supplied by Fisher 
Scientific UK (Loughborough, UK) and were of at least HPLC analytical grade. 
Where stated, water was ultra pure produced by reverse osmosis (MilliQ; 
Millipore, Molsheim, France).  
 
3.2.1 Crystal Substrate Crystallisation  
Identifying the differences in Young’s modulus of pharmaceutically relevant 
APIs required selection of drugs used in the field of inhaled drug delivery. Two 
long acting beta-2 agonists (LABAs) salmeterol xinafoate and formoterol 
fumerate dihydrate were chosen alongside two glucocorticosteroids, fluticasone 
propionate and budesonide. For comparison, a common excipient used in DPI 
formulations, lactose monohydrate was also included in this study (Table 3.1). 
 
Table 3.1 Crystalline substrates grown for AFM measurements 
Substrate Class 
Lactose monohydrate Excipient  
Salmeterol Xinafoate LABA 
Budesonide  Glucocorticosteroid 





In order to produce uniformly smooth crystal surfaces for reproducible 
mechanical measurements and suitable for cohesive-adhesive measurements, 
individual substrates were grown using primary nucleation on circular 
microscope glass coverslips (diameter 12mm, Agar Scientific, Essex, UK).  
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Briefly, saturated solutions of each sample were prepared in sealed glass vials 
using a suitable solvent and an individual drop was placed on to the glass slip 
by passing the solution through a 0.22 µm PTFE membrane syringe filter 
(Whatman Inc., Clifton, NJ, USA). In the case of lactose and salmeterol, a 
second glass coverslip was placed on top of the droplet to create a “sandwich” 
to allow nucleation and crystal growth. Upon the presence of crystals, the two 
coverslips were cleaved apart to reveal substrate crystals on each side. For 
fluticasone, budesonide and formoterol however, the cover slip was placed onto 
a glass vertical post support over a crystallisation vessel that contained a 
miscible non-solvent. A saturated droplet of the respective drugs was then 
placed onto the coverslip. A glass beaker was then used to seal the system and 
allowed equilibration of the vapour phases ensuring controlled nucleation and 
crystal growth (sitting-drop method) (Begat et al., 2004a) . After a given amount 
of time required to complete crystallisation, the glass cover slips were removed 
and affixed to magnetic AFM stubs using epoxy glue (Araldite Precision; 
Huntsman International, UK) prior to analysis. Details of both methods are given 
in Table 3.2. 
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Table 3.2 Details of the crystallisation solvents and methods used in producing substrate 
crystals for analysis 
Substrate Solvent Non-Solvent Method 


























3.2.2 Topographical and Mechanical Analysis using Atomic Force 
Microscopy (AFM) 
Investigation of the nanoscale properties of the crystalline substrates was 
performed using an atomic force microscope (Nanoscope IIIa and J-scanner (all 
(Bruker Nano AFM,Santa Barbara, CA, USA) in force or tapping mode. Two 
different AFM probes were used in this study, one with large indenting spherical 
tip (R150-NCL, Nanosensors, Neuchatel, Switzerland) and one with smaller 
spherical tip (Veeco-TESP, DI, Cambridge, UK), both of similar nominal 
cantilever stiffness. 
 
3.2.3 AFM Probe Tip Size Characterisation 
For accurate extrapolation of AFM force-distance data for Young’s modulus 
determination, the true radius of the indenting tip must be known. Though in 
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many cases the tip radius of these probes are provided by the supplier, high 
levels of uncertainty in these values, compounded by batch-to-batch variations, 
in certain cases 25-50%, can lead to wide ranges in modulus measurements 
using this number alone.    
 
In this study, qualitative observation of the tip radius was performed using 
scanning electron microscopy (SEM) at the apex of each fresh probe. The 
probe from each manufacturer was affixed to an SEM tray using Tempfix (Agar 
Scientific, Essex, UK) and then coated with gold for two minutes (Edwards 
Sputter Coater, Crawley, UK) prior to imaging using SEM (Joel JSM6480LV, 
Tokyo, Japan) under an accelerating voltage of 20 kV.  
 
Accurate determination of the tip radius was performed using a tip-
characterisation grating (TGT01; NT-MDT, Moscow, Russia) in which the probe 
being investigated is raster scanned over the test grating composed of a 
uniform array of sharp spikes which in turn, reverse images the investigational 
tip. This image was then deconvoluted to determine tip radius using image 
analysis software (SPIP Image Metrology ApS, Lingby, Denmark). This process 
was performed before and after indentation measurements to ensure 
measurements had not altered tip parameters.  
 
3.2.4 Young’s Modulus Determination 
Prior to indentation, suitable areas of investigation were identified using tapping 
mode (TM) AFM. Areas of 5 x 5 µm with suitably smooth surfaces, as 
determined by measurements of surface roughness, Ra (mean surface 
roughness) and Rq (root mean squared surface roughness), were selected for 
nanoindentation measurements.  
 
In order to calibrate the AFM nanoindentation system, a constant compliance 
gradient was obtained by recording a force-distance curve between the silicon 
AFM probe and silica (Agar Scientific, Cambridge, UK). The silica provided a 
suitably hard and non-elastic reference surface. The spring constant of the  
cantilever was measured using a thermal tuning method (Sader et al., 1995).  
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The same AFM probes were then used to assess the mechanical properties of 
each crystal using a trigger threshold of 40 nm and a scan rate of 0.5 Hz, 
indenting in a 3x3 grid with a distance of 1 µm between each measurement 
(n=9). The force-distance curves were exported and processed using custom 
software to covert recorded voltage measurements into tip deflections alongside 
relative piezo displacements. At a predetermined loading force, by subtracting 
the deformation profile of the suitably hard reference surface from the sample 
deformation profile, the true deformation of the sample, hence the indentation 
depth was calculated. Plotting the loading force against indentation3/2, the 
gradient can be used to determine the Young’s modulus for each individual 






4δ3 / 2R1/ 2
 
Equation 3.1 The Hertz model of deformation 
 
3.2.5 Cohesive-Adhesive Balance (CAB) Measurements 
Micronised particles of each API were attached onto standard V-shaped tipless 
cantilevers with pre-defined spring constants (DNP-020, DI, CA, USA) using an 
epoxy resin glue (Araldite, Cambridge, UK), as previously described (Begat et 
al., 2004b). Five probes were prepared for each drug, and all probes were 
examined with an optical microscope (magnification 50x) to ensure the integrity 
of the attached particle, before allowing the thin layer of glue to dry.  
 
The substrate was loaded on to the AFM scanner stage, which was enclosed in 
a custom-built environmental chamber, in which the ambient conditions were 
maintained at a constant temperature of 25 °C (± 1.5 °C) and relative humidity 
of 35 % RH (± 3 %). The interaction forces were measured by recording the 
deflection of the AFM cantilever as a function of the substrate displacement (z) 
by applying Hooke’s Law (F = -kz). Individual force curves (n = 1024) were 
conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a compressive 
load of 40 nN. Parameters were kept constant over the study. Spring constants 
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of the cantilevers used employed in this study were measured using the thermal 
tuning method.   
 
Due to the vast array of force data generated, custom-built software was used 
to extract data contained within each force-volume measurement.  The 
collected force data was analyzed to ensure normal distribution, indicating 
uniform contact between the drug probe and excipient substrate. Arithmetic 
mean and standard deviation were obtained from force data and used to 
produce CAB plots for the interactions of the different substrates to HOPG.   
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3.3 RESULTS AND DISCUSSION 
 
3.3.1 Quantification of Spring Constant and Contact Radius of AFM 
probes 
In order to obtain accurate values from indentation profiles and to allow direct 
comparison between different indenting AFM cantilever probes, the stiffness 
and contact radius must be determined. It is known that nominal values for both 
properties can vary significantly and therefore a single probe from each batch 
was used in this study and that same probe was subsequently characterised.  
 
SEM investigation provided qualitative assessment of probe radius and clearly 
highlighted differences in probe geometry, showing the sharper tip of Veeco-
TESP probes, compared to the blunter Nanosensors-R150 tip (Figure 3.1). At 
higher magnifications however, stress placed on cantilevers from the electron 
beam caused flexing of the probe and resulted in blurring of the tip. This effect, 
coupled with the unknown deposition thickness of gold from prior coating 
allowed only indicative measurements of probe radius. 
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Figure 3.1 Representative scanning electron micrograph images of the two different AFM 
cantilever probes used for nanoindentation in this study (A-B: Veeco TESP; C-D: 
Nanosensors R150-NCL) qualitatively indicating differences in probe tip-radius  
 
A non-destructive and accurate method of determining probe radius involved 
use of a tip characterisation grid. Deconvolution of the image produced from 
this grating confirmed the SEM observations and assigned a tip radius of 55 nm 
and 318 nm for the Veeco and Nanosensor probes, respectively. Details of the 
radius and cantilever stiffness are shown in Table 3.3.  
 
Table 3.3 The two different AFM probes used in this study ((a) measured by thermal 






TESP 55 36.0 a 
Nanosensors 318 36.5 b 
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3.3.2 Determination of Young’s Modulus of Crystalline Substrates  
Areas suitable for indentation were located on each crystal substrate and a 5 x 
5 µm image was taken in tapping mode to confirm nano-scale smoothness. 
Mean roughness (Ra) and root mean squared roughness (Rq) values are shown 
in Table 3.4. Optical microscopy revealed well-defined crystals of all samples 
and atomic force microscopy investigation confirmed smooth crystal substrates, 
suitable for mechanical and CAB analysis (Figure 3.2).  
 
Table 3.4 Surface roughness measurements for all substrates using TM-AFM (Ra, Mean 






Lactose monohydrate 0.137 0.231 
Salmeterol Xinafoate 0.317 0.482 
Budesonide 0.484 1.051 
Fluticasone Propionate 0.418 0.626 
Formoterol Fumarate Dihydrate 0.556 0.898 
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Figure 3.2 Representative optical and AFM images of all samples prior to indentation (A) 
Lactose, (B) Salmeterol, (C) Budesonide, (D) Fluticasone, (E) Formoterol 
 
Initial observations of indentation profiles suggested plastic deformation of the 
sharper Veeco-TESP tip into the budesonide, fluticasone and formoterol 
crystals, resulting in non-linear loading profiles and visual observation of crystal 
surface disruption after grid indentation. When repeated measurements were 
performed using the Nanosensor probe with a larger tip radius, and therefore, 
reduced loading pressure, Hertzian deformation was observed which allowed 
data to be modelled within the elastic region. Representative images of the 
crystal surfaces of a single lactose and fluticasone propionate crystal 
investigated using the respective AFM probes are shown in Figure 3.3. 
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Regardless of probe used, the sharp and forceful initial contact made with each 
tip was observed to cause non-elastic damage to the surface and therefore, 
data from such regions were not included in the measurement of crystal 
mechanical properties.     
 
(A) (B)  
Figure 3.3 AFM TM images of crystal surfaces after nanoindentation with the respective 
indenting probes (A: Lactose-TESP, B: FP-Nanosensors). The white squares indicate 
areas of loading and the arrows indicate initial point of probe contact which were 
unsuitable for Hertzian extrapolation 
 
Clear differences in the indentation profiles of the different crystals and 
indenting probes were observed as shown in Figure 3.4. Greater loading forces 
on the lactose crystal surface resulted in smaller indentation depths, which 
suggested that lactose had high resistance to elastic deformation. In 
comparison, low loading forces on the salmeterol xinafoate crystal resulted in 
large indentation depths, which suggested that the crystal had low resistance to 
elastic deformation. 
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Figure 3.4 Indiviual loading forces plotted against the indentation depths of salmeterol 
and lactose monohydrate crystals using a Veeco-TESP AFM probe 
 
The indentation profiles of budesonide, formoterol and fluticasone are shown in 
Figure 3.5 These data suggest that formoterol had the lowest resistance to 
elastic deformation followed by fluticasone propionate. In contrast, budesonide 
had a greater resistance to elastic deformation. 
 
The gradients of the individual loading curves shown in indentation plots in 
Figure 3.4 and Figure 3.5, were extrapolated and fitted to the Hertzian model of 
deformation to produce Young’s modulus values for each sample. The Young’s 
modulus measurements of each crystal are shown in Figure 3.6 and 
summarised in Table 3.5. 
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Figure 3.5 Indiviual loading forces against the indentation depths of fluticasone, 
budesonide and formoterol crystals using a Nanosensor probe AFM probe 
 
These data show that the Young’s modulus of each of the crystals was different 
and therefore exhibited different mechanical properties. The rank order of the 
Young’s modulus measurements from those of the highest stiffness (high 
Young’s modulus) to the lowest followed the rank order lactose > salmeterol 
and budesonide > fluticasone > formoterol.  
 
The different mechanical properties of the crystals may be related to the kinetics 
of the specific crystallisation process for each crystal. Surrounding solvent 
environment and energy input all affect the external morphology of individual 
crystals, which in turn have their own unique physicochemical and mechanical 
properties. Solvent inclusion, defects and imperfections within the lattice may 
also play an important part in determining the mechanical parameters of the 
material.  
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Figure 3.6 Young’s modulus measurements of different pharmaceutical crystals 
determined by AFM nanoindentation 
 






Lactose monohydrate 3.55 ± 0.10 
Salmeterol xinafoate 2.79 ± 0.47 
Budesonide 2.61 ± 0.54 
Fluticasone propionate 1.60 ± 0.05 
Formoterol fumerate dihydrate 0.93 ± 0.13 
 
In addition to determining the nanomechanical properties of the primary API 
crystals, the physicochemical and surface interfacial properties of the 
secondary-processed micronised forms of the same APIs were determined.  
 
The particle size and specific surface area are shown in Table 3.7, which 
indicate that the APIs were within the 1 – 5 µm range required for pulmonary 
drug delivery. Analysis of the specific surface area of the APIs suggests that 
micronised budesonide had the largest surface area, which was then followed 
by micronised salmeterol xinafoate and micronised formoterol fumerate 
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dihydrate, respectively. In contrast, the specific surface area of fluticasone 
propionate was the smallest of all the samples analysed. The surface interfacial 
properties of the APIs were measured with respect to highly ordered pyrolytic 
graphite (HOPG) using the CAB approach to colloidal probe AFM. The CAB 
plots and summary of CAB ratio of the APIs are shown in Figure 3.7 and Table 
3.7, respectively. The measured CAB ratio of sample fluticasone propionate 
(FP) with respect to HOPG was 1.13, which suggests that cohesive FP-FP 
interactions were 1.13 times greater than the FP-HOPG. The interactions of 
formoterol fumerate dihydrate produced a CAB ratio of 0.86, which suggests 
that adhesive interactions of formoterol to HOPG were 1.16 times greater than 
the cohesive interactions of formoterol. Similarly, the CAB ratio of salmeterol 
was 0.73 with respect to HOPG, which suggests that the adhesive interaction of 
salmeterol to HOPG were 1.37 times greater than the cohesive interactions of 
salmeterol. The CAB ratio of budesonide suggested that the adhesive affinity of 
budesonide to HOPG was 1.54 times greater than the cohesive budesonide-
budesonide interactions. These data suggest that budesonide had the highest 
adhesive tendency to HOPG. 
 
These CAB ratio data alone do not provide any quantitative discrimination of the 
cohesive strengths of these APIs in relation to their adhesion to HOPG. Since 
the dispersive surface energy of HOPG has been determined as 71 mJ.m-2 and 
the dispersive surface energy of the micronised drug material is available from 
reference data shown in Table 3.6, the cohesive strength of each API may be 
estimated using equations Equation 1.15, Equation 1.16 and Equation 1.18 











FDrug−HOPG = 3πR * . (γ1γ3)  
Equation 3.3 
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is the dispersive surface energy of HOPG. Since the CAB ratio is 
calculated from the ratio of the force of cohesion to the force of adhesion, and 
HOPG is known to not have a polar contribution, the cohesive strength of the 











Calculated values for the cohesive strength for each investigated API can be 
seen in Table 3.6. These data suggest the following rank order of the cohesive 
strength of the APIs;  
 
FP > FFD > SX > BUD 
 
Table 3.6 Calculated cohesive strength values of API samples interacted with HOPG 
using AFM colloidal probe microscopy. IGC reference values were provided from a 
previous study (Jones et al., 2008) 
Drug Substrate 
IGC Reference Value 
(mJ.m-2) 
Calculated Cohesive 
Strength  (mJ.m-2) 
FP 60.8 74.3 
BUD 60.2 42.5 
SX 47.9 42.6 
FFD 57.5 54.3 
 
The calculated cohesive strength is a combination of the dispersive and polor 
components of the surface energies of the micronised and crystalline drug 
substrates. These data indicate the polar van der Waals interactions may have 
an infuence on these drug-drug cohesive interactions.  
 
The nano-mechanical analysis of the APIs suggested significant differences in 
their respective crystalline Young’s moduli. These data suggest that the 
efficiency of further processing of the crystals by air-jet micronisation may be 
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different. For example, the lower Young’s modulus of FP indicates that the 
material may undergo elastic deformation more readily upon milling than SX or 
lactose, which have a higher Young’s modulus and therefore, less likely to 
undergo elastic deformation.  
 
Similarly, differences in the material surface interfacial properties of the 
micronised APIs in this study, with respect to HOPG highlighted the different 
cohesive strengths of the API. Since the interfacial properties of micronised 
materials play an important role in the formation of homogenous powder blends 
for inhalers and their subsequent disaggregation efficiency, robust 
characterisation of the API is necessary. The different cohesive strengths of the 
APIs are therefore expected to affect their functionality in DPI formulations.  
 
 
Figure 3.7 Cohesive-adhesive balance of the different inhaled APIs with respect to Highly 
Ordered Pyrolytic Graphite (HOPG) where the dashed line represents a CAB ratio of 1.0 
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Table 3.7 Summary of the physicochemical properties and CAB ratios of the micronised 
form of the different APIs 








 d10 d50 d90    
Salmeterol 
xinafoate 
1.10 2.34 4.39 7.22 0.73 ± 0.01 0.9966 
Budesonide 1.11 2.49 4.41 8.92 0.65 ± 0.02 0.9978 
Fluticasone 
propionate 




1.27 2.55 4.67 6.21 0.86 ± 0.02 0.9940 
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3.4 CONCLUSIONS 
The atomic force microscope has been shown to be suitable for differentiating 
the differences in elastic response of pharmaceutically relevant crystals and will 
aid understanding of the processing behaviour of these materials. Additionally, 
this study has demonstrated that evaluation of the indentation profiles and 
topography of the resultant measurements is critical to selecting suitable 
indentation parameters in order to stay within the elastic constraints of the 
investigated material. The interfacial properties of these materials have also 
been seen to have differing properties and provide a further parameter upon 
which the functionality of micronised APIs may alter the performance of these 
materials when included within a DPI formulation.  
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Chapter 4: Investigation into the influence of primary 
crystallisation conditions on the mechanical properties 
and secondary processing behaviour of fluticasone 
propionate  
 
4.1 INTRODUCTION  
 
Carrier-based dry powder inhalers (DPI) are complex dosage forms, which are 
comprised of micronised drug particles (less than 5 µm) that are blended with 
coarse lactose monohydrate carrier particles. The fluidisation and entrainment 
of the formulation in the device is driven by the patient’s inspirational force, 
which together with the resistance of the device, provide the de-aggregation 
energy to overcome the surface interfacial forces within a DPI blend to disperse 
the fine drug particles. 
 
Conventional methods of producing drug for inclusion in DPI formulations begin 
with batch crystallisation processes, which routinely use an anti-solvent to 
precipitate or crystallise the drug. The use of an anti-solvent alongside 
mechanical agitation during crystallisation can lead to poor mixing and local 
levels of high supersaturation resulting in heterogeneous particle growth. This in 
turn can lead to variability in particle size and morphology of the crystalline 
material (Dhumal et al., 2009). The isolated primary crystals then undergo 
micronisation to reduce the overall drug particle size. The mechanical stresses 
created within the micronisation process, coupled with the relative inefficiency of 
this unit operation, highlight the importance of understanding the critical 
properties of the primary crystalline feed material, in order to produce materials 
for inclusion in the final drug product with defined specification and functionality.  
 
The bulk crystallisation step of the API is primarily utilised to isolate and purify 
APIs. However, the possible influence of the physico-chemical properties of the 
primary API crystals on downstream secondary processing (e.g. micronisation) 
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and its resultant effect on formulation structure and product functionality is not 
well understood. The crystallisation process, however, is known to influence the 
mechanical properties of primary crystals (Liao and Wiedmann, 2005) and has 
been reported to have a strong influence on the micronisation behaviour of 
solids (Zugner et al., 2006).  
 
The mechanical (elastic–plastic) properties of the crystalline API to be 
micronised play a fundamental role in determining the resistance to fracture. For 
the low variation in the hardness of organic materials, this property may define 
the degree of particle size reduction of the primary crystals. The Young’s 
modulus represents a material’s resistance to elastic deformation and has been 
reported to have a strong influence on the micronisation efficiency of 
pharmaceutical solids (Zugner et al., 2006). Materials with low Young’s modulus 
tend to have low resistance to elastic deformation and therefore are difficult to 
micronise, whereas materials with a high Young’s modulus micronise more 
efficiently owing to their greater resistance to elastic deformation. Materials that 
exhibit a low Young’s modulus may therefore pose significant challenges during 
development of DPI drug products, as they tend to require multiple milling 
cycles to achieve the desired particle size specification. The process of multiple 
milling cycles may significantly impact the surface interfacial properties of the 
drug particles, which could result in formulations that are variable. Hence, 
determination and characterisation of the mechanical properties of primary drug 
crystals may help improve the efficiency of secondary micronisation processing 
of primary drug crystals, and therefore, provide drug particles with the desired 
properties for inclusion in the final drug product. 
 
Use of commercially available nano-indenting platforms that apply a load via a 
sharp indenter and measure the elastic response, have been shown to measure 
differences in the elastic modulus of different pharmaceutical ingredients (Taylor 
et al., 2004b) and detect differences in this property as a function of 
crystallisation conditions (Liao and Wiedmann, 2005). The atomic force 
microscope (AFM) has emerged as an alternative tool in the assessment of 
nanoscale properties of pharmaceutical materials and has enabled the 
measurement of the Young’s modulus by placing a load force on an 
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investigational material through an AFM cantilever of defined stiffness and 
possessing a probe tip of defined contact area (Fraxedas et al., 2002) (Perkins 
et al., 2007). The AFM based approach has been compared to an established 
nano-indenting instrument in order to determine the Young’s modulus of lactose 
monohydrate crystals (Perkins et al., 2007). The work highlighted the 
advantages of this non-destructive AFM technique as a means of accurately 
obtaining the elastic modulus of pharmaceutically relevant materials. 
Furthermore, It appears that in most single particle loading situations, plastic 
flow occurs on the impacted surface, depending upon the relative mechanical 
strength at the contact region and this is then followed by cracking and 
fragmentation. In some studies, the processes of impact attrition of brittle 
crystalline particles have been likened to those occurring during the indentation 
cracking of such materials. This seems quite reasonable, as the fragmentation 
processes are a consequence of localised loading with stress conditions, which 
are fairly similar to those existing during the loading on a flat surface by a hard 
indenter. Therefore, nanoindentation studies by AFM may be a suitable 
approach to assess the mechanical properties of pharmaceutical solids. AFM 
nanoindentation has been used to quantify the elastic modulus of many 
pharmaceutical APIs. For example carbamazepine revealed differences in the 
Young’s modulus for different polymorphs of the API, ranging from 2.69 to 5.18 
GPa and suggested this parameter influenced the milling behaviour and the 
resulting interfacial properties of the micronised materials for each polymorph 
(Perkins et al., 2009).  
 
Comminution of crystalline drugs can lead to significant changes in the physico-
chemical nature on the surfaces of drugs (Buckton, 1997) (Brittain, 2002). The 
atomic force microscope enables the investigation of these changes through the 
use of a colloidal particle technique, interacting a cantilever based probe with 
nanometer and nanoNewton resolution (Cappella and Dietler, 1999). Using a 
tipless AFM cantilever and attaching a colloidal probe, interactions between a 
substrate sample and single micrometer sized particles, such as micronised 
APIs, can be investigated. This form of measurement has had significant 
implications to the field of DPI formulation, as the interactive forces between 
inter-particle components play a critical role in the behaviour of these mixtures 
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(Roberts, 2005). Two approaches are commonly used to assess these 
interfacial properties, quantifying the contact area of the attached colloidal 
particle (Hooton et al., 2003) or interacting the same colloidal probes with 
smooth surfaces of interest (Begat et al., 2004a).  
 
The cohesive-adhesive balance (CAB) approach enables the evaluation of the 
cohesive and adhesive forces resulting on micronised materials for inclusion 
within DPI formulations against another component of the formulation (Begat et 
al., 2004c) and has been investigated alongside in vitro performance of DPI 
formulations (Hooton et al., 2006) (Jones et al., 2008). This assessment of APIs 
that have been secondary processed is routinely performed prior to formulation 
of the final product, yet the influence of the primary crystallisation process on 
these materials is not fully recognised. 
 
The aim of this study was to assess the influence of different anti-solvent 
crystallisation processes on the mechanical properties of the resulting 
fluticasone propionate crystals and the effect these properties had on the 
micronisation and performance in both binary and combination based DPI 
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Crystalline fluticasone propionate was supplied by Sterling (Perugia, Italy). All 
solvents used were of HPLC grade (Fisher Chemicals, Loughborough, UK). 
Ultra pure water was produced by reverse osmosis (MilliQ, Millipore, Molsheim, 
France). Inhalation grade of lactose monohydrate (SV003, Vehgel, 




Methodology for the crystallisation of fluticasone propionate 
 
Saturated solutions of fluticasone propionate were prepared in acetone at 21°C 
under continual stirring. The solutions were then filtered in heated labware 
using a 0.45 µm nylon membrane filter (Whatman, Brentford, UK) and 
introduced to a sealed glass crystallisation vessel continually stirred by an 
overhead stainless steel three blade stirrer with a water-jacket temperature 
control maintained at 21°C (K20; Haake, Karlsruhe, Germany). For the control 
sample (A), the drug was crystallised by controlled evaporation of the solution 
at  21°C. For the other samples, an excess of 3 different anti-solvents were 
added to the saturated solutions (B, C and D) at a rate of 50 ml/min followed by 
a reduction of jacket temperature of all samples to 5°C. Crystals were collected 
by vacuum filtration and allowed to dry under ambient conditions until a stable 
weight was achieved. The resulting materials were stored at 19°C over silica 
gel. 
 
Particle Size Analysis 
 
Particle size distributions of all samples were measured in the wet state using a 
Sympatec HELOS and CUVETTE (Sympatec GmbH, Clausthal-Zellerfeld, 
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Germany) laser diffraction system using an R3 lens (0.5-175 µm). 
Approximately 20 mg of powder was suspended in HPLC grade cyclohexane 
containing 0.5% Lecithin (Lot: A0204330001, Acros Organics, Geel, Belgium) 
using sonication for 5 minutes and immediately transferred into a 50 ml cuvette 
to produce an appropriate optical concentration (10-25%). Each measurement 
was performed in triplicate and particle size analysis was performed using 
WINDOX 5.0 software CUVETTE (Sympatec GmbH, Clausthal-Zellerfeld, 
Germany).  
 
Scanning Electron Microscopy 
 
Particle morphology of all fluticasone propionate samples was investigated 
using scanning electron microscopy (SEM). Sample aliquots were fixed onto 
sticky carbon tabs (Agar Scientific, Cambridge, UK) followed by removal of 
excess powder using pressurised air.  Samples were subsequently sputter 
coated with gold (Edwards Sputter Coater S150B, Edwards High Vacuum, 
Sussex, UK) to achieve a thickness of approximately 20 nm. Imaging was 
performed using a scanning electron microscope (JEOL JSM6480LV, Tokyo, 
Japan) using 15 kV accelerating voltage. 
 
X-ray powder diffraction (XRPD) analysis of crystalline fluticasone 
propionate samples 
 
To determine the X-ray powder diffraction (XRPD) pattern of the FP samples, all 
samples were analysed on a Bruker Powder Diffractometer (D8; Bruker AXS 
Inc., Madison, USA) using CuKα radiation (=1.54 Å). The data were collected 
over a single 2θ sweep with range 2θ = 5 - 30° and step size of 0.025°/step and 
step time of 1.5 seconds. 
 
Young’s Modulus measurements of fluticasone propionate samples  
 
FP samples were mounted on to a freshly cleaved mica surface using an 
appropriate adhesive (Microstik, Agar Scientific, Stansted, UK), ensuring 
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particles were held immobile with the dominant crystal face exposed. Mica was 
pre-fixed to an AFM stub using an epoxy resin glue (Araldite Precision, Bostik 
Ltd, Leicester, UK). To calibrate the AFM nanoindentation system (Nanoscope 
IIIa and J-scanner (all Bruker Nano AFM,Santa Barbara, CA, USA), a constant 
compliance gradient was obtained by interacting a silicon probe AFM probe, 
with a tip radius of 318 nm and a spring constant of k = 36 N/m, with a silica 
substrate, which has a suitably hard and non-elastic surface (E = 75GPa). The 
spring constant was measured by the manufacturer using the Sadder method 
(Clifford and Seah, 2005b), (R150-NCL, Nanosensors, Neuchatel, Switzerland). 
 
The same AFM probe was then used to assess the mechanical properties of 
single crystal samples using a loading force of (2 µN) and a scan rate of 0.5 Hz. 
Repeated force-distance measurements were performed on virgin areas of 
each crystal, orientated so that the dominant face with respect to the indenter 
was indented. The force-distance curves were exported and processed using 
custom-built software to determine the Young’s modulus for each individual 
indentation. 
 
For accurate extrapolation of AFM force-distance data to a Young’s modulus 
value, the true radius of the indenting tip must be known. Tip radius 
determination was performed using a tip-characterisation grating (TGT01; NT-
MDT, Moscow, Russia) in which the probe being investigated is raster scanned 
over the test grating composed of a uniform array of sharp spikes which in turn, 
produces a reverse image of the probing tip. This image was deconvoluted to 
determine tip radius, using a well-established technique using image analysis 
software (SPIP Image Metrology ApS, Lingby, Denmark) (Hutter and 
Bechhoefer, 1993) (Clifford and Seah, 2005a) (Hooton et al., 2004). This 
measurement was performed before and after indentation measurements to 
ensure indenting probe integrity was maintained. In this study, the 
hemispherical probe radius was determined to be 318 nm. 
 
Quantification of the probe cantilever nominal spring constant was performed 
using a dynamic method of thermal noise analysis (Hutter and Bechhoefer, 
1993). A spring constant of 36.2 ± 0.2 N/m was recorded using this approach 
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and agreed with the manufacturer’s quoted value measured using the Sader 
method (Sader et al., 1995).  
   
Force-distance measurements were performed on different areas of a single 
crystal so that the dominant face with respect to the indenter was indented. The 
cantilever deflection and piezo displacement were derived into a Young’s 
modulus value using the Hertzian model of deformation shown in Equation 4.1 






4δ3 / 2R1/ 2
 
 
Equation 4.1 The Hertz model of deformation (  
€ 
E : Young’s modulus,   
€ 
k : spring constant of the 
indenting cantilever,   
€ 
Δz: relative piezo displacement, 
€ 
δ: indentation depth,   
€ 
R : radius of 
indenter, 
€ 
ν: Poisson ratio of the indenting probe) 
 
4.2.3 Micronisation of crystalline samples of fluticasone propionate by 
air-jet milling 
 
Particle size reduction of selected FP samples was performed using air jet 
milling (McOne, Jetpharma, Balerna, Switzerland) under nitrogen at an 
operating venturi and ring pressure of 7 bar and 5 bar, respectively. Samples 
were micronised to a d90 size of less than 4.50 µm for formulation use. Samples 
not meeting this specification were re-processed in the mill until the required 
particle size was obtained. Approximately 1 g of sample was introduced to the 
venturi over a milling time of 2 minutes. All samples were collected and stored 
at 19°C over silica gel. 
 
4.2.4 Methodology of the cohesive-adhesive balance (CAB) approach to 
colloidal probe atomic force microscopy (AFM) 
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In order to perform quantitative binary and combination AFM-CAB analysis of 
secondary processed FP samples, smooth single crystal surfaces of fluticasone 
propionate, salmeterol xinafoate and lactose monohydrate were produced. 
Briefly, saturated solutions of FP in 2 ml of acetone were prepared and 
sonicated prior to filtration via a 0.22-µm PTFE membrane filter (Whatman Inc., 
Clifton, NJ, USA). FP was crystallised using water as the anti-solvent. Briefly, a 
microscope cover slip (12 mm x 12 mm) was supported on a vertical post in a 
crystallisation dish that contained the anti-solvent. A droplet of the saturated 
solution of the drug was then placed on the coverslip using a syringe attached 
to the 0.22-µm-membrane filter. The system was sealed by inverting a glass lid 
in the crystallisation dish to allow vapour phases of the miscible solvents to 
come into equilibrium resulting in heterogeneous nucleation and crystal growth 
within the droplet. The glass cover slip was then attached to a magnetic AFM 
stub.  
 
Atomically smooth lactose crystals were generated in a similar process that is 
described elsewhere (Begat et al., 2004b). Briefly, a solution of lactose (1 g.m-1) 
in double-distilled water was heated to 100 °C with constant stirring and, then 
filtered through a 0.2 µm PTFE membrane filter (Whatman Inc, Clifton, NJ, 
USA). A single saturated drop of the lactose solution was administered on to 
the centre of a glass cover slip (Agar Scientific, Stansted, UK) and a second 
cover slip was placed on top to form a sandwich. The sandwich was then 
allowed to cool resulting in the production of large atomically smooth crystals of 
lactose. The process of crystallisation was monitored by optical microscopy and 
the cover slips carefully separated once all the solvent had evaporated, 
resulting in the growth of crystals over the surface of both cover slips. A similar 
process was followed for salmeterol, whereby a 75% solution of API was made 
in methanol at 25 °C, filtered as above and sandwiched with a coverslip to 
produce crystals on both surfaces.  
 
4.2.5 Atomic Force Microscopy – Colloidal Probe Force Measurements 
 
Prior to force measurements, individual particles from each sample of FP were 
attached onto standard V-shaped tipless cantilevers with pre-defined spring 
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constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK), as previously described (Begat et al., 2004b). Five probes 
were prepared for each batch of FP, and all probes were examined with an 
optical microscope (magnification 50x) to ensure the integrity of the attached 
particle, before allowing the thin layer of glue to dry.  
 
The single crystal substrate was loaded onto an AFM scanner stage, which was 
enclosed in a custom-built environmental chamber, in which the ambient 
conditions were maintained at a constant temperature of 25 °C (± 1.5 °C) and 
relative humidity of 35 % RH (± 3 %). The interaction forces were measured by 
recording the deflection of the AFM cantilever as a function of the substrate 
displacement (z) by applying Hooke’s Law (F = -kz). Individual force curves (n = 
1024) were performed over a 10 µm x 10 µm area at a scan rate of 4 Hz and a 




Due to the vast array of force data generated, custom-built software was used 
to extract the information contained within each force-volume measurement.  
The collected force data was analyzed to ensure normal distribution, indicating 
uniform contact area between the drug probe and the smooth substrate 
surfaces. Arithmetic mean and standard deviation were obtained from force 
data and used to produce CAB plots for the interactions of the different batches 
of fluticasone propionate to lactose monohydrate.  
 
4.2.6 Preparation of Powder Formulations 
 
Binary formulation blends (0.8 % w/w) FP samples A and C were produced with 
a coarse grade of lactose monohydrate (Respitose, SV003, DMV-Fonterra 
Excipients, Vehgel. Netherlands). Briefly, coarse lactose was added 
geometrically to the drug, and mixed with a Whirlimixer (Fisons Scientific 
Apparatus, Ipswich, UK) for 30s between each addition. Sufficient amount of 
the carrier material was added to produce 200 µg doses of respective batches 
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of FP per 25 mg of blend. Following the complete addition of the carrier, the 
formulation was further mixed in a Turbula for 40 min (Type T2F, Bachofen AG, 
Basel) at an operating rate of 46 rpm. 
 
Similarly, combination DPI blends containing FP samples A and C, salmeterol 
xinafoate (SX) and lactose monohydrate were prepared using the same 
protocol. Combination DPI blends were prepared contained 0.8 % w/w of each 
drug in each respective combination preparation with lactose. 
 
4.2.7 HPLC Analysis of Fluticasone Propionate and Salmeterol Xinafoate 
 
Determination of drug content and analysis of NGI measurements was carried 
out using HPLC methodology. Briefly, the HPLC consisted of a pump (Jasco 
PU-980, Jasco Corp., Japan) coupled to a UV detector (Jasco UV-975) set at 
228nm for parallel detection of both APIs (tr for salmeterol 3.4 min; tr for 
fluticasone propionate 6.7 min). The pump flow rate was set to 1 ml.min-1 
through a RP-8 column (LiChroChart 125-4, LiChroSpher 100, 5 mm, Merck, 
Germany) with a pre column (LiChroChart 4-4, LiChroSpher 100, 5 mm, Merck, 
Germany) was used as stationary phase, which was conditioned to 40 °C in a 
column oven. Quantification was carried out by an external standard method. 
Linearity was checked between 1 and 100 mg/mL for each individual API.  
 
4.2.8 Content Uniformity Measurements 
 
Following blending and subsequent storage for 24 hours in 44%RH, ten random 
samples of 25 ± 1 mg, from different areas of the powder bed were weighed 
and dissolved in 50 ml of mobile phase. The amount of drug in each sample 
was obtained from HPLC assay and the content uniformity expressed as 
percentage relative standard deviation (RSD).  
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Following content uniformity testing, 25 ± 1 mg of each blend was loaded into 
size 3 hydroxypropylmethyl cellulose (HPMC, Shionogi Qualicaps SA, 
Basingstoke, UK) capsules. The capsules were stored at 44 % RH for 24 h prior 
to in vitro testing. This was done to ensure the dissipation of any electrostatic 
charges introduced during processing. Testing was performed using a Next 
Generation Impactor (NGI, Copley Scientific, Nottingham, UK) with pre-
separator, which was connected to a vacuum pump (GE Motors). The pre-
separator contained 15 ml of mobile phase. The NGI cups were coated with 1 
% v/v silicone oil in hexane to eliminate any particle bounce. For each 
experiment, ten individual 25 mg capsules of the same blend were discharged 
into the NGI at 90 L.min-1 for 2.7 s, equivalent to a total volume of 4L,  from a 
Cyclohaler® DPI device (TEVA, Haarlem, Netherlands). Before beginning each 
test, the flow rate was verified with a flow meter (DFM 2000, Copley Scientific, 
Nottingham, UK). The amount of drug deposited on each part of the NGI was 
determined by the HPLC method used for determining content uniformity. This 
protocol was repeated three times for each blend, in order to calculate the mass 
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), 
fine particle dose (FPD) that reaches stages 3 and below within the NGI and 
fine particle fraction (FPF), which is the percentage that is delivered to the lower 




Linear regression analysis was used for the assessment of HPLC calibration. 
Statistical analysis between different populations was carried out using one-way 
analysis of variance. Comparison of the mean values was performed by 
Tukey’s multiple comparison. All statistical analyses were performed using 
GraphPad Prism software (GraphPad Software Inc, California, USA). Error bars 
in graphical representations of data show ± 1 standard deviation in all cases. 
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4.3 RESULTS AND DISCUSSION 
 
The complex nature of the interfacial interactions between drug and excipient 
governs the overall relationship between device and de-aggregation efficiency 
of the formulation and therefore directly influences the functionality and 
therapeutic effectiveness of the drug product. Subtle variations in the 
processing of materials for inclusion in DPI drug products will impact the surface 
interfacial free energy of the components, which may directly affect the 
performance and efficacy of the final drug product. Hence, it is important to 
understand the relationship between material processing and material 
physicochemical properties to produce DPI drug products with the desired 
performance and stability attributes. 
 
4.3.1 Characterisation of the physicochemical properties of crystals of 
fluticasone propionate produced using different anti-solvents 
 
The particle shape and morphology of crystals of FP produced using different 
anti-solvents were analysed by SEM and the crystal faces identified via crystal 
modelling. As shown in Figure 4.1, the addition of different anti-solvents 
resulted in different crystal morphologies, although the dominant crystal face for 
all samples was the (010) face. Sample B and Sample D possessed a needle 
like morphology, whilst Sample A and Sample C exhibited a defined plate like 
shape. The difference in the crystalline habits of samples A – C and B – D can 
be related to the different rates of crystal growth of the crystal faces, which is a 
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Figure 4.1 Representative SEM images and corresponding simulated morphologies of 
crystals of fluticasone propionate produced using different anti-solvents. 
 
The particle size distributions of all the batches of unmicronised FP are shown 
in Figure 4.2 and are summarised by the 10 %, 50 % and 90 % undersize 
particle size measurements in Table 4.1. The particle size distribution (PSD) of 
all the crystalline samples of FP was broad, where particles ranged from 1 – 60 
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µm. In addition, the particle size of samples B and D are smaller than samples 




Figure 4.2 Cumulative particle size distribution of crystals of fluticasone propionate 
produced using different anti-solvents. 
 
Table 4.1 Particle size distribution (PSD) and Young’s modulus of crystals of fluticasone 
propionate using different solvents. 
Sample d10 (µm) d50 (µm) d90 (µm) 
Young’s 
modulus  
(GPa ± S.D.) 
A 5.54 ± 0.05 26.56 ± 0.21 64.82 ± 0.36 0.61 ± 0.07 
B 2.08 ± 0.04 6.45 ± 0.08 16.57 ± 0.15 2.42 ± 0.53 
C 5.37 ± 0.02 26.61 ± 0.05 54.26 ± 0.27 12.44 ± 2.48 
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The X-ray powder diffractograms (XRPD) of each of the FP samples are shown 
in Figure 4.3. The presence of distinct peaks in the XRPD diffractogram 
between 10°-40° at angle 2θ° of all batches of FP was present, which suggests 
that the materials were of the same polymorphic form and therefore, the use of 




Figure 4.3 X-ray powder diffractograms of the different samples of fluticasone 
propionate. 
 
4.3.2 Nanomechanical measurements of the Young’s modulus of FP 
samples  
 
The AFM was used to indent individual crystals of fluticasone propionate from 
each batch of crystallised material. The loading force against the measured 
indentation depth of each of the samples was directly compared and a 
representative measurement from each batch is shown in Figure 4.4. These 
data suggest that with an increasing loading force sample A indented the most, 
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followed by samples D and B. However, sample C required loading forces 
greater than 1.6 µN to create an indentation depth of approximately 10 nm3/2 
into crystal.  Extrapolating the data into a Hertzian model of deformation, the 
Young’s modulus of FP crystals produced using different solvent/anti-solvent 
conditions were calculated using Equation 4.1. 
 
 
Figure 4.4 The measured loading force against indentation depth(3/2) for each sample of 
crystalline fluticasone propionate. 
 
The Young’s modulus of all the samples ranged from 0.61 – 12.44 GPa. 
Sample A had the lowest Young’s modulus E = 0.61 ± 0.07 GPa, whilst the 
Young’s modulus of sample C was E = 12.44 ± 2.48 GPa. The Young’s 
modulus of samples B and D were 2.42 ± 0.53 GPa and 1.49 ± 1.15 GPa, 
respectively. These data suggest that FP crystals of sample C had a 
significantly (p<0.05) greater resistance to elastic deformation than the other 
samples, whilst sample A was likely to undergo elastic deformation. The 
Young’s modulus of FP crystals of sample C suggests that these primary 
crystals may exhibit greater degree of stiffness and therefore more likely to 
fracture more efficiently upon air-jet milling than the other samples (Zugner et 
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al., 2006). Hence, the use of different anti-solvents to crystallise FP yielded 
crystals with different mechanical properties, which may directly influence 
secondary processing behaviour, which, in turn, may directly influence the 
physicochemical and interfacial properties of the API. 
 
In order to investigate the relationship between the mechanical properties and 
their micronisation efficiency, primary crystals of samples A and C were chosen 
for secondary processing by air-jet milling. The physicochemical and surface 
interfacial properties of the resultant secondary processed samples were also 
determined and related to their performance in binary and combination DPI 
formulations. 
 
4.3.3 Physicochemical and surface interfacial properties of secondary 
processed crystals of sample A and C   
 
The possible relationship between mechanical properties of primary crystals of 
FP and the micronised API product, the micronisation behaviour, particle size 
reduction properties, interfacial properties and in vitro performance of binary 
formulations of FP and combination formulations with SX was investigated. 
 
In order to obtain the required specification in the d90% of the particle size 
distribution (d90% < 4.5 um) of the micronised FP for formulation, Sample A 
needed multiple cycles in the air-jet mill. Sample A had  to be passed through 
the air jet mill a total of four times. Meanwhile, primary crystals of sample C, 
which exhibited a similar PSD and morphology to sample A, only required a 
single cycle in the mill. The PSD of the micronised samples that matched the 
required PSD specification, alongside their particle size reduction ratios with 
respect to the primary crystals and total number of milling cycles are shown in 
Table 4.2. These data suggest that the Young’s modulus of the primary crystals 
may influence micronisation efficiency, where materials with a low Young’s 
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Table 4.2 An overview of the number of milling cycles required to obtaine the defined 
particle size requirements and the final particle size distributions of the micronised 
fluticasone propionate. 












A 4 1.01 ± 0.01 2.31 ± 0.01 4.25 ± 0.01 
C 1 0.93 ± 0.01 2.23 ± 0.01 4.31 ± 0.01 
 
Thermal analysis of the micronised samples A and C indicated that both 
materials had an onset of melting at approximately 295 °C, which was related to 
the melting of form I of FP (Pitchayajittipong et al., 2009). 
 
In order to determine the effect of the mechanical properties of the primary 
crystals and the possible influence of multiple micronisation cycles on the 
surface interfacial properties of the process micronised materials, the cohesive-
adhesive balance (CAB) of the micronised FP after each cycle was measured 
with respect to crystal substrates of fluticasone propionate, lactose 
monohydrate and salmeterol xinafoate (SX).  
 
The CAB plots and summary of the CAB ratios of sample A following each 
micronisation cycle are shown in Figure 4.5 and Table 4.3. The CAB value of 
sample A FP following the 1st milling cycle with respect to lactose and SX was 
1.35 ± 0.01 and 1.21 ± 0.02, respectively. These data suggest that for 
equivalent contact geometry, the cohesive FP-FP interactions were 1.35 and 
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Figure 4.5 Comparison of the force of cohesion, force of adhesion and CAB ratio of 
fluticasone propionate – lactose systems (FP-Lactose) and fluticasone propionate – 
salmeterol xinafoate systems (FP-SX) produced following re-pass air-jet milling of 
sample A crystals of fluticasone propionate over four cycles. 
 
Table 4.3 Comparison of the force of cohesion, force of adhesion and CAB ratio of 
fluticasone propionate – lactose systems (FP-Lactose) and fluticasone propionate – 
salmeterol xinafoate systems (FP-SX) produced following re-pass air-jet milling of 
sample A crystals of fluticasone propionate over four cycles. 
Number of 
Milling Cycles 
FP-Lactose CAB Ratio  
(±SD) 
FP-SX  CAB Ratio  
(± S.D.) 
Milling Cycle 1 1.35 ± 0.01 1.21 ± 0.02 
Milling Cycle 2 1.21 ± 0.02 1.08 ± 0.01 
Milling Cycle 3 1.15 ± 0.01 0.90 ± 0.02 
Milling Cycle 4 1.06 ± 0.01 0.73 ± 0.02 
 
The CAB ratio of sample A with respect to lactose decreased to 1.21 after the 
second pass, processing of the material for a third time resulted in a CAB ratio 
of 1.15 and after the final milling cycle the CAB ratio of sample A was 1.06. 
These data suggest that that each milling cycle of sample A significantly 
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increased the adhesive tendency of the FP to the lactose, although the 
cohesive FP-FP interaction of sample A still remained dominant force of 
interaction.  
 
The CAB ratio of sample A FP with respect to SX decreased from 1.21 following 
the 1st milling cycle to 0.73 after the fourth milling cycle. Interestingly, multiple 
milling cycles of the FP shifted the force balance of the FP-SX interactions from 
an initial cohesive (FP-FP) led system to an adhesive (FP-SX) led system. For a 
combination based product, this shift in the overall balance of forces may 
significantly affect the blending dynamics and formulation structure of a carrier 
based DPI formulations. 
 
The CAB ratios of the material used to formulate both binary and combination 
based formulations of sample A with respect to lactose and SX were 1.06 ± 
0.01 and 0.73 ± 0.02, respectively.  
 
The CAB plots and summary of the CAB ratios of sample C following each 
micronisation cycle are shown in Figure 4.6 and Table 4.4. The CAB ratios of 
this higher Young’s modulus FP following micronisation with respect to lactose 
and SX were 1.01 ± 0.01 and 0.95 ± 0.02, respectively. These data suggest that 
for equivalent contact geometry, the FP-FP interactions exhibited a similar force 
of interaction as the adhesion of the FP to lactose, while the FP-SX force of 
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Figure 4.6 Comparison of the force of cohesion, force of adhesion and CAB ratio of 
fluticasone propionate – lactose systems (FP-Lactose) and fluticasone propionate – 
salmeterol xinafoate systems (FP-SX) produced following air-jet milling of sample C 
crystals of fluticasone propionate. 
 
Table 4.4 Comparison of the force of cohesion, force of adhesion and CAB ratio of 
fluticasone propionate – lactose systems (FP-Lactose) and fluticasone propionate – 
salmeterol xinafoate systems (FP-SX) produced following air-jet milling of sample C 
crystals of fluticasone propionate. 
Number of 
Milling Cycles 
FP-Lactose CAB Ratio  
(±SD) 
FP-SX  CAB Ratio  
(± S.D.) 
Milling Cycle 1 1.01 ± 0.01 0.95 ± 0.02 
 
Interestingly, the FP-lactose interactions of sample A following the 4th 
micronisation cycle and sample C after one-pass of the microniser were similar. 
However, the adhesive FP-SX interactions of sample A after four-passes of the 
microniser were significantly (p<0.05) greater than that of sample C. This may 
result in variations in the delivery of SX from a combination DPI formulation if 
formulated with sample A FP.  
 
These data suggest that the use of different anti-solvents can change the 
Young’s modulus of the primary crystalline FP samples. Our study has indicated 
that the particle reduction efficiency of the micronised product is directly 
Chapter 4: 
 
   117 
affected by the Young’s modulus of the FP and as a result may directly 
influence the physico-chemical and interfacial properties of the secondary 
processed API. 
 
4.3.4 In vitro inhalation performance of binary and combination DPI 
formulations containing secondary processed FP from samples A 
and C 
 
The aerosolisation performance of binary DPI formulations containing 
secondary processed sample A and C FP was evaluated. In addition both 
batches of micronised FP were also formulated with SX to enable evaluation of 
combination DPI formulations of FP and SX. Of particular interest was to 
determine the influence of primary and secondary processing on the 
physicochemical and surface interfacial properties of FP and the resultant effect 
on DPI formulation performance and stability.  
 
The relationship between drug concentration (0.2, 0.5, 1, 5, 10 and 50 µg.ml-1) 
and peak area for each drug was found to be linear, with linear regression 
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Figure 4.7 Representative HPLC calibration curve obtained for FP 
A representative HPLC trace for a calibration sample of FP 10 µg.ml-1 is shown 
in Figure 4.8. 
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Drug content uniformity 
 
The relative standard deviation (%RSD) of the drug content of two binary DPI 
formulations containing either micronised sample A or C is shown in Table 4.5. 
The %RSD was less than 5% indicating that homogenous binary blends were 
produced with both batches of FP. In addition, the %RSD of FP and SX of two 
combination DPI formulations containing micronised sample A or C are shown 
in Table 4.6 and Table 4.7, respectively. The %RSD of the actives in either 
formulation was less than 5 %, which suggests a homogeneous distribution in 
the formulated blend.  
 
Table 4.5 In vitro formulation performance (emitted dose (ED), fine particle dose (FPD), 
fine particle fraction of the emitted dose (FPFED) and mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD)) from aerosolisation of binary DPI 
formulations of fluticasone propionate into the NGI (n = 3).  
Formulations          
Batch 
Mean ED 
(µg ± S.D.) 
Mean FPD 
(µg ± S.D.) 
Mean 
FPFED 
(% ± S.D.) 
MMAD      
(µm ± GSD.) 
%RSD 
A 166.9 ± 4.2 17.5 ± 1.8 10.5 ± 0.9 3.0 ±1.5 4.6 
C 161.3 ± 6.0 13.4 ± 1.1 8.3 ± 0.8 3.3 ±1.5 3.7 
 
 
Table 4.6 In vitro formulation performance (emitted dose (ED), fine particle dose (FPD), 
fine particle fraction of the emitted dose (FPFED) and mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD)) from aerosolisation of combination DPI 
formulations containing micronised fluticasone propionate (FP) sample A and salmeterol 
xinafoate (SX) into the NGI (n = 3). 
Formulations          
Batch 
Mean ED 
(µg ± S.D.) 
Mean FPD 
(µg ± S.D.) 
Mean 
FPFED 
(% ± S.D.) 
MMAD 
(µm ± GSD.) 
%RSD 
FP 165.4 ± 4.7 16.5 ± 1.0 10.0 ± 0.6 3.3 ±1.4 4.7 
SX 142.5 ± 9.1 32.2 ± 1.9 21.0 ± 3.4 2.5 ±1.3 4.2 
 
 
Table 4.7 In vitro formulation performance (emitted dose (ED), fine particle dose (FPD), 
fine particle fraction of the emitted dose (FPFED) and mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) from aerosolisation of combination DPI 
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formulations containing micronised fluticasone propionate (FP) sample C and salmeterol 
xinafoate (SX) into the NGI (n = 3). 
Formulations          
Batch 
Mean ED 
(µg ± S.D.) 
Mean FPD 
(µg ± S.D.) 
Mean 
FPFED 
(% ± S.D.) 
MMAD 
(µm ± GSD.) 
% RSD 
FP 153.8 ± 6.8 20.0 ± 1.7 13.0 ± 1.5 3.1 ±1.5 4.3 
SX 141.0 ± 5.9 18.2 ± 0.6 12.9 ± 0.7 2.8 ±1.5 3.5 
 
4.3.5 In vitro aerosolisation performance of binary DPI formulations 
containing micronised samples A and C 
 
The FPD of sample A micronised FP was 17.5 ± 1.8 µg whereas the FPD of 
sample C micronised FP was 13.4 ± 1.1 µg. However, as shown in Table 4.5 
the emitted doses of the formulations were different. Upon normalization of the 
FPD by the emitted dose and expressed as the percentage fine particle fraction 
of the emitted dose (%FPFED), the %FPFED of the sample A was 10.5 ± 0.9 and 
sample C was 8.3 ± 0.8, which suggests that performance of the formulations 
were similar. These data are supported by the stage-by-stage data for both 
formulations, which are shown in Figure 4.9. These data corroborate well with 
the force balance measurements of the FP samples, with both materials having 
similar adhesive affinity to the carrier lactose, as suggested by CAB 
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Figure 4.9 In vitro stage-by-stage deposition of fluiticasone propionate following 
aerosolisation of binary DPI formulations containing samples A and C of micronised 
fluticasone propionate. 
 
4.3.6 In vitro aerosolisation performance of combination DPI 
formulations of FP and SX containing micronised FP from samples 
A and C 
 
The in vitro stage-by-stage deposition of combination DPI formulations of SX 
and FP, prepared with samples A and C are shown in Figure 4.10 and Figure 
4.11, respectively. Furthermore, the mean emitted dose, fine particle dose 
(FPD) and the percentage fine particle fraction of the emitted dose (%FPFED) 
along with the mass median aerodynamic diameter (MMAD) and geometric 
standard deviation (GSD) of SX and FP samples A and C following 
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Figure 4.10 In vitro stage-by-stage deposition of fluiticasone propionate and salmeterol 
xinafoate following aerosolisation of combination DPI formulations containing 
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Figure 4.11 In vitro stage-by-stage deposition of fluticasone propionate and salmeterol 
xinafoate following aerosolisation of combination DPI formulations containing 
micronised fluticasone propionate sample C. 
 
The emitted dose of the combination FP/SX formulation containing sample A 
was determined as 165.4 ± 4.7 µg for FP and 142.5 ± 9.1 µg for SX (Table 4). 
The FPD and % FPFED of FP and SX upon aerosolisation of this formulation 
was 16.5 ± 1.0 µg and 32.2 ± 1.9 µg and 10.0 ± 0.6 % and 21.0 ± 3.4 %, 
respectively. These data suggest that the performance of SX was significantly 
better than that of FP (p<0.05). These measurements are supported by the 
stage-by-stage deposition data shown in Figure 4.10, which shows greater 
deposition of SX on to the lower stages of the impactor.  
 
No significant changes were seen in the performance of FP in combination with 
SX when compared to the binary formulation, suggesting the addition of SX had 




   124 
In comparison, the emitted dose of the combination FP/SX formulation 
containing sample C micronised FP was determined as 153.8 ± 6.8 µg for FP 
and 141.0 ± 5.9 µg for SX (Table 5). The FPD and % FPFED of FP and SX upon 
aerosolisation of this formulation was 20.0 ± 1.7 and 18.2 ± 0.6 µg and 13.0 ± 
1.5 and 12.9 ± 0.7 %, respectively. These data suggest that there was an 
improvement in the performance of the FP in the combination DPI formulation 
containing FP sample C and SX.  
 
Whilst the CAB ratios of the two micronised FP samples with respect to lactose 
monohydrate are similar, these in vitro data suggest that the difference in the 
adhesive interactions between FP and SX of sample C may influence the 
performance of FP within the combination formulation.  
 
Evaluation of the performance of SX in combination with FP sample A and 
sample C show significant differences between the two formulations. In 
combination with FP sample A, a significantly higher FPD and  FPF is seen for 
the SX dose. For FP sample C in combination with SX, the SX performance 
falls by almost 40%, suggesting the differences in the interactive nature of the 
micronised FP with SX may influence the in vitro performance of these two 
samples. The CAB value for FP with respect to lactose for both samples was 
similar. However, differences for the FP samples with respect to SX were 
measured, indicating that of the increase in adhesive tendency for sample A FP 
to SX had resulted in significant improvement of the delivery of SX with respect 
to sample C.  
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4.4 CONCLUSIONS 
This study has demonstrated the use of a modern technique to detect subtle 
modifications in the mechanical properties of crystalline fluticasone propionate 
particles produced using different anti solvents and standard processing 
methods. The choice of primary crystallisation conditions was found to be 
critical in determining the physico-chemical properties of the secondary 
processed material. These variations were  highlighted by the range of Young’s 
modulus measured for different crystallisation conditions of FP. These 
variations in the mechanical properties of FP also directly influenced the particle 
size reduction efficiencies upon micronisation. Low Young’s modulus FP 
samples required additional milling cycles to sufficiently reduce the particle size 
distribution to a respirable size range. These variations in mechanical properties 
and different energy requirements, via multiple micronisation cycles, for particle 
size reduction were also shown to influence the cohesive-adhesive properties of 
the FP samples with respect to lactose monohydrate and in combination with 
SX. These changes in the balance of interfacial forces may ultimately lead to 
variability in formulation performance of the DPI formulations, as indicated by 
the aerosolisation performance of these samples when formulated in 
combination with SX and suggested that variations in the interactive forces 
significantly affected the fine particle delivery performance of a DPI formulation.  
By gaining an understanding of how the primary crystallisation process affects 
secondary processing, interfacial forces and the functionality of a DPI 
formulation, greater quality control in the formation of these complex products 
may be achieved.  
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Chapter 5: Influence of primary crystallisation 
conditions on the mechanical and interfacial properties 





To achieve therapeutic delivery of an active pharmaceutical ingredient (API) to 
the lung via dry powder inhalers (DPI), the aerodynamic particle of the API 
needs to be less than 5 µm (Timsina et al., 1994b). However, the cohesive 
behaviour of particles less than 20 µm precludes efficient handling and accurate 
metering of into a DPI device. As a result, API particles need to be blended 
under relatively high shear with a coarse excipient, such as lactose 
monohydrate, to form an ordered mixture (Bell et al., 1971). The overall 
performance of these ordered mixtures is highly dependent on the interfacial 
forces of the API and the relative magnitude of the cohesive (drug-drug) and 
adhesive (drug-excipient) interactions. This balance of these forces is 
dominated by the physico-chemical properties of the API, which is directly 
influenced by the process history of the material. An understanding of the 
processing and its influence on API properties needs to be defined and 
controlled in order to produce a stable and robust DPI formulation.  
 
The common approach of processing API’s for lung delivery is based on a  “top-
down” strategy, where large, primary crystals from a bulk crystalliser are 
secondary processed using energetic comminution techniques (e.g. 
micronisation) to reduce the particle size of the API to meet set specifications 
(Chow et al., 2007). The particle size reduction operation is energy intensive 
and exerts high stresses on the input crystalline API material during particle-
particle collisions. The result of these stresses is the generation of undesirable 
product properties such as the formation of defects and dislocations within the 
crystalline lattice and possible generation of amorphous disorder. This surface 
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disorder may adversely impact the stability of the final drug product and 
interfacial properties of the API which may directly influence inter-particle 
interactions and concomitantly the mixing dynamics and performance of the 
final product (Krycer and Hersey, 1981) (Buckton, 1997) (Begat et al., 2003). 
 
The bulk crystallisation step of the API is primarily utilised to isolate and purify 
APIs. However, the possible influence of the physico-chemical properties of the 
primary API crystals on downstream secondary processing (e.g. micronisation) 
and its resultant affect on formulation structure and product functionality is not 
well understood. The crystallisation process, however, is known to influence the 
mechanical properties of primary crystals (Liao and Wiedmann, 2005) and has 
been reported to have a strong influence on the micronisation behaviour of 
solids (Zugner et al., 2006).  
 
The mechanical properties of crystalline solids are characterised by the 
hardness and Young’s modulus of a solid. For organic crystals, the hardness is 
generally low and its range small. The Young’s modulus of a material 
represents it’s resistance to elastic deformation and has been reported to have 
a strong influence on the micronisation behaviour of solids (Zugner et al., 2006) 
and provides a meaningful parameter to characterise possible variations in 
mechanical behaviour. Use of commercially available nano-indenting platforms 
that apply a load via a sharp indenter and measure the elastic response, have 
been shown to observe differences in the elastic modulus of different 
pharmaceutical ingredients (Taylor et al., 2004b) and detect differences in this 
property as a function of crystallisation conditions (Liao and Wiedmann, 2005).  
 
The atomic force microscope (AFM) has emerged as an alternative tool in the 
assessment of nanoscale properties of pharmaceutical materials and enables 
the measurement of the Young’s modulus by placing a load force on an 
investigational material through an AFM cantilever of defined stiffness 
possessing a probe tip of defined contact area (Fraxedas et al., 2002) (Perkins 
et al., 2007). The AFM based approach has been compared to an established 
nano-indenting instrument to determine the Young’s modulus of lactose 
monohydrate crystals (Perkins et al., 2007). The work highlighted the 
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advantages of this non-destructive AFM technique as a means of accurately 
obtaining the elastic modulus of pharmaceutically relevant materials. 
Additionally, AFM nanoindentation has been used to quantify the elastic 
modulus of pharmaceutical APIs including budesonide, whereby a Young’s 
modulus of approximately 10 GPa was found (Davies et al., 2005). A further 
study into carbamazepine revealed differences in the Young’s modulus for 
different polymorphs of the API, ranging from 2.69 to 5.18 GPa and suggested 
this parameter influenced the milling behaviour and the resulting interfacial 
properties of the micronised materials for each polymorph (Perkins et al., 2009).  
 
Comminution of crystalline APIs can lead to significant changes in the physico-
chemical nature of the surfaces of APIs (Buckton, 1997) (Brittain, 2002). The 
atomic force microscope enables the investigation of these changes through the 
use of a colloidal particle technique, interacting a cantilever based probe  with 
nanometer and nanoNewton resolution (Cappella and Dietler, 1999). Using a 
tipless AFM cantilever and attaching a colloidal probe, interactions between a 
substrate sample and single micrometer sized particles, such as micronised 
APIs, can be investigated. This form of measurement has had significant 
implications to the field of DPI formulation, as the interactive forces between 
inter-particle components play a critical role in the behaviour of these mixtures 
(Roberts, 2005). Two approaches are commonly used to assess these 
interfacial properties, quantifying the contact area of the attached colloidal 
particle (Hooton et al., 2003) or interacting the same colloidal probes with 
smooth surfaces of interest (Begat et al., 2004a).  
 
The cohesive-adhesive balance (CAB) approach enables evaluation of the 
cohesive and adhesive forces on micronised materials for inclusion within DPI 
formulations against another component of the formulation (Begat et al., 2004c) 
and has been investigated alongside in vitro performance of DPI formulations 
(Hooton et al., 2006) (Jones et al., 2008). This assessment of APIs that have 
been secondary processed is routinely performed prior to formulation of the 
final product, yet the influence of the primary crystallisation process on these 
materials is not fully recognised. 
 
Chapter 5:  
 
   129 
Optimising the crystallisation conditions to engineer crystalline APIs of desired 
quality is an approach used by pharmaceutical manufacturers to produce 
crystalline material suitable for the processing and manufacturing of DPI 
products (Chow et al., 2008). Current practices include controlling impurity 
levels (Wood, 2001), particle size (Beach et al., 1999) (Hu et al., 2008) 
(Murnane et al., 2009) and crystal habit of the primary API (Murnane et al., 
2008) (Abu Bakar et al., 2009). Changes to the crystal morphology of the 
harvested crystals are known to lead to changes in the processing behaviour of 
APIs, for example the compaction behaviour (Garekani et al., 2001) (Banga et 
al., 2007). Investigation into the milling of two different habits of succinic acid 
suggested that crystal morphology influenced the milling behaviour of this 
material (Chikhalia et al., 2006), further influencing the functionality of the 
processed material.  
 
Additionally, changes in the crystal habit have been shown to modify the 
interfacial properties (e.g., surface free energy) of the crystal due to 
modifications in the relative proportions of different chemical groups exposed on 
the respective growth faces. Muster and Prestidge have demonstrated the 
influence of molecule orientation at crystal faces on the surface free energy and 
interfacial interactions of model hydrophobic silica particles (Muster and 
Prestidge, 2002). Furthermore, two different budesonide habits were shown to 
have dissimilar cohesive-adhesive balance values on the {102} and {002} faces 
against different sugars (Hooton et al., 2008), highlighting the importance of 
crystal face specific properties and their possible implications on processing, 
formulation and delivery of APIs.   
 
While it is understood that modification of the crystal habit can affect the milling 
properties of organic materials, the relationship between the physico-
mechanical nature of primary crystals, including elastic modulus and the 
resulting physico-chemical attributes of the micronised materials in the context 
of DPI formulations is poorly understood.  
 
The aim of the present study was to investigate the influence of crystal 
morphology on the mechanical properties of unprocessed API and the effect on 
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the physicochemical and interfacial interactions of the secondary processed 
material including the downstream effect on carrier-based DPI formulation 
performance. In this study, budesonide, a hydrophobic corticosteroid, was 
crystallised using two different solvents. The Young’s modulus of the primary 
crystals on the same crystal faces was determined by AFM nanoindentation 
and related to the secondary processing of the materials. The interfacial 
properties of the secondary processed samples produced from the two different 
crystalline habits were determined using the cohesive-adhesive balance (CAB) 
method to colloidal-probe AFM with respect to lactose monohydrate. 
Furthermore, in vitro performance of the two samples was investigated in a 
carrier-based DPI formulation.  
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5.2 METHODS AND MATERIALS 
 
5.2.1 Materials 
Crystalline budesonide was supplied by Sicor (Santhia, Italy). Acetone, N,N-
dimethylformamide and heptane were supplied by Fisher Scientific UK 
(Loughborough, UK) and were 99.9% pure. Ultra pure water was prepared by 
MilliQ using reverse osmosis (Millipore, Molsheim, France).  
 
5.2.2 Crystallisation of Budesonide 
Crystalline particles of budesonide were produced in a water-jacketed glass 
crystallisation vessel using conventional solvent/anti-solvent crystallisation. Two 
different organic solvents were selected and water was used as the anti-
solvent. Saturated solutions of budesonide were made using acetone (Sample 
A) and N,N-dimethylformamide (Sample B) at 25°C followed by filtration using 
heated glass lab-ware and a 0.45 µm nylon membrane filter (Whatman, 
Brentford, UK). Exactly 60 mL of these solutions were rapidly introduced to a 
sealed glass crystallisation vessel continually stirred using a magnetic stirrer at 
700 RPM with water-jacket maintaining the vessel temperature at 25±0.01°C 
(K20; Haake, Karlsruhe, Germany). 
 
Ultra pure water was added to the vessel at a rate of 600 mL/hr to obtain a ratio 
of 1:7 saturated budesonide solution to anti-solvent, using a computer 
controlled syringe driver (Harvard PHD2000 Infusion Pump, Harvard Apparatus, 
Massachusetts, USA) connected to a hypodermic needle (21G, BD, New 
Jersey, USA). The resulting crystalline materials were extracted using vacuum 
filtration and washed using 100 mL cold water then dried under vacuum at 40°C 
until a steady weight was achieved. Samples of these materials were then 
stored at 19°C over silica gel.  
 
5.2.3 Particle Size Reduction 
Particle size reduction of the manufactured crystals of budesonide was 
performed using an air jet mill (McOne, Jetpharma, Balerna, Switzerland) with a 
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feed rate of approximately 0.5 g/min using dry nitrogen gas at operating venturi 
and ring pressures of 6 and 3 bar, respectively. 
 
5.2.4 Physico-Chemical Characterisation  
5.2.4.1 Particle Morphology and Size Analysis 
All samples were characterised to determine their morphology using scanning 
electron microscopy (Joel, Japan) at 20 kV. Particles were attached to a carbon 
sticky tab and sputter coated with gold for 5 minutes (Edwards Sputter Coater, 
Crawly, UK) prior to imaging, producing a thickness of approximately 20 nm.  
 
The particle size distribution of primary crystals and micronised samples of 
budesonide was measured using laser diffraction (HELOS, Sympatec, 
Clausthal-Zellerfeld, Germany) using a wet dispersion system (CUVETTE, 
Sympatec, Clausthal-Zellerfeld, Germany). Approximately 5 mg of sample was 
suspended in 5 mL of dispersion media, composed of heptane (HPLC grade) 
and 0.1% w/w lecithin. The suspension was sonicated for 180 s following prior 
investigation to ensure no sample dissolution or destruction, before addition to a 
glass cuvette containing 50 mL of dispersant and a magnetic stirring bar 
rotating at 1000 rpm. Sizing was performed (a series of 5 repeats) when the 
optical concentration was equal to or greater than 10%, over a duration of 20 s. 
Particle size analysis was performed using Windox 5.0 software (Sympatec, 
Clausthal-Zellerfeld, Germany) following Fraunhoffer diffraction theory to 
calculate the cumulative undersize particle parameters d10, d50 and d90, the 










5.2.4.2 Crystal Modelling 
Computational molecular dynamic modelling was used to predict the physical 
crystal habit of the budesonide samples (MS Modelling, Accelrrys Software Inc., 
Cambridge, UK). Crystallographic data for budesonide were obtained from the 
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Cambridge Structural Database and based on single crystal diffraction data 
(Albertsson et al., 1978). With reference to the SEM images of each sample, the 
Miller indices of the crystal faces produced from each solvent were identified.  
 
5.2.4.3 X-Ray Powder Diffraction (XRPD) 
To determine the X-ray powder diffraction (XRPD) pattern of crystalline 
budesonide, samples were analysed on a Bruker Powder Diffractometer (D8 
Advance AXS; Bruker Inc., Madison, USA). Samples were filled into 0.7 mm 
glass capillaries and mounted on a goniometer head. The data were collected 
using CuKα radiation (=1.5418 Å) over a single 2θ sweep with range 2θ = 5 - 
50° and step size of 0.025°/step and step time of 1.5 seconds. The 
monochromater slit was set to 2 mm and the detector was Si(Li).   
 
5.2.4.4 Differential Scanning Calorimetry (DSC) 
A differential scanning calorimeter (DSC, 2190, TA Instruments, Surrey, UK) 
was used to perform thermal analysis on all crystalline samples of budesonide 
after previous calibration using indium. Powder samples (n=3) of approximately 
3.0 mg were accurately weighed into aluminium pans, ensuring a total covering 
of the base by pressing down the samples and then hermetically sealed. The 
temperature was equilibrated to 50°C before heating at a rate of 10°C/min to 
350°C under dry nitrogen purge (0.30 L/min). 
 
5.2.4.5 AFM Nanoindentation measurements 
An atomic force microscope (AFM) was used to indent (n=9) individual crystals 
(n=3) using a Nanoscope IIIa and J-scanner (all DI, Santa Barbara, CA, USA). 
The indenting probe was hemispherical in shape and possessed a nominally 
high spring constant (R150-NCL, Nanosensors, Neuchatel, Switzerland).  
 
For accurate extrapolation of AFM force-distance data to a Young’s modulus 
value, the true radius of the indenting tip must be known. Tip radius 
determination was performed using a tip-characterisation grating (TGT01; NT-
MDT, Moscow, Russia) in which the probe being investigated is raster scanned 
over the test grating composed of a uniform array of sharp spikes which in turn, 
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produces a reverse image of the probing tip. This image was deconvoluted to 
determine tip radius, using a well-established technique using image analysis 
software (SPIP Image Metrology ApS, Lingby, Denmark) (Hutter and 
Bechhoefer, 1993) (Clifford and Seah, 2005a) (Hooton et al., 2004). This 
measurement was performed before and after indentation measurements to 
ensure indenting probe integrity was maintained. In this study, the 
hemispherical probe radius was determined to be 318 nm. 
 
Quantification of the probe cantilever nominal spring constant was performed 
using a dynamic method of thermal noise analysis (Hutter and Bechhoefer, 
1993). A spring constant of 36.2 ± 0.2 N/m was recorded using this approach 
and agreed with the manufacturer’s quoted value measured using the Sader 
method (Sader et al., 1995).  
   
Force-distance measurements were performed on different areas of a single 
crystal so that the dominant face with respect to the indenter was indented. The 
cantilever deflection and piezo displacement were derived into a Young’s 
modulus value using Hertzian model of deformation shown in Equation 5.2 






4δ3 / 2R1 / 2
 
 
Equation 5.2 The Hertz model of deformation (  
€ 
E : Young’s modulus,   
€ 
k : spring constant of the 
indenting cantilever,   
€ 
Δz: relative piezo displacement, 
€ 
δ: indentation depth,   
€ 
R : radius of 
indenter, 
€ 
ν: Poisson ratio of the indenting probe) 
 
5.2.5 Cohesive-Adhesive Balance  
5.2.5.1 Atomic Force Microscopy – Topography analysis of substrate 
surfaces 
The surface topography and roughness measurements of budesonide and 
lactose crystals were investigated using a Nanoscope IIIa controller, a 
Multimode AFM and a J-type scanner (all (Bruker Nano AFM,Santa Barbara, 
CA, USA). All AFM surface topography images were recorded in Tapping Mode 
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operation, in which, imaging was conducted using TESP Olympus tips (Di, 
Cambridge, UK) at a scan rate of 1 Hz. Surface roughness measurements were 
analysed over a 10 µm X 10 µm area. To quantify the variations in the surface 
properties of the crystal surfaces, the root-mean-squared surface roughness 
measurement (Rq) and the mean surface roughness (Ra) of the height 
deviations of the surface asperities were computed using Nanoscope software 
(v 4.23r4, (Bruker Nano AFM,Santa Barbara, CA, USA). 
 
5.2.5.2 Atomic Force Microscopy – Interaction Force Measurements 
Prior to force measurements, particles from each batch of budesonide were 
attached onto standard V-shaped tipless cantilevers with pre-defined spring 
constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK), using a previously described method (Begat et al., 2004a). 
Five tips were prepared for each of the batches of budesonide, and all probes 
were examined with an optical microscope (magnification 50x) to ensure the 
integrity of the attached particle, before allowing the thin layer of glue to dry.  
 
A single crystal of lactose monohydrate with well-defined habit and appropriate 
smoothness (<1 nm Ra and Rq) was carefully grown to provide a uniform 
surface for force of adhesion measurements while an unmicronised crystal of 
similar surface smoothness on the (002) face was selected from each primary 
source of budesonide samples for the force of cohesion measurements.  
   
The substrate was loaded on to the AFM scanner stage, which was enclosed in 
a custom-built environmental chamber, in which the ambient conditions were 
maintained at a constant temperature of 25 °C (± 1.5 °C) and relative humidity 
of 35 % RH (± 3 %). The interaction forces between lactose and budesonide 
substrates were measured by recording the deflection of the AFM cantilever as 
a function of the substrate displacement (z) by applying Hooke’s Law (F = -kz). 
Individual force curves (n = 1024) were performed over a 10 µm x 10 µm area 
at a scan rate of 4 Hz and a compressive load of 40 nN. The instruments other 
operating parameters, including the laser position were kept constant over the 
study. To quantify AFM force measurements it is imperative to measure the 
spring constants of the cantilevers used. However, as described by Begat et al 
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(2004), the CAB technique compares adhesion and cohesion with an individual 
colloid probe, which eliminates the need to accurately determine the spring 
constant. 
 
5.2.5.3 Data Processing 
With the vast array of data generated during force volume measurements, 
custom-built software was used to extract data.  The collected force data were 
analysed to ensure normal distribution, indicating uniform contact between the 
drug probe and excipient substrate. Arithmetic mean and standard deviation 
were obtained from force data and used to produce CAB plots for the 
interactions of the different batches of budesonide to lactose monohydrate. 
 
5.2.6 HPLC Analysis of Budesonide  
Quantification of budesonide utilised HPLC coupled with UV detection. The 
system comprised a high pressure pump (Jasco PU-980, Jasco Corp., Japan) 
flowing at 1.5 mL/min through a 5 µm ODS HPLC column (Hypersil, Jones 
Chromatography Ltd., Hengoed, UK) fixed within a temperature controlling 
column oven (Jasco CO-965, Jasco Corp., Japan) at 40°C and a UV detector 
(HP-1050, Agilent Technologies UK Ltd., Wokingham, UK) set to 235 nm. The 
mobile phase consisted of HPLC grade methanol (45%), acetonitrile (35%) and 
20% ultra pure water. 
 
5.2.7 Preparation of DPI formulation 
Binary formulations containing 200 µg micronised budesonide and lactose 
monohydrate (Respitose, SV003, DMV-Fonterra Excipients, Vehgel. 
Netherlands) per 25 mg shot weight were prepared to evaluate aerosolisation 
performance. Each 4 g of formulation contained 0.0320 g API and 3.968 g of 
lactose monohydrate.  
 
Blends were prepared in glass vials using a geometric blending sequence. 
Briefly, the weighed drug was placed between two layers of lactose of 
approximately the same volume and mixed for 60 s (Whirlimixer, Fisons, 
Loughborough, UK). Subsequent additions of lactose were added 
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geometrically, with a further 60 s of mixing after each addition. The vial was 
transferred into a Turbula mixer (Turbula T2F, Willy A Bachofen AG, Basel, 
Switzerland) and subsequently mixed for a further 45 minutes. The samples 
were then stored at 44 % RH for 24 hours prior to content uniformity 
determination. 
 
5.2.8 Content Uniformity 
Following blending, ten random samples of 25 ± 1 mg, from different areas of 
the powder bed were weighed and dissolved in 50 mL of mobile phase. The 
amount of drug in each sample was obtained from HPLC assay and the content 
uniformity was expressed as percentage relative standard deviation (%RSD).  
 
5.2.9 In Vitro Aerosol Deposition Studies  
Prepared blends of each material was accurately filled into HPMC capsules (25 
± 1 mg, QualiV, Qualicaps, bn. E0701921, Madrid, Spain) and stored at 44% 
RH for 24 hours prior to testing. The in vitro performance of each formulation 
was evaluated using a Next Generation Impactor (NGI, Copley Scientific, 
Nottingham, UK) with pre-separator. The pre-separator was charged with 15 mL 
mobile phase. Each of the individual stages were coated with 1% silicon oil 
(Agros Organics, Geel, Belgium) in hexane solution and allowed to air dry. The 
flow rate of through the impactor was set to 90 L.min-1 using a digital flow meter 
(DFM2000, Copley Scientific, Nottingham, UK). The formulations were 
aerosolised from a Cyclohaler (TEVA, Netherlands) over a duration of 2.7 s at 
90 L.min-1. For each repeat (n=3), two capsules were actuated after which the 
whole system was individually washed down with mobile phase. The capsules, 
device, mouthpiece and throat were individually washed into 50 mL volumetric 
flasks. The pre-separator was removed from the NGI and filled with 85 mL of 
mobile phase, sealed and then shaken for 1 minute. An aliquot was then taken 
from all samples for HPLC analysis. For each of the stages within the NGI, 
mobile phase was pipetted directly onto each stage. Stages 1 – 5 were 
allocated 20 mL, stages 6 and 7 received 10 mL and stage 8 had 10 mL. The 
stages were then shaken on a bench-top laboratory shaker (IKA Vibramax 
VXR, Staufen, Germany) for five minutes before removing aliquots of each for 
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HPLC analysis. The HPLC assay was the same as above, using the drug 
content analysis by HPLC process outlined above.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Physicochemical Characterisation of Primary Budesonide Crystals 
 
The particle size distributions (PSD) of the primary sources of the two 
budesonide samples are shown in Table 5.1. The volume mean diameter of 
samples A and B were similar, although the span of the PSD was wider for 
sample B with the presence of a greater number of coarser crystals. Scanning 
electron micrographs and crystal modelling of the dominant crystal faces of 
samples A and B are shown in Figure 5.1. SEM images of samples supported 
the particle size analysis data with the suggestion of a wider distribution in 
particle size of sample B. Two distinctive crystal morphologies were evident for 
the 2 samples, in which the crystals produced from acetone (sample A) 
possessed a diamond like habit, while budesonide crystallised from DMF 
(sample B) conformed to a more tabular morphology.  Together with the 
modelling of the crystal habit, these images suggest that the different solvents 
used in the primary solvent/anti-solvent crystallisation affected the growth 
kinetics of the different faces of the crystalline samples, although there was no 
evidence that a new crystalline face was formed. For sample B, the slow 
growing {002} faces dominated, while the addition of anti-solvent to the acetone 
solution (sample A), under otherwise identical crystallisation conditions, 
suggested that the {011} and {101} faces grew at a much lower slower rate than 
{002}. Previous work investigating the surface chemistry of different budesonide 
faces modelled in silico, identified differences in the polarity of the {002} and 
{101} faces of budesonide (Hooton et al., 2008). It was found that the {002} face 
was capable of apolar interaction only and by altering the relative dominance of 
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(a)  (b)  
(c)  (d)     
Figure 5.1 Scanning electron micrographs and computer models of the crystal habits of 
Sample A (a,b) and Sample B (c, d)  
 
Table 5.1 Particle size distribution of crystalline budesonide samples A and B. 
SAMPLE 
D10% 
(µm ± SD) 
D50% 
(µm ± SD) 
D90% 
(µm ± SD) 
Span VMD 

















1.33 ± 0.01 57.87 ± 
0.54 
 
Representative DSC thermograms of samples A and B are shown in Figure 5.2. 
For both samples, an endothermic peak was observed at ~260°C, consistent 
with the previously reported melting point of crystalline budesonide (Velaga et 
al., 2002) (Bandi et al., 2004) (Tajber et al., 2009). There is however, a 
suggestion in the DSC thermograms that the melting endotherm for sample B is 
broader and the onset temperature of melting was observed to be 
approximately 3 degrees lower than sample A. The melting point of sample A 
was approximately 263°C and for sample B was approximately 260°C. This 
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lowering in the onset and peak melting temperatures may suggest greater 
levels of impurities or greater levels of disorder in the primary crystals of sample 
B (Clas et al., 1999). Endothermic events occurring below 100°C were 
observed in both samples and may be indicative of the presence of residual 
solvents or the presence of crystal disorder.  
 
The XRPD diffractograms of the two samples are shown in Figure 5.3. The 
representative diffractograms for the two samples displayed similar sharp 
diffraction peaks at the same two-theta angles, which suggested that the 
samples were crystalline and exhibited the same polymorphic form. 
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Figure 5.2 Representative thermograms of budesonide samples A and B.  
 
Figure 5.3 The X-ray powder diffraction profiles of the primary budesonide crystals of 
samples A and B. 
 
5.3.2 Mechanical measurements of the primary budesonide crystals 
 
All mechanical measurements were performed on the {002} faces, particularly 
as it provided the most accessible face for probe-substrate interaction during 
force loading experiments, and allowed direct comparison of the influence of 
crystallisation conditions on the Young’s modulus. With the use of a 
hemispherical probe with a large radius and a stiff cantilever, the press-on 
forces were controlled to maintain Hertzian deformation during mechanical 
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loading and unloading of the crystal substrates. Topographical imaging of the 
crystal surfaces were recorded before and after each indentation cycle to 
ensure the suitability of the crystal surface for indentation and to ensure that no 
plastic deformation had occurred upon loading and unloading.   
 
Representative surface topography images of the {002} faces of samples A and 
B before and upon indentation are shown in Figure 5.4. The arrows in Fig. 5.4B 
and D indicate the regions where the probe made initial contact with the 
substrate during tip-substrate engagement. This is the point at which high 
loading stresses being placed on the crystal surface during engagement led to 
plastic deformation. The additional loading and unloading measurements on the 
substrate surfaces show no sign of plastic deformation. 
 
 
Figure 5.4 Atomic force microscope images (3 x 3 µm) of Sample A before indentation 
(a), Sample A post indentation (b) and Sample B prior to indentation (c) and Sample B 
after indentation. The boxes (☐) indicate areas where mechanical measurements were 
undertaken. The black arrows indicate the point of initial contact upon tip-substrate 
engagement, where high loading has resulted in plastic deformation. 
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Representative indentation3/2 versus loading force plots of samples A and B are 
shown in Figure 5.5. These data indicate that the indentation of sample A was 
significantly greater than that of sample B, suggesting that sample B exhibited a 
greater resistance to elastic deformation.   
 
The gradients of the individual loading versus indentation3/2 curves were 
calculated and used to measure the Young’s modulus values via the Hertzian 
model of deformation (Equation 5.2). The Young’s modulus measurements for 
samples A and B are summarised in Table 5.2. The Young’s modulus of sample 
B was significantly higher than sample A (ANOVA, p<0.01), indicating that 
changing the solvent environment during primary crystallisation may directly 
impact the mechanical properties of these materials.  
 
These observed variations in Young’s modulus and the possible influence of 
primary crystallisation conditions are further supported by AFM nanoindentation 
measurements on the (002) face of budesonide by Davies et al. (2005), who 
recorded an E value of 10GPa for unmicronised budesonide. These range of 
values obtained in this study and that of Davies, suggest that primary 
crystallisation conditions, which directly influence nucleation kinetics and crystal 
growth, may directly influence the material’s resistance to deformation. A similar 
range of Young’s modulus measurements were measured for the dominant 
{010} crystal face of fluticasone propionate, in which the addition of different 
anti-solvents to a solution of fluticasone propionate (FP) in acetone significantly 
altered the mechanical properties of the resulting crystals (Kubavat et al., 
2009). Moreover, the study by Kubavat et al. demonstrated the need for 
repeated micronisation cycles of FP with a low Young’s modulus, suggesting 
the influence of elastic modulus on this material’s resulting secondary 
processing behaviour.  
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Figure 5.5 Individual loading force against indentation3/2 for the contact of a 
hemispherical probe on the {002} faces of a number of different crystals of samples A 
and B.  
 
Table 5.2 The Young’s modulus values obtained on the {002} face of different crystals of 
samples A and B using AFM nanoindentation. At total of 8 nanoindentation 
measurements were undertaken on three different crystals of each sample (n=24).   
SAMPLE Young’s Modulus 
(GPa ± SD) 
Sample A 0.95 ± 0.50 
Sample B 4.04 ± 1.35 
 
5.3.3 Effect of crystal habit and mechanical properties of primary 
budesonide crystals on secondary processing and DPI formulation 
performance 
 
An air-jet microniser was employed to reduce the crystalline particles to a 
respirable size range (less than 5 µm). The micronised batches were 
investigated for differences in their interfacial interactions using the CAB 
approach to colloidal probe AFM, and in vitro deposition performance upon 
being blended with a coarse grade of lactose monohydrate. 
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The particle size distribution (PSD) of the unmicronised and micronised 
budesonide samples A and B are shown in Figure 5.6 and PSD analysis of the 
micronised material is provided in Table 5.3. Although the volume median 
diameter and span of the primary crystals of sample A was smaller than sample 
B, the particle size reduction ratios and span of the respective micronised PSDs 
were not conserved.  The VMD reduction of sample A was 88.7%, which was 
smaller than that of sample B that had a VMD reduction of 93.8%. The increase 
in the span of the PSD for sample A suggests that the efficiency of particle size 
reduction for sample A was not as efficient as sample B. This observation in the 
milling behaviour could be related to a change in the crystal morphology, as 
highlighted by the study of adipic acid (Chikhalia et al., 2006) whereby the 
milling was altered by differing crystal habits. This chapter’s work suggest that 
exposed crystalline faces can be fractured more effectively, or that the increase 
in the Young’s modulus of sample B may have a contributing factor to the 
efficiency of particle size reduction, as previously shown for fluticasone 
propionate (Kubavat et al., 2009). 
 
Figure 5.6 The particle size distribution of the unmicronised (primary) and micronised  
(secondary) samples of budesonide. 
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Span (±SD) VMD 
(µm±SD) 







2.11 ± 0.05 4.18 ± 
0.09 







1.90 ± 0.03 3.59 ± 
0.04 
 
The surface interfacial properties of each of the micronised materials were 
investigated using AFM-CAB with respect to surfaces of lactose monohydrate.  
 
The CAB data of the two micronised budesonide samples with respect to their 
interactions with the {002} faces of their respective unmicronised forms and 
lactose monohydrate are shown plotted in Figure 5.7. The CAB measurements 
of the micronised particles were 0.728 (R2 = 0.9970) and 0.578 (R2 = 0.9980) 
for samples A and B, respectively. The CAB value of sample B was similar to 
previously reported measurements of commercially supplied micronised 
budesonide of 0.543 with respect to lactose monohydrate (Hooton et al., 2008). 
These data suggest that the force of adhesion of micronised budesonide 
samples to lactose was greater than the corresponding force of cohesion. 
Further analysis suggests that for a equivalent force of cohesion the adhesion 
of the micronised particles from sample B to lactose was approximately 22 % 
greater than particles from sample A. These data suggest that a greater 
deaggregation energy may therefore be required to elutriate the respirable 
sized particles of sample B from a lactose monohydrate surface.   
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Figure 5.7 CAB plots for micronised samples A and B of budesonide with respect to 
lactose  
 
To enable accurate quantification of API during in vitro  testing, HPLC analysis 
was performed. The relationship between budesonide drug concentration (0.5, 
1, 5, 10 and 50 µg.mL-1) and peak area for each drug was found to be linear, 
with linear regression analysis yielding a R2 value of 0.99999 and is shown in 
Figure 5.8. 
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Figure 5.8 Representative HPLC calibration curve obtained for budesonide 
 
A representative HPLC trace for a calibration sample of budesonide 1 µg.mL-1 is 
shown in Figure 5.9. 
 
 
Figure 5.9 A representative HPLC trace for budesonide 
 
The content uniformity of each formulation was evaluated prior to impaction 
testing and is expressed as a percentage relative standard deviation (%RSD). 
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These were determined to be 1.72 % and 1.03 % for samples A and B, 
respectively, suggesting homogeneous distribution of the API throughout the 
formulation blend. Given that these values were lower than 5 %, both 
formulations were deemed suitable for in vitro impaction testing.  
 
The in vitro aerosolisation performance of carrier based DPI formulations 
containing samples A and B was assessed using a next generation impactor 
(NGI). The drug deposition profiles of both formulations are shown in Figure 
5.10 and the emitted dose (ED), fine particle dose (FPD) and fine particle 
fraction (FPF) data are summarised in Table 5.4.  
 
The stage-by-stage deposition profiles of samples A and B upon aerosolisation 
from the Cyclohaler device were similar. However, there was a significantly 
greater mass of drug deposited on stages 2 – 8 of the impactor upon 
aersolisation of sample A (ANOVA, P<0.05) as indicated by the significant 
increase in fine particle dose (Table 5.4). The fine particle dose (FPD) of 
sample A was 15.9 ± 0.37 µg, whereas the FPD of sample B was 11.7 ± 0.29 
µg. These data indicate that the deaggregation efficacy of sample A was 
greater than that of sample B. In addition, there were no significant differences 
between the emitted dose of each formulation containing either sample A or 
sample B.  
  
Figure 5.10 NGI stage-by-stage deposition profile of budesonide samples A and B  
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Table 5.4 In vitro performance characteristics of the two samples of budesonide using 
NGI testing (FPFRD – fine particle fraction of the recovered dose, FPFED – fine particle 
fraction of the emitted dose) 
 Sample A Sample B 
Emitted Dose (µg ± SD) 164.1 (1.44) 161.8 (1.64) 
Fine Particle Dose (µg ± SD) 15.9 (0.37) 11.7 (0.29) 
FPFRD (% ± SD) 8.15 (0.23) 5.27 (0.11) 
FPFED (% ± SD) 9.68 (0.28) 7.24 (0.11) 
MMAD ± GSD (µm) 4.38 ± 2.43 5.20 ± 2.54 
 
The aersolisation performances of carrier-based formulations are influenced by 
the interfacial forces of interaction between the API and carrier lactose. CAB 
analysis of budesonide samples A and B indicated that the adhesive tendency 
of budesonide sample B to lactose was greater than that of sample A. Hence, 
the higher aerosolisation efficiency of sample A may be related to its lower 
adhesive affinity to lactose which may have resulted in greater deaggregation 
efficiency in comparison to sample B. These data suggest that the use of 
different crystallisation conditions may lead to significant differences in the 
mechanical properties of the primary crystalline material, which may affect the 
surface interfacial force balance of secondary processed micronised materials. 
The impact of these changes to the surface properties of the micronised 
materials may affect the final drug product performance. 
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5.4 CONCLUSIONS 
This study has demonstrated the importance of understanding the implications 
of modifying the crystal habit for budesonide included in carrier-based DPI 
formulations. The use of different crystallisation conditions has led to significant 
differences in the mechanical properties of the primary crystalline material and 
altered the CAB value of the micronised materials. In turn, these differences are 
suggested to influence the in vitro performance of DPI formulations. This work 
highlighted the effect and implications resulting from changes in the primary 
crystallisation of APIs and advocates careful consideration when developing 
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Chapter 6: The Influence of Crystal Form on the 
Primary Crystallisation and Secondary Processing of 





For therapeutic delivery of active pharmaceutical ingredients (APIs) to the lungs 
via a dry powder inhaler (DPI), the particle size range of the API needs to be 
between 1 – 5 µm (Timsina et al., 1994a). For these particles, gravitational and 
inertial forces are weak and van der Waals, capillary and electrostatic forces 
dominate. The dominance of the physical forces versus body mass results in 
sub-10 µm particles being highly cohesive.  
 
The cohesive behaviour of micron-sized API particles prevents accurate 
metering and handling of the material for inclusion in the final DPI drug product.  
To circumvent this problem, API particles are generally blended with large inert 
carrier particles of lactose monohydrate (Bell et al., 1971), which enables 
metering of the dose and filling of the formulation into the device (Malcolmson 
and Embleton, 1998). The aerosolisation efficiency of this interactive mixture is 
dependent on the balance of cohesive (drug-drug) and adhesive (drug-lactose) 
interparticulate forces. This force balance within a DPI formulation is dependent 
on the process history of the API, which will affect the surface interfacial 
properties of the API particles and, therefore, their cohesive and adhesive 
interactions (Begat et al., 2004a).  
 
The dominant approach in producing API particles for DPI drug products 
centres on destructive top-down strategies, where primary API crystals are 
secondary processed by micronisation using high-energy air-jet mills (Shekunov 
and York, 2000). The primary crystallisation process of APIs is a key step in the 
production of pharmaceutical products, and any variability in the properties of 
Chapter 6:  
 
   154 
the primary crystals may directly influence variability down-stream upon 
secondary processing of the material. Thus, control of material properties during 
primary crystallisation is required in developing drug products within a well-
defined design space (Yu, 2008) (Variankaval et al., 2008). Key to this process 
is the selection of appropriate solvents and operating conditions in order to 
produce primary crystals with defined crystal habit, crystal form and particle size 
in enabling safe and effective handling upon secondary processing.  
 
Traditional methods of reducing the particle size of APIs to the respirable size 
range have included various comminution techniques such as ball, hammer and 
air-jet milling. The industrial standard for producing these materials however, is 
air-jet milling (Chow et al., 2007). This process requires feeding of primary 
crystals into a turbulent centrifugal airflow under high pressure. The resulting 
attrition is created by particle-particle and particle-wall collisions, which cause 
fracturing, chipping and overall particle size reduction of the coarser particles. 
Larger particles are held within the centrifuge for further size reduction whilst 
finer materials, due to the loss of inertia, enable cyclonic collection of the 
micronised product and subsequent filtration of the micronised materials 
(Midoux et al., 1999). Though the feed rate of input material and the operating 
pressures of the air-jet mill can be specified, the degree of particle size 
reduction in this process is relatively uncontrolled and often results in a non-
uniform distribution of micronised materials (Parrot, 1990). If the process has 
failed to deliver products of a defined specification, the materials are generally 
reprocessed through the microniser until the required particle size distribution 
(PSD) is obtained.  
 
Crystal properties such as physical form, pre-existing imperfections and flaws 
within the crystalline lattice influence the mechanical properties of these 
materials and, are attributed therefore, to the milling efficiency of organic 
crystals (Zugner et al., 2006). One property that represents a material’s 
resistance to plastic deformation is the Young’s modulus. The degree of 
elasticity has been previously shown to affect the size reduction operation 
(Zugner et al., 2006)  and is increasingly investigated at the micro and nano-
Newton range using atomic force microscopy (AFM) (Perkins et al., 2007).   
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The selection of appropriate salts or hydrates of APIs has been well established 
for many marketed products and is investigated to provide a crystal form of 
optimum stability, solubility and pharmacokinetic properties (Datta and Grant, 
2004) (Gardner et al., 2004). Physicochemical properties of materials are 
known to be affected by the inclusion of water in the crystal lattice in the form of 
pharmaceutical hydrates (Khankari and Grant, 1995) (Agbada and York, 1994) 
and have been shown to alter their tabletting behaviour (Di Martino et al., 2007). 
The influence of the effects of crystal form selection on the mechanical 
properties and subsequent processing behaviour of these materials is not well 
understood, although recent work has investigated the modification of 
nanomechanical properties by different polymorphic forms (Perkins et al., 
2009).  
 
The purpose of this study was to investigate the mechanical and processing 
differences between anhydrous and monohydrate forms of ipratropium bromide. 
The aerosolisation efficiency of these materials from DPI formulations was 
measured to determine the effect of crystal form on the functionality of the two 
samples. Ipratropium bromide (8-isopropyl-nor-atropine-methylbromide) is an 
anti-cholinergic agent used as a bronchodilator in patients with chronic 
obstructive pulmonary disease (COPD), in the maintenance of normal 
respiratory function and treatment of associated bronchospams. It is marketed 
as a carrier-based DPI drug product Atrovent®, which utilises glucose as the 
carrier particles. 
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6.2 MATERIALS AND METHODS 
 
Materials 
Crystalline ipratropium bromide (IB) was supplied by Amplachem Inc. (Indiana, 
USA). Lactose monohydrate (Respitose, SV003) was obtained from DMV-
Fonterra Excipients (Vehgel. Netherlands). All solvents used were supplied by 
Fisher Scientific UK (Loughborough, UK) and were 99.9% pure. Ultra pure 
water was produced by MilliQ from reverse osmosis (Millipore, Molsheim, 
France).  
  
6.2.1 Determination of IB Solubility 
 
The solubility of ipratropium bromide was determined in ethanol and ultra pure 
MilliQ water over a range of temperatures (5-40°C for H2O and 20-40°C for 
ethanol). An excess of IB was placed into a 100 ml conical flask and 
approximately 75 ml of solvent was added. Flasks containing drug and solvent 
were sealed using a glass Quickfit glass stopper and tightly sealed with Parafilm 
(Pechiney Plastic Packaging, Chicago, USA) prior to being placed into an 
agitating water bath (Grant SS40D, Grant Instruments, Chelmsford, UK) with 
additional cooling unit (Grant C1G, Grant Instruments, Chelmsford, UK). 
Samples of approximately 1.0 ml were taken after 48 hours of shaking at a set 
temperature, using an extended steel needle and glass syringe stored at the 
appropriate temperature prior to filtration via a 0.22 μm membrane syringe filter 
(Whatman Inc., Clifton, NJ, USA). From the filtered solution, 100 μL samples 
(n=3) were taken using a Gilson pipette and placed into volumetric flasks and 
made up to the appropriate volume using 0.1mM HCl. Solubility of IB was 
calculated by comparison of AUC for samples and calibration curves performed 
at the same time using the same HPLC protocol outlined below. 
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6.2.2 Crystallisation of IB  
 
Ipratropium bromide monohydrate crystals were produced using a seeding 
crystallisation approach. Crystal seeds were first produced from a saturated 
solution of IB in water. An excess of IB was added to 50ml ultra pure water and 
was continuously stired by a magnetic stirring bar over 2 hours whilst the 
temperature was maintained at 25°C. This solution was then filtered using a 
0.45 µm nylon filter (Whatman International Ltd., Maidstone, UK) fitted within 
heated glassware. The resulting solution was then stirred at 500 RPM by a 
PTFE coated octahedral magnetic stirrer bar (25 x 5 mm) and cooled to 5°C, at 
a rate of 0.2°C.min-1. After 24 hours, crystals were isolated using vacuum 
filtration (Whatman International Ltd., Maidstone, UK) and dried at 30°C under 
vacuum. Once a stable weight was achieved, the seed crystals were passed 
through a stainless steel 500 µm sieve (Endecotts Ltd., London, UK). An aliquot 
of 500 mg was used as the seeding material. 
 
The IB seeds were then placed into another 50ml saturated solution of IB at 
25°C, prepared as before, and stirred at 500 RPM by a magnetic stirrer (25 x 5 
mm) for 5 minutes after which the temperature was reduced to 21.5°C at a rate 
of 0.2°C.min-1. Crystals were harvested 24 hours later using vacuum filtration 
through a 0.45 µm nylon filter and rinsed once with 50 ml cold acetone before 
being placed into vacuum oven at 30°C. Once a steady weight of IB was 
achieved, these materials were removed from the oven and stored at 19°C 
under ambient RH (30 – 40% RH).  
 
In an effort to produce anhydrous ipratropium bromide, crystals were prepared 
using supercritical carbon dioxide (SCO2) to remove solvent from a solution of 
IB in ethanol. This anti-solvent crystallisation approach is often nominally 
termed GAS (gas anti-solvent) or SAS (supercritical anti-solvent) (Jung and 
Perrut, 2001) (Fages et al., 2004) (Shoyele and Cawthorne, 2006) .  
 
 A schematic diagram of the process is shown in Figure 6.1. A saturated 
solution of IB in 50 ml ethanol at 25°C was made using the previous method 
and placed into a 150 ml fritted glass extraction vessel with a 0.2 µm porous 
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membrane. SCO2 was passed through the ethanolic solution by pumping liquid 
CO2 through a high-pressure pump connected to a heat exchanger (P-500, Thar 
Technologies Inc., Pittsburgh, PA, USA) at a flow rate of 10 g.min-1. The 
temperature of the rig was maintained at 40°C by an air heated oven (Thar 
Inc.), minimizing secondary crystallisation prior to solvent extraction. During 
operation, a constant working pressure of 100 bar was maintained using an 
automated backpressure regulator (BP-1580-81, Thar Inc.) and effluent CO2 
was expelled through a custom HEPA filtration system. The process was 
performed for a total of 3 hours after which depressurisation at a rate of 2 
bar.min-1 followed. Resulting crystals were subsequently removed from the 
extraction vessel and stored at 19°C under ambient RH (30 – 40% RH). 
 
 
Figure 6.1 A schematic representation of the supercritical fluid extraction rig used to 
produce anhydrous IB.  
 
Particle Size Reduction 
 
Particle size reduction of crystalline IB was performed using an air jet mill 
(McOne, Jetpharma, Balerna, Switzerland) with a feed rate of approximately 
0.25 g.min-1 using dry nitrogen with operating venturi and ring pressures of 5 
and 3 bar, respectively.  Micronised materials were immediately recovered and 
placed into storage at 19°C and 44% RH for 7 days prior to further investigation.  
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6.2.3 Physicochemical Properties Analysis 
 
6.2.3.1 Particle Morphology and Size Analysis 
Particle morphology was investigated using scanning electron microscopy 
(SEM). Primary crystalline and micronised samples were placed onto carbon 
sticky tabs affixed to aluminium SEM trays. Excess material was removed from 
the tab using compressed air and immediately after, sputter coated with gold 
(Edwards Sputter Coater S150B, Edwards High Vacuum, Sussex, UK) for 5 
minutes to produce a thickness of 20 nm. SEM imaging was performed using a 
JEOL microscope (JSM6180LV, Tokyo, Japan) under an accelerating voltage of 
15 kV. 
 
The particle size distribution of primary crystals and micronised samples of IB 
were measured using laser diffraction (HELOS, Sympatec, Clausthal-Zellerfeld, 
Germany) using a wet dispersion system (CUVETTE, Sympatec, Clausthal-
Zellerfeld, Germany). Approximately 5 mg of sample was suspended in 5 ml of 
dispersion media, comprising of hexane (HPLC grade) and 0.1% w/w lethicin. 
The suspension was sonicated for 180 s following prior investigation ensuring 
no sample dissolution or destruction, before addition to a glass cuvette 
containing 50 ml of dispersant and a magnetic stirring bar rotating at 1000 rpm. 
Sizing was performed by laser diffraction over a series of 5 repeats when the 
optical concentration was equal to or greater than 10%, over a duration of 20 s. 
Particle size analysis was performed using Windox 5.0 software (Sympatec, 
Clausthal-Zellerfeld, Germany) following Fraunhoffer diffraction theory in order 
to calculate the cumulative undersize particle parameters d10, d50 and d90, the 
volume median diameter (VMD) and the sample span (Equation 5.1).  
 
Chapter 6:  
 









6.2.3.2 Topographical Atomic Force Microscope Imaging 
The surface topography of IB crystals was investigated using tapping modeTM 
imaging using a Nanoscope IIIa and J-scanner (all DI, Santa Barbara, CA, 
USA). Samples were immobilized on steel AFM stubs using carbon adhesive 
tape (Agar Scientific, Cambridge, UK). The surface morphology was 
investigated using TESP Olympus tips (Di, Cambridge UK)) at a scan rate of 0.5 
Hz.  
 
6.2.3.3 Nanoindentation Measurements performed using Atomic Force 
Microscopy 
 
An atomic force microscope (AFM) was used to indent (n=10) individual crystals 
(n=3) using a Nanoscope IIIa and J-scanner (all DI, Santa Barbara, CA, USA). 
The indenting probe (R150-NCL, Nanosensors, Neuchatel, Switzerland), 
possessed a hemispherical tip radius of 318 nm, measured by reverse image of 
the probing tip against a tip-characterisation grating (TGT01; NT-MDT, Moscow, 
Russia) and deconvolution of the image using analysis software (SPIP Image 
Metrology ApS, Lingby, Denmark) (Hutter and Bechhoefer, 1993) (Clifford and 
Seah, 2005a) (Hooton et al., 2004). The spring constant was measured using a 
dynamic method of thermal noise analysis (Hutter and Bechhoefer, 1993) and 
was recorded to be 36.2 ± 0.2 N/m in agreement with the manufacturers quoted 
value which was obtained using the Sader method (Sader et al., 1995).  
 
Force-distance measurements were performed on different areas of a single 
crystal so that the dominant face with respect to the indenter was indented such 
that a 1µm space was provided between measurements. The cantilever 
deflection and piezo displacement were derived into a Young’s modulus value 
using Hertzian model of deformation, shown in Equation 6.2 (Hertz, 1881) 
(Plassard et al., 2004).  
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4δ3 / 2R1 / 2
 
Equation 6.2 The Hertz model of deformation (  
€ 
E : Young’s modulus,   
€ 
k : spring constant of the 
indenting cantilever,   
€ 
Δz: relative piezo displacement, 
€ 
δ: indentation depth,   
€ 
R : radius of 
indenter, 
€ 
ν: Poisson ratio of the indenting probe) 
 
6.2.3.4 Differential Scanning Calorimetry 
A differential scanning calorimeter (DSC, 2190, TA Instruments, Surry, UK) was 
used to perform thermal analysis on all crystalline samples of IB after calibration 
using indium. Samples of approximately 3.0 mg were accurately weighed in 
aluminium pans, ensuring a total covering of the base by pressing down the 
material and subsequently covered with an aluminium pan lid, which were not 
hermetically sealed. The temperature was equilibrated to 50°C before heating 
at a rate of 10°C.min-1 to 350°C under dry nitrogen purge (0.30 L/min). 
 
6.2.3.5 X-Ray Powder Diffraction (XRPD) 
The X-ray powder diffraction (XRPD) pattern of the IB samples were analysed 
on a Bruker Powder Diffractometer (D8 Advance AXS; Bruker Inc., Madison, 
USA). Samples were filled into 0.7 mm glass capillaries and mounted onto a 
goniometer. The data were collected using CuKα radiation (=1.5418 Å) over a 
single 2θ sweep with range 2θ = 5 - 50° and step size of 0.025°/step and step 
time of 1.5 seconds. The monochromater slit was set to 2 mm and the detector 
was Si(Li).   
 
6.2.4 Atomic Force Microscopy – Interactive Force Measurements 
 
A single crystal of lactose monohydrate with well-defined habit and appropriate 
smoothness (<1 nm Ra and Rq) was carefully grown to provide a uniform 
surface for force of adhesion measurements and is described in detail 
elsewhere (Hooton et al., 2006). 
 
Prior to force measurements, individual micronised particles of each IB sample 
were attached onto standard V-shaped tipless cantilevers with pre-defined 
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spring constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK) (Begat et al., 2004a). Seven probes were prepared for each of 
the batches of IB and all probes were examined with an optical microscope 
(magnification 50x) to ensure the integrity of the attached particle, before 
allowing the thin layer of glue to dry.  
 
The substrate was loaded on to the AFM scanner stage, which was enclosed in 
a custom-built environmental chamber, in which the ambient conditions were 
maintained at a constant temperature of 25 °C (± 1.5 °C) and relative humidity 
of 35 % RH (± 3 %). The interaction forces were measured by recording the 
deflection of the AFM cantilever as a function of the substrate displacement (z) 
by applying Hooke’s Law (F = -kz). Individual force curves (n = 1024) were 
conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a compressive 
load of 40 nN. Parameters were kept constant over the study. In order to 
quantify AFM force measurements it is imperative to measure the spring 
constants of the cantilevers used. However, as described by Begat et al. 
(2004b), the CAB technique compares adhesion and cohesion with an 
individual colloid probe, which eliminates the need to accurately determine the 
spring constant. 
 
6.2.4.1 Data Processing 
Due to the vast array of force data generated, custom-built software was used 
to extract data contained within each force-volume measurement. The collected 
force data was analysed to ensure normal distribution, indicating uniform 
contact between the drug probe and excipient substrate. Arithmetic mean and 
standard deviation were obtained from force data and used to produce CAB 
plots for the interactions of the different batches of IB to lactose monohydrate.  
 
 
6.2.5 HPLC Analysis of Ipratropium Bromide 
 
Quantification of IB utilised HPLC coupled with UV detection (Agilent 1200 
HPLC system, London, UK). The HPLC consisted of a binary pump, 
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autosampler injecting 100 µL per sample, temperature controlled column oven. 
The HPLC method was modified from a previous approach and utilised a 
gradient HPLC approach (Simms et al., 1998). The mobile phase consisted of a 
mixture of an ion-pair buffer and acetonitrile. The buffer consisted of 100mM 
KH2PO4 in which the pH was adjusted to 4.0 using dilute phosphoric acid 
(H3PO4). Mobile phase A was produced by the addition of 800 ml buffer to 200 
ml acetonitrile and mobile phase B was produced by the addition of 550 ml 
buffer to 450 ml acetonitrile. Both mobile phases were thoroughly mixed and 
degassed prior to use in analysis. The gradient was established over 
approximately 20 mins, which is described in Table 6.1. 
 
A Hypersil BDS C18 column (Fisher, Loughborough, 5 µm, 250 x 4.6 mm i.d.) 
was used for high-throughput analysis of samples and the multi-wavelength 
detector set to 210 nm. IB had a retention time of approximately 7 minutes and 
was quantified to a level of 0.25 µg.ml-1 with reproducible linearity over standard 
concentrations up to 50 µg.ml-1 (R2 > 0.999). 
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Table 6.1 Binary pump settings for the gradient mixing of two different buffer 
compositions used in the detection of IB. 
Time (minutes) % Mobile Phase B Flow Rate 
(ml.min-1) 
0 0 1.0 
4.99 0 1.0 
8.00 100 1.0 
12.99 100 1.0 
14.00 0 2.0 
19.00 0 2.0 
19.80 0 1.0 
 
6.2.6 Preparation of carried-based DPI formulations 
 
Binary formulations containing lactose monohydrate (Respitose, SV003, DMV-
Fonterra Excipients, Vehgel. Netherlands) and 200 µg micronised IB per 25 mg 
shot weight were prepared in order to evaluate aerosolisation performance. 
Since 41.7 µg IB monohydrate is equivalent to 40 µg of anhydrous IB, each 4 g 
formulations were prepared with 0.0320 g anhydrous ipratropium bromide or 
0.0336g ipratropium bromide monohydrate in addition to the corresponding 
amount of lactose monohydrate (3.96800 g and 3.96664 g respectively).  
 
Blends were prepared in glass vials using a geometric blending sequence. The 
API was placed in-between two layers of lactose of approximately the same 
volume and mixed for 60 s (Whirlimixer, Fisons, Loughborough, UK). 
Subsequent additions of lactose were added geometrically, with a further 60 s 
of mixing after each addition. The vial was transferred into a Turbula mixer 
(Turbula T2F, Willy A Bachofen AG, Basel, Switzerland) and mixed for a further 
45 minutes. The samples were then stored at 44 % RH for 24 hours prior to 
content uniformity determination. 
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6.2.7 Content Uniformity 
Following blending, ten random samples of 25 ± 1 mg, from different areas of 
the powder bed were weighed and dissolved in 50 ml of 0.1mM HCl. The 
amount of drug in each sample was obtained from HPLC assay and the content 
uniformity expressed as percentage relative standard deviation (RSD).  
 
6.2.8 In Vitro Aerosol Deposition Studies  
Prepared blends of each material was accurately filled into HPMC capsules (25 
± 1 mg, QualiV, Qualicaps, bn. E0701921, Madrid, Spain) and stored at 44% 
RH for 24 hours prior to testing. The in vitro performance of each formulation 
was evaluated using a Next Generation Impactor (NGI, Copley Scientific, 
Nottingham, UK) with a pre-separator. The pre-separator was charged with 15 
ml mobile phase. Each of the individual stages were coated in 1% silicon oil 
(Agros Organics, Geel, Belgium) in hexane solution and allowed to air dry. The 
flow rate of through the impactor was set to 90 L.min-1 using a digital flow meter 
(DFM2000, Copley Scientific, Nottingham, UK). The formulations were 
aerosolised from a Cyclohaler (TEVA, Netherlands) for a duration of 2.7 s at 90 
L.min-1, equivalent to a total inhaled volume of 4 L. For each repeat (n=3), two 
capsules were actuated after which the whole system was individually washed 
down with mobile phase. The capsules, device, mouthpiece and throat were 
individually washed into 50 ml volumetric flasks. The pre-separator was 
removed from the NGI and filled with 85 ml of mobile phase, sealed and then 
shaken for 1.0 minute. An aliquot was then taken from all samples for HPLC 
analysis. For each of the stages within the NGI, mobile phase was pipetted 
directly onto each stage. Stages 1 – 5 were allocated 20 ml, stages 6 and 7 
received 10 ml and stage 8 was delivered 10 ml. The stages were then shaken 
on a bench-top laboratory shaker (IKA Vibramax VXR, Staufen, Germany) for 
five minutes before removing aliquots of each for HPLC analysis. The HPLC 
assay was the same as above, using the drug content analysis by HPLC 
process outlined above.  
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6.3 RESULTS AND DISCUSSION  
 
6.3.1 Solubility of IB in Experimental Solvents 
 
The solubility of IB in ethanol and ultra pure MilliQ water was investigated over 
a range of operating temperatures in accordance to the crystallisation approach 
utilised in each study and is shown in Figure 6.2. IB demonstrated high 
aqueous solubility in comparison to ethanol at higher temperatures and 
therefore, required a significantly greater amount of material to saturate solvent 
solutions used in the crystallisation of IB.  
 
Figure 6.2 The determined solubility of IB in ethanol and H2O 
 
6.3.2 Physicochemical Characterisation of primary IB crystals 
 
In order to characterise the materials produced from the primary crystallisation 
process, the thermal properties of each sample were assessed using differential 
scanning calorimetry (DSC) and the crystallinity was investigated using powder 
X-ray diffraction. Scanning electron microscopy was used to assess the 
morphological differences and laser diffraction was employed to determine 
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particle size information. In addition, the Young’s modulus of the dominant face 
of each crystal was determined by AFM nanoindentation. 
 
6.3.2.1 Differential Scanning Calorimetry of primary IB crystals 
 
Thermal analysis of the primary crystals aided the characterisation of the 
crystalline nature and hydrated state of ipratropium bromide. Representative 
thermograms of the IB samples grown from seeded crystallisation in aqueous 
solution and SCO2 anti-solvent crystallisation are shown in Figure 6.3. Both 
samples exhibited a melting point followed by degradation at 240°C, consistent 
with the pharmacopeia literature. The overlapping endothermic peaks starting at 
approximately 90°C for the monohydrate sample reveal the loss of water from 
the crystalline lattice (Corrigan et al., 2006), while the absence of this event for 
crystals formed by SCO2 anti-solvent crystallisation confirmed the presence of 
the anhydrous form of IB.  
 
Figure 6.3 Differential scanning calorimetry thermograms of two crystalline ipratropium 
bromide samples produced using a seeded aqueous and supercritical approach.  
 
6.3.2.2 X-Ray Powder Diffraction of primary IB crystals 
Investigation into the crystal nature of each sample was performed using 
powder X-ray diffraction. The resulting diffraction profiles, shown in Figure 6.4, 
indicate differences between the two samples, which may be due to the 
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presence of water within the crystalline lattice. The inclusion of water within the 
crystal lattice is known to change the shape, symmetry and number of 
molecules within the unit cell (Khankari and Grant, 1995), which will directly 
influence the diffraction behaviour. The sharp diffraction peak observed in the 
anhydrous sample at approximately 18 degrees is in keeping with previously 
published data, whereby a relative intensity of 76.76% for a peak was observed 
at 18.908 degrees (Florey, 2003), whilst the diffraction pattern observed for the 
monohydrate sample in this study appears similar to another investigation into 
IB monohydrate (Xu et al., 2010).    
 
Figure 6.4 The X-ray powder diffraction profiles for the primary crystals of ipratropium 
bromide anhydrous and monohydrate. 
 
In keeping with the findings from XRPD and DSC analysis, the samples 
obtained by seeded aqueous crystallisation and SCO2 anti-solvent 
crystallisation will be referred to in the rest of this study as the monohydrate and 
anhydrous samples of IB, respectively.  
 
6.3.2.3 Scanning Electron Microscopy of Monohydrate and Anhydrous IB 
crystals 
 
Particle morphology of the crystallised materials was investigated using 
scanning electron microscopy. As shown in Figure 6.5(A,B), the monohydrate 
IB crystals grown from seeds displayed an irregular acicular nature with no 
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defined habit. This may be due to the irregular nature of the IB seed material 
introduced during the aqueous crystallisation process. In contrast, the 
anhydrous form of IB prepared using supercritical fluid carbon dioxide anti-












Figure 6.5 Scanning electron micrographs of the crystalline monohydrate (A-B) and 
anhydrous (C-D) forms of ipratropium bromide. 
 
Particle size analyses of the primary IB crystals are shown in Table 6.2. The 
PSD of both crystals were similar and,  enabled comparison therefore, of the 
preceding processing of these materials.  
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Table 6.2 Particle size distribution (PSD) of the crystalline samples obtained using laser 
diffraction (VMD – Volume median-mass diameter). 
SAMPLE D10%  
(µm ± SD) 
D50%  
(µm ± SD) 
D90%  




(µm ± SD) 




1.94 (0.02) 12.89 
(0.01) 




1.62 (0.03) 16.23 
(0.02) 
 
6.3.3 Nanomechanical Analysis of Monohydrate and Anhydrous IB 
crystals 
 
The dominant growth faces of the monohydrate and anhydrous IB crystals were 
nanomechanically indented, while maintaining Hertzian deformation. The force-
distance loading curves were then extrapolated to derive the Young’s modulus 
for these materials. Representative force-indentation curves for individual 
crystal faces of the monohydrate IB and anhydrous crystals are shown in Figure 
6.6. The AFM was also used before and after each indentation cycle, in 
topographical mode, to image the crystal surface, ensuring suitability of the 
area for indentation and to observe evidence of plastic deformation. Areas that 
had undergone plastic deformation were removed from subsequent analysis.  
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Figure 6.6 Representative force-indentation curves for both samples of IB investigated 
using AFM nanoindentation 
 
As shown in Figure 6.7, repeated mechanical measurements revealed no 
significant differences between the anhydrous and monohydrate form of IB 
(P>0.05). Both forms had an average elastic modulus of 3.68±0.73 and 
3.20±0.50 GPa for the monohydrate and anhydrous samples, respectively. A 
previous study has shown that the physical effect of crystal hydrates directly 
affected tabletting properties and the pharmacokinetic profile of pharmaceutical 
materials (Khankari and Grant, 1995). Moreover, an investigation into the 
physical properties of anhydrous and monohydrate lactose crystals revealed 
significant differences in the Young’s modulus of the individual crystals (Wong 
et al., 1988). These data highlight the anisotropic nature of the monohydrate 
form of lactose, showing variability of elasticity on different crystal faces.  
 
Interestingly, the Young’s modulus of the two different forms of IB suggest no 
differences between the nanomechanical properties of these materials. While 
the physico-mechanical properties are known to influence the functionality of 
processed APIs, these findings imply that neither form directly influences the 
secondary processing efficiency of IB. 
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6.3.4 Physicochemical Characterisation of secondary processed 
monohydrate and anhydrous IB 
 
In order to compare the in vitro formulation behaviour of the two samples, air-jet 
milling was employed to reduce the crystalline particles to a respirable size 
range. The physico-chemical micronised samples of monohydrate and 
anhydrous IB were characterised by SEM, and then investigated for differences 
in their interfacial interactions using the CAB approach to colloidal probe AFM.  
 
A fluid air-jet mill was utilised to comminute each of the monohydrate and 
anhydrous IB samples to the respirable particle size range. Though it has been 
suggested that multiple milling cycles were required for IB in a previous study 
(Xu et al., 2010), both samples produced in this study only required a single 
pass. Representative SEM micrographs of the micronised samples of 
monohydrate IB and anhydrous IB are shown in Figure 6.8.  
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Figure 6.8 Scanning electron micrographs of the micronised monohydrate (A) and 
anhydrous.  
 
Particle size distributions of the micronised materials produced from the 
monohydrate and anhydrous crystals are shown in Figure 6.9, together with 
their unmicronised form. The particle size distributions of the secondary 
processed materials were similar (Table 6.3), highlighted by Span values of 
1.62 and 1.69 µm and volume median-mass diameters of 3.34 and 3.36 µm, for 
the monohydrate and anhydrous form, respectively. These data suggest that 
the micronisation efficiency of the monohydrate and anhydrous crystals of IB 
were similar. Particle size analyses of these distributions are shown in Table 
6.3, and were shown to be reduced sufficiently for dry powder inhaler 
formulation preparations. 
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Figure 6.9 Cumulative particle size distribution of the crystalline and micronised samples 
of anhydrous and monohydrate forms of ipratropium bromide.  
 
It was noted that the anhydrous form was reduced in size to a greater extent 
than the monohydrate sample (Table 6.3) despite possessing a greater 
unprocessed PSD. Though differences in Young’s modulus were not seen in 
previous measurements (Figure 6.7) these results may be attributed to the 
physical form of the crystalline materials, such as particle size or shape, 
resulting an altered flow and fracture behaviour within the mill.  
 
Table 6.3 Particle size distribution of the micronised materials determined by laser 
diffraction (VMD – Volume median-mass diameter). 
SAMPLE D10%  
(µm ± SD) 
D50%  
(µm ± SD) 
D90%  




(µm ± SD) 
Monohydrate 1.12 (0.01) 3.00 (0.01) 5.97 (0.01) 1.62 (0.01) 3.34 (0.01) 
Anhydrous 1.08 (0.01) 2.68 (0.01) 5.61 (0.04) 1.69 (0.01) 3.36 (0.11) 
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6.3.5 Investigation into the Interfacial properties of Micronised anhydrous 
and monohydrate IB using Cohesive-Adhesive Balance (CAB) 
Measurements 
 
The surface interfacial interactions of the micronised materials were 
investigated using AFM-CAB with respect to surfaces of lactose monohydrate. 
A substrate crystal of lactose monohydrate with defined habit and appropriate 
smoothness (<1 nm Ra and Rq) was carefully grown to provide a uniform 
surface for adhesion measurements while an unmicronised crystal of similar 
smoothness on the dominant face was selected from the monohydrate and 
anhydrous IB crystals for the cohesion measurements. 
 
The CAB plots of the micronised IB samples produced upon micronisation with 
respect to their monohydrate and anhydrous forms and lactose monohydrate 
are shown in Figure 6.10 and Figure 6.11, respectively. 
 
The CAB measurements of the micronised particles produced from primary 
crystals of monohydrate or anhydrous forms of IB with respect to lactose 
monohydrate were 0.701 (R2 = 0.9984) and 0.770 (R2 = 0.999), respectively. 
These data suggest that both samples had a greater tendency to adhere to 
lactose with respect to the their respective forms of IB and that the 
monohydrate and anhydrous forms of IB have little or no direct influence on the 
interfacial behaviour.   
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Figure 6.10 CAB plot of monohydrate IB with respect to lactose. (The dashed line 
represents where FCOH = FADH = 1.0) 
 
 
Figure 6.11 CAB plot of anhydrous IB with respect to lactose (The dashed line represents 
where FCOH = FADH = 1.0). 
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6.3.6 In Vitro Aerosolisation Performance of Carrier-Based DPI 
formulations 
 
Each micronised sample of IB was formulated with coarse lactose to produce a 
DPI formulation suitable for the investigation of fluidisation and delivery 
efficiency by inertial impaction. Formulations containing the equivalent of 200µg 
IB per shot were actuated into a Next Generation Impactor (NGI) and evaluated 
by HPLC once formulations were assessed for blend uniformity.  
 
Quantification of IB was achieved using HPLC. The relationship between drug 
concentration (0.5, 1, 5, 10 and 50 µg.ml-1) and peak area for each drug was 
found to be linear, with linear regression analysis yielding a coefficient of 
determination (R2) of 0.99964 and is shown in Figure 6.12. 
 
 
Figure 6.12 Representative HPLC calibration curve obtained for IB 
 
A representative HPLC trace for a calibration sample of IB 10 µg.ml-1 is shown 
in Figure 6.13, with a retention time of approximately 7.2 minutes.  
 
Chapter 6:  
 
   178 
 
Figure 6.13 A Representative HPLC trace for IB 
 
The content uniformity of each formulation was evaluated and is expressed as a 
percentage relative standard deviation (%RSD). These were determined to be 
1.95 % and 2.17 % for the monohydrate and anhydrous IB samples, 
respectively, suggesting a homogeneous distribution of the API throughout the 
formulation blend. Given that these values were lower than 5 %, both 
formulations were deemed suitable for in vitro impaction testing.  
 
The stage-by-stage deposition profile of the formulations using inertial 
impaction in the NGI are shown in Figure 6.14 and in vitro deposition analyses 
are summarised in Table 6.4. Although differences in fine particle dose (FPD) 
were observed between the monohydrate and anhydrous IB formulations, 
201.70±18.33 and 228.58±4.31 µg respectively, when normalised as a function 
of emitted dose, the fine particle fraction showed no significant difference. 
These data suggest that there was no significant impact on performance by the 
crystallisation of the anhydrous form of IB, supporting the nanomechanical and 
CAB measurements for the interfacial properties of these samples.  
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Table 6.4 In vitro aerosolisation properties of DPI formulations produced from the 
monohydrate and anhydrous crystal form of ipratropium bromide (ED: emitted dose, 
FPD: fine-particle dose, MMAD: mass median aerodynamic diameter, GSD: geometric 





ED (µg) 201.70 ± 18.33 228.58 ± 4.31 
FPD (µg) 45.71 ± 5.99 53.28 ± 2.64 
MMAD (µm) 3.83 3.33 
GSD (µm) 2.02 1.99 
FPFED (%) 22.62 ± 1.32 23.30 ± 0.81 
 
 
Figure 6.14 Mean mass deposition profiles for monohydrate and anhydrous carrier-based 
DPI formulations.  
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6.4 CONCLUSIONS 
 
This study has demonstrated the use of supercritical fluid technology in 
producing an anhydrous form of ipratropium bromide suitable for inclusion in a 
carrier-based DPI formulation when compared to the monohydrate form. 
Investigation into the mechanical nature of the primary crystalline material by 
atomic force nanoindentation suggested no differences in the elastic modulus of 
these materials. Subsequent micronisation and assessment of interfacial 
properties by the CAB approach also indicated no observable differences. A 
better understanding of the influence of crystallisation conditions on the 
physico-mechanical properties of APIs produced with conventional and novel 
techniques may therefore lead to materials of superior quality and functionality.  
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The process of crystallisation is a fundamental step in the isolation and 
purification of active pharmaceutical ingredients. Defining the physical and 
chemical characteristics of the resulting material, this process traditionally has 
been tailored to produce materials of suitable handling characteristics, such as 
ease of filtration and powder flow. Due to the complexity of many drug delivery 
approaches, for example dry powder inhaler formulations, further processing of 
these primary crystals is required to produce suitable material for incorporation 
into these products.  
 
Described in the opening section of this body of work, the micronisation of 
pharmaceutical materials by jet-milling is often implicated in significant and 
detrimental changes in material behaviour. For DPI formulations containing 
these micronised materials and larger coarse carrier particles, this can often be 
seen as a source of variability in their performance and is associated with the 
input of high energies and the relatively uncontrolled nature of the process. In 
response, studies have investigated the role of crystallisation in determining the 
mechanical properties of model drugs, such as acetominophen (Liao and 
Wiedmann, 2005), and compared the mechanical properties of a wide variety of 
APIs (Taylor et al., 2004b).  
 
Research into the relationship between mechanical properties of APIs and 
micronisation performance has highlighted the Young’s modulus as an 
important characteristic in influencing the milling behaviour (Zugner et al., 2006) 
(Meier et al., 2008) and this property has been demonstrated to be readily 
measured using an atomic force microscope based approach (Perkins et al., 
2007) (James et al., 2009). There remained however, a lack of understanding 
as to whether the crystallisation process alters the Young’s modulus of the 
resulting primary crystals significantly enough to translate into specific 
Chapter 7: 
 
   182 
differences in the processing or performance of these materials intended for 
DPI delivery.  
 
7.2 Summary  
 
The development and understanding of an AFM based nanoindentation 
technique enabled the investigation of the nanomechanical properties of the 
primary crystals of various APIs that were produced using differing 
crystallisation techniques. This enabled investigation of the Young’s modulus of 
APIs specifically used in the therapeutic treatment of asthma and COPD, prior 
to the processing of these materials in order to assess their performance when 
included within a DPI formulation. Alongside other established characterisation 
techniques to characterise the primary crystals and resulting micronised 
materials, the Young’s modulus was shown to influence the milling behaviour 
and resulting interparticle forces which corroborated with observed in vitro 
impaction testing. The resulting chapters presented in this thesis highlight the 
range of the measured Young’s modulus for different APIs when solvent 
composition, crystal habit and crystal form are altered during the crystallisation. 
 
In the first experimental section, chapter 3, a series of different APIs were 
grown under controlled conditions in order to determine a reference technique 
suitable for assessment of primary crystalline samples produced on a small 
scale. Moreover, the observed indentation profile of two samples, lactose 
monohydrate and salmeterol xinofoate, indicated that these crystals presented 
significantly greater resistance to deformation from a relatively large radius AFM 
probe. These findings led to investigation of a wide range of probes that were 
suitable in stiffness and contact area to produce deformation within the elastic 
limit and supported early work by Perkins et al. (2007) suggesting that true 
Young’s modulus measurements using the Hertzian model of deformation 
required the appropriate selection of operating parameters. This led to the 
quantification of the elastic modulus of lactose (3.55 ± 0.10 GPa), salmeterol 
xinafoate (2.79 ± 0.47 GPa), Budesonide (2.61 ± 0.54 GPa), fluticasone 
propionate (1.60 ± 0.05 GPa) and formoterol fumarate dihydrate (0.93 ± 0.13 
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GPa). As a secondary study within this chapter, the interactive nature of the 
secondary processed micronised forms of each material was investigated 
against HOPG, a well characterised reference surface. From these AFM based 
interactive force measurements and knowledge of the dispersive surface 
energy of HOPG, the cohesive nature of each sample was estimated and 
suggested that the relative differences between these forces for each API could 
result in differences in DPI formulation performance and functionality.  
 
The investigation into the crystallisation of fluticasone propionate by changing 
the solvent composition enabled investigation of the nanomechanical properties 
of the resulting primary crystals. As shown in chapter 4, this study indicated that 
a wide range of Young’s modulus was obtained, depending on the solvents 
used. Furthermore, these differences were observed in two samples whereby 
the material with the highest elasticity, sample A (0.61 ± 0.07 GPa) required a 
further three micronisation cycles to reduce the primary crystal size similar to 
another sample with significantly higher stiffness, sample C (12.44 ± 2.48 GPa) 
that only required one milling cycle. This result highlighted the importance of 
solvent selection as a precursor to determining physico-mechanical behaviour. 
Investigation of the CAB of the micronised materials after each cycle of milling 
indicated that successive cycles caused the material to have an increasing 
tendency to adhere to lactose. Interestingly, the sample that required only one 
milling cycle showed a similar affinity to adhere to lactose and these findings 
were supported by in vitro assessment of DPI formulations of binary FP 
formulations for each sample. For FP samples A and C in combination with SX, 
the SX performance was decreased by approximately 40% when combined with 
FP sample C. This indicated disturbance of the intricate balance of forces within 
the tertiary formulation and suggested that the inclusion of a processed form of  
FP had resulted in the modification of DPI function and performance in vitro.   
 
The changes in crystallisation solvents can also lead to differences in the 
crystal habit. This area was explored by the use of acetone and N-N-
dimethylformamide as solvents in the crystallisation of budesonide in chapter 5. 
Significant differences in the Young’s modulus of the resulting crystals were 
evident, alongside changes to the physical appearance of the resulting primary 
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crystals. These findings supported the size reduction data of the micronised 
materials and resulted in the material of greatest elasticity, having greater 
adhesive tendency towards lactose when investigated with AFM-CAB.  The 
possible loss of crystallinity of the budesonide sample measured by DSC, with 
highest elastic modulus suggests that the inclusion of crystal defects or residual 
solvents has lead to a material of greater stiffness. This supports the findings of 
Liao and Wiedmann (2005), who observed changes to the mechanical nature of 
acetaminophen and KCl as a function of the crystallisation rate and inclusion of 
crystal defects. Our work in this chapter highlights the importance of the 
physical nature of the primary crystals alongside the nanomechanical properties 
of these materials in relation to the milling behaviour of APIs and the 
subsequent variations in in vitro performance within a DPI formulation. 
 
In the final experimental section, chapter 6, the role of crystal form for 
ipratropium bromide was investigated. The monohydrate form was produced 
using a temperature drop, seeded crystallisation method whilst the anhydrous 
form was produced from an organic solution of ipratropium and supercritical 
CO2 using a GAS process. The findings in this study revealed no significant 
differences in the mechanical nature of the primary crystals and although the 
physical appearances of the crystalline material were different, the milling 
behaviour of these samples were conserved. Moreover, the CAB values of each 
material and their in vitro performance showed no distinction between each 
form. Whilst the crystal form of each sample was different, these data 
suggested that the elastic modulus of each sample was sufficiently high to 
overcome the barriers of micronisation and therefore process these materials 
into a suitable DPI formulation. In keeping with chapter 4 and chapter 5, this 
study indicates that material with a greater Young’s modulus may result in a 
finer end product and that the Young’s modulus can influence the milling 
behaviour in addition to the crystal habit.  
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The main body of the experimental work contained in this thesis suggests that 
the crystallisation process alters the elastic nature of organic crystalline 
materials. This may be due to loss of crystallinity, by the creation of dislocations 
and defects within the crystal lattice, or by inclusion of residual solvents. In the 
case of FP, this is demonstrated to a greater extent when the solvent 
composition has been altered, and as a result has been shown to influence the 
milling behaviour and interparticluate forces that occur.  Consequentially, these 
data indicate that with the appropriate selection of solvents and crystallisation 
processes, output material may be tailored to meet specific criteria for future 
processing.  These findings are not limited to just DPI formulations but to any 
API that is subsequently processed in a similar fashion, including poorly soluble 
drugs and liquid-suspension formulations. Moreover, using this approach, 
variability as a result of sourcing a material from various suppliers may be 
reduced, as the characterisation of the Young’s modulus provides insight into 
the possible micronisation behaviour of certain materials. This is of significant 
benefit to those obtaining drug materials from an array of sources, or those 
wishing to match competitor products, such as those within the pharmaceutical 
generics market.  
 
The elastic modulus is therefore not an individual measurement that surpasses 
any previous technique, rather an additional tool in the characterisation of 
primary crystals, alongside established and validated approaches that 
characterise physico-chemical attributes. Understanding and controlling the 
variability of individual components of complex formulations may, therefore, 
produce products of defined specification and quality.  
 
7.4 Future Work 
 
The crystallisation process has many different contributing elements that 
determine the properties of the end-product. These include operating 
conditions, solvent/anti-solvents and addition rates, for example. Any 
differences within this unit operation will often lead to changes in the material 
output. Advanced, in-line monitoring processes that enable the real-time 
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investigation of the crystallisation process provide important tools in  
understanding the rates (kinetics) of crystal growth. Investigating how these 
properties influence the Young’s modulus of the resulting materials and how 
this property can be modified by the use of appropriate solvent conditions may 
lead to less empirical efforts in the development of crystallisation techniques. 
 
Whilst this body of work has investigated the effect of traditional crystallisation 
techniques on the mechanical nature of the resulting material, greater interest 
has been placed on new approaches to the crystallisation process, such as 
ultrasound-assisted nucleation and microfluidic generated crystalline material. 
Understanding whether these processes lead to materials of greater quality or 
functionality is vital for the successful application of these techniques within the 
pharmaceutical arena and therefore, the characterisation of processability 
would be beneficial using a AFM nanoindentation approach. 
 
Ultimately, this project concludes that the milling and processing of primary 
crystal APIs is deeply rooted in the pharmaceutical processing of DPI 
formulations. Though novel approaches in producing primary material of the 
inhalable size range do exist, limits to scale up, cost and complexity of these 
methods has led to a reliance on “top-down” culture in DPI formulation design. 
Successfully incorporating a technique, such as AFM nano-indenation, 
alongside other tools may lead to a better understanding of the processability of 
APIs incorporated in these formulations and thereby reduce variability in the 
final product.  
References 
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